<!DOCTYPE html>
<html>

  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, user-scalable=no, initial-scale=0.95, maximum-scale=0.95, minimum-scale=0.95"/>
    <meta http-equiv="x-ua-compatible" content="IE=edge">
    <title>Liverpool HIV Interactions</title>
    <link rel="stylesheet" media="all" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv_site-0a478b945d0a5a038ce1c2c7353d4cdcc80f95b7d764296440f4a7790aac6305.css" />
    <!--[if IE 8]>
        <script src="//cdnjs.cloudflare.com/ajax/libs/es5-shim/4.0.5/es5-shim.min.js"></script>
        <style>
            .ng-hide {
                display: none !important;
            }
        </style>
    <![endif]-->
    <script src="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/application-558b3c2a3e06dc8db0be037ca1d2b0a8b417b18dfe38e0d45ee242ed38ca7613.js"></script>
    
    <meta name="csrf-param" content="authenticity_token" />
<meta name="csrf-token" content="2gpfKSu+e1H5yn+f0lmYG/+wNXRBe7oXKsxQQEe1cINtThcAT85Ijjc3nyLGrBeIn+fjNF9G/Ra7ESMkWwM/mQ==" />
    
    <link rel="icon" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv-favicon-6af0467185368caf8c843f5fbf2095eb85d3057e8a2dbfadc5ffbb7bda4d8f59.ico" sizes="32x32">
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv-favicon-152px-8970667e12c076f671daad84dcacda13b40c6f22672b38c55ad61f72e857b460.png">
    <link rel="apple-touch-icon-precomposed" sizes="144x144" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv-favicon-144px-24f03e597ce22e8446280458d4f244e00620008785ccc07c52ae61f18f50911a.png">
    <link rel="apple-touch-icon-precomposed" sizes="120x120" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv-favicon-120px-e5b3af06dec7a9a0f9965209b7ffba504447096d086d79b26dbb8f1962b6251f.png">
    <link rel="apple-touch-icon-precomposed" sizes="114x114" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv-favicon-114px-106d37d88ee6e9a4275d2de639a68b139ae7d66416b4bb64b317a37e8b2673e6.png">
    <link rel="apple-touch-icon-precomposed" sizes="72x72" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv-favicon-72px-b24efd122931fef6f36ce176141fd6d47a46fa7e0770b5f98e8e2eec849d57ac.png">
    <link rel="apple-touch-icon-precomposed" sizes="57x57" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hiv-favicon-57px-154d723ded7ac95257566911bfbe8b158829cf0ada223a9f737d453dbd3e293b.png">
    <link href='http://fonts.googleapis.com/css?family=Varela+Round' rel='stylesheet' type='text/css'>
    <!-- start Mixpanel --><script type="text/javascript">(function(e,b){if(!b.__SV){var a,f,i,g;window.mixpanel=b;b._i=[];b.init=function(a,e,d){function f(b,h){var a=h.split(".");2==a.length&&(b=b[a[0]],h=a[1]);b[h]=function(){b.push([h].concat(Array.prototype.slice.call(arguments,0)))}}var c=b;"undefined"!==typeof d?c=b[d]=[]:d="mixpanel";c.people=c.people||[];c.toString=function(b){var a="mixpanel";"mixpanel"!==d&&(a+="."+d);b||(a+=" (stub)");return a};c.people.toString=function(){return c.toString(1)+".people (stub)"};i="disable time_event track track_pageview track_links track_forms register register_once alias unregister identify name_tag set_config people.set people.set_once people.increment people.append people.union people.track_charge people.clear_charges people.delete_user".split(" ");
for(g=0;g<i.length;g++)f(c,i[g]);b._i.push([a,e,d])};b.__SV=1.2;a=e.createElement("script");a.type="text/javascript";a.async=!0;a.src="undefined"!==typeof MIXPANEL_CUSTOM_LIB_URL?MIXPANEL_CUSTOM_LIB_URL:"file:"===e.location.protocol&&"//cdn.mxpnl.com/libs/mixpanel-2-latest.min.js".match(/^\/\//)?"https://cdn.mxpnl.com/libs/mixpanel-2-latest.min.js":"//cdn.mxpnl.com/libs/mixpanel-2-latest.min.js";f=e.getElementsByTagName("script")[0];f.parentNode.insertBefore(a,f)}})(document,window.mixpanel||[]);
mixpanel.init("cac4e9c0b9aef2c3bc30326ca7d1683f");</script><!-- end Mixpanel -->
    <!--[if lt IE 8]>
  <p class="browserupgrade">You are using an <strong>outdated</strong> browser. Please <a href="http://browsehappy.com/">upgrade your browser</a> to improve your experience.</p>
<![endif]-->

<!--[if lte IE 9]>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv.min.js"></script>
<![endif]-->

    <script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-75467942-1', 'auto');
  ga('send', 'pageview');
</script>

  </head>

  <body>
    <div class="header">
  <div class="inner-wrapper">
    <a class="logo" href="/">
      <p class="logo-icon"></p><p>HIV Drug Interactions</p>
</a>    <div class="header-right-column">
      <a href="https://www.liverpool.ac.uk/" target="_blank" class="uol-header-logo"></a>
          <div class="header-button-stack">
            <a href="https://alumni.liv.ac.uk/give-back/donate/drug-interactions-donation-page" target="_blank" class="header-right-column-button">
              <p>Donate Now</p>
              <p class="header-button-icon"></p>
            </a>

            <div class="apps-dropdown-nav-wrapper">
              <a href="#" class="header-right-column-button apps-dropdown-button">
                <p>Apps</p>
                <p class="header-button-icon"></p>
              </a>
                <div class="apps-dropdown-nav">
                  <a href="https://itunes.apple.com/gb/app/liverpool-hiv-ichart/id979962744?mt=8" target="_blank" class="appstore-link">
                    <p class="icon"></p>
                    <p>Download from the AppStore</p>
                  </a>
                  <a href="https://play.google.com/store/apps/details?id=com.liverpooluni.icharthiv&hl=en_GB" target="_blank" class="google-play-link">
                    <p class="icon"></p>
                    <p>Download from Google Play</p>
                  </a>
                </div>
            </div>
          </div>


    </div>


    <a href="javascript:;" class="mobile-nav-icon">
      <p></p>
      <p></p>
      <p></p>
    </a>
    <a href="https://www.liverpool.ac.uk/" target="_blank" class="uol-header-logo mobile-uol"></a>

  </div>
</div>
<a class="mobile-interaction-link" href="/checker">
  <p>Interaction Checker</p>
  <p class="header-button-icon"></p>
</a><a href="https://alumni.liv.ac.uk/give-back/donate/drug-interactions-donation-page" target="_blank" class="mobile-interaction-link donate-mobile-link">
  <p>Donate Now</p>
  <p class="header-button-icon"></p>
</a>

<div class="navigation">
  <div class="inner-wrapper">


    <div class="drop-down-nav-wrapper">
      <a href="javascript:;">Interaction Charts</a>

      <div class="drop-down-nav interaction-charts">
        <a href="/checker">Interaction Checker</a>
        <a href="/drug_queries/new">Interaction Checker Lite</a>
        <a href="/view_all_interactions/new">View All Checker</a>
        <a href="/printable_charts">Printable Charts</a>
        <a href="/treatment_selectors">Treatment Selectors</a>
      </div>
    </div>

    <a href="/site_updates">Site Updates</a>
    <!--
    <div class="drop-down-nav-wrapper">
      <a href="javascript:;">Site News/Updates</a>
      <div class="drop-down-nav site-news">
        <a href="/articles">Latest Articles</a>
        <a href="/site_updates">Site Updates</a>
      </div>
    </div>
    -->




    <div class="drop-down-nav-wrapper">
      <a href="javascript:;">About Us</a>
      <div class="drop-down-nav about-drop-down">
        <a href="/mission">Mission Statement</a>
        <a href="/board">Editorial Board</a>
      </div>
    </div>

    <div class="drop-down-nav-wrapper">
      <a href="javascript:;">Pharmacology Resources</a>
      <div class="drop-down-nav resources-drop-down">
        <a href="/fact_sheets">Fact Sheets</a>
      </div>
    </div>

    <a href="/feedback">Contact Us</a>

    <a href="/support-us">Support Us</a>

  </div>
</div>

    <div class="row">
  <div class="col-lg-12">


  </div>
</div>

    <div class="inner-body-wrapper">
  <div class="inner-wrapper">

    <div class="interaction-block-single-page-wrapper">


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green outline">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Abacavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Not Available</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Not Available</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Acarbose</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. After ingestion of acarbose, the majority of active unchanged drug remains in the lumen of the gastrointestinal tract to exert its pharmacological activity and is metabolised by intestinal enzymes and by the microbial flora.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Acenocoumarol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as acenocoumarol is mainly metabolized by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Acetazolamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Acetazolamide is predominantly excreted unchanged via active renal tubular secretion. In vitro studies have shown that acetazolamide may competitively inhibit the renal transporters hOAT1, hOAT3 and hOAT4. However, a clinically relevant interaction is unlikely in the range of observed clinical concentrations.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Aciclovir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Aciclovir is eliminated renally via glomerular filtration and active renal secretion by OAT1. A clinically relevant interaction is unlikely in the range of observed clinical concentrations.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Acitretin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as acitretin undergoes isomerisation and glucuronidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Adefovir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Adefovir is eliminated renally via glomerular filtration and active renal secretion by OAT1. A pharmacokinetic interaction is unlikely in the range of observed clinical concentrations. However, as adefovir is nephrotoxic, renal function should be monitored and stavudine dosage adjusted accordingly.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Adrenaline (Epinephrine)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Adrenaline is rapidly inactivated, mostly in the liver by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). There is therefore little potential for interaction with stavudine via modulation of, or competition for metabolic or elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Adrenaline is a naturally occurring catecholamine secreted by the adrenal medulla in response to exertion or stress. Adrenaline is rapidly inactivated in the body, mostly in the liver by the enzymes catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Much of a dose of adrenaline is excreted as metabolites in urine. The plasma half-life is about 2-3 minutes. However, when given by subcutaneous or intramuscular injection, local vasoconstriction may delay absorption so that the effects may last longer than the half-life suggests.<br /><em>Adrenaline (Epinephrine) Injection BP 1 in 1000 UK Summary of Product Characteristics, Hameln pharmaceuticals ltd, updated August 2010</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>African Potato</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on the metabolic data there is little potential for pharmacokinetic interactions.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See&nbsp;Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Agomelatine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely as agomelatine is metabolised predominantly by CYP1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Albendazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction via competition with stavudine for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Albendazole rapidly undergoes extensive first-pass metabolism in the liver, and is generally not detected in plasma. Albendazole sulphoxide is the primary metabolite, which is thought to be the active moiety in effectiveness against systemic tissue infections. Albendazole sulphoxide and its metabolites appear to be principally eliminated in bile, with only a small proportion appearing in the urine.<br /><em>Zentel&#174; Australian Product Information, GlaxoSmithKline Updated January 2009<br />Eskazole&#174; Australian Product Information, GlaxoSmithKline Updated September 2010</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Alcohol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as alcohol is metabolized by alcohol dehydrogenase and aldehyde dehydrogenase. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Alcuronium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This Interaction has not been studied. Alcuronium is predominantly excreted unchanged via the kidneys. As there are no available data determining whether excretion is via active tubular secretion or glomerular filtration, there is some potential for competition with stavudine for active renal transport mechanisms, which may lead to increased levels of either drug.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>An intravenous (IV) single-bolus injection of alcuronium (0.25 mg/kg = ED95) was administered to 10 patients undergoing maxillofacial surgery during nitrous-oxide opioid anesthesia. Alcuronium neuromuscular block, plasma concentration, and renal elimination (HPLC assay) were measured during the 12-h after its administration. Two hours after the injection of alcuronium, partial recovery from the neuromuscular block had occurred from 100% to 26% +/- 24% depression of twitch tension, although less than 25% of the injected dose was recovered from the urine. The 12-h plasma concentration and urinary recovery were 0.1 +/- 0.08 mg/L and 61% +/- 20%, respectively. Recovery from neuromuscular block was dominated by intercompartmental distribution rather than by renal elimination. Alcuronium does not undergo biodegradation; apart from negligible biliary excretion, the kidney represented the only excretory pathway.<br /><em>Diefenbach C, K&#252;nzer T, Buzello W, Theisohn M. Alcuronium: a pharmacodynamic and pharmacokinetic update. Anesth Analg. 1995 Feb;80(2):373-7</em></div>
<div>&nbsp;</div>
<div>Since stavudine is actively secreted by the renal tubules, interactions with other actively secreted medicinal products are possible, e.g. with trimethoprim.<br /><em>Zerit&#174; (stavudine) Hard Capsules UK Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceutical Ltd, updated April 2011</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Alendronic Acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary) </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Alfentanil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as alfentanil undergoes extensive CYP3A4 metabolism. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Alfuzosin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as alfuzosin is metabolized mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Aliskiren</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aliskiren is minimally metabolized and is mainly excreted unchanged in faeces. P-glycoprotein is a major determinant of aliskiren bioavailability.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Allopurinol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as allopurinol is converted to oxipurinol by xanthine oxidase and aldehyde oxidase. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Almotriptan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Almotriptan is partly eliminated unchanged in the urine and partly metabolized (mainly via monoamine oxidase-A and to a lesser extent by CYP3A4, CYP2D6 and flavin monooxygenase).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Aloe vera</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Aloe vera is only a weak inhibitor of CYPs in vitro and therefore is unlikely to cause clinically significant interactions. It does not inhibit P-gp and there is no evidence to suggest it impacts UGTs.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Alosetron</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. In vitro data indicate that alosetron is metabolized by CYPs 2C9, 3A4 and 1A2, with in vivo data suggesting that CYP1A2 plays a more prominent role.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Alprazolam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on  metabolism and clearance a clinically significant interaction is unlikely as alprazolam is metabolized mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Aluminium hydroxide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Aluminium hydroxide is slowly but perhaps incompletely converted to aluminium chloride in the stomach. Some absorption of soluble aluminium salts occurs from the gastro-intestinal tract with some excretion in the urine. Some unabsorbed aluminium hydroxide combines with phosphates and some form carbonates and salts of fatty acids, all these salts are excreted in the faeces.<br /><em>Alu-Cap&#174; (Aluminium hydroxide) Capsules UK Summary of Product Characteristics, Meda Pharmaceuticals, updated June 2012</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Amantadine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amantadine is mainly eliminated renally by glomerular filtration and active secretion. A bicarbonate dependent organic cation transporter has been identified as the major uptake transporter of amantadine in the renal proximal tubule.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Amikacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as amikacin is eliminated renally by glomerular filtration. However as amikacin is nephrotoxic, renal function should be monitored and stavudine dosage adjusted accordingly.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Amiloride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amiloride is eliminated unchanged by the kidney. In vitro data indicate that amiloride is a substrate of OCT2 and an interaction is unlikely as stavudine is eliminated by other renal transporters.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Amiodarone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amiodarone is metabolized by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Amisulpride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amisulpride is weakly metabolized and is primarily eliminated renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Amitriptyline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amitriptyline is metabolized predominantly by CYP2D6 and CYP2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Amlodipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amlodipine is metabolized by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Amodiaquine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amodiaquine is mainly metabolized by CYP2C8 to N-desethylamodiaquine, an active metabolite but less potent than the parent compound.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Amoxicillin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amoxicillin is mainly eliminated unchanged in the kidney and in vitro data indicate that it is a substrate of OAT3 whereas stavudine is eliminated by other renal transporters.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Amphetamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amphetamine is metabolized by CYP2D6. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Amphotericin B</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but amphotericin B is nephrotoxic and therefore renal function should be monitored and stavudine dosage adjusted accordingly.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ampicillin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Renal clearance of ampicillin occurs partly by glomerular filtration and partly by tubular secretion. After oral administration, approximately 20-40% is excreted unchanged in the urine, whereas about 60-80% is excreted unchanged in the urine after parenteral administration. As stavudine is eliminated by renal tubular secretion, there is potential for competition with ampicillin for renal transporters, which could lead to increased levels of either drug when ampicillin is administered intravenously. When administered orally, there is little potential for significant interaction.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Amyl nitrate (Poppers)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Amyl nitrate is metabolized rapidly by hydrolytic denitration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Anastrozole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Anastrozole is mainly oxidized to hydroxyanastrozole by CYP3A4 (major) and glucuronidated by UGT1A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Anidulafungin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Anidulafungin is not metabolised hepatically but undergoes chemical degradation at physiological temperature.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Antacids</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as antacids are unlikely to alter stavudine absorption.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Apixaban</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Apixaban is metabolized by CYP3A4 and to a lesser extent by CYP1A2, CYP2C8, CYP2C9 and CYP2C19.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See&nbsp;Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Apomorphine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as apomorphine is metabolized by several pathways including glucuronidation, sulfation and to a lesser extent N-demethylation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Aprepitant</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aprepitant is mainly metabolized by CYP3A4 and to a lesser extent by CYPs 1A2 and 2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Aripiprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as aripiprazole is metabolized by CYP3A4 and CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Artemisinin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Artemisinins undergo rapid metabolism via several CYP450 (CYPs 3A4, 2A6, 2B6) and the active metabolite (dihydroartemisinin, which has greater potency than the parent drug) is further metabolized via UGTs 1A9 and 2B7. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ascorbic Acid (Vitamin C)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Large doses of ascorbic acid may cause the urine to become acidic causing unexpected renal tubular reabsorption of acidic drugs, thus producing an exaggerated response. Conversely basic drugs may exhibit decreased reabsorption resulting in a decreased therapeutic effect. Stavudine is predominantly eliminated unchanged via active renal tubular secretion, however unless treatment with ascorbic acid involves large doses of prolonged duration, significant interactions are not expected.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Large doses of ascorbic acid may cause the urine to become acidic causing unexpected renal tubular reabsorption of acidic drugs, thus producing an exaggerated response. Conversely basic drugs may exhibit decreased reabsorption resulting in a decreased therapeutic effect.&nbsp; Ascorbic acid is readily oxidised to dehydroascorbic acid where some is metabolised to oxalic acid and the inactive ascorbate - 2 - sulphate. Metabolic turnover appears to be greater in females than males. Large doses are rapidly excreted in the urine when in excess of the requirements of the body and after an intravenous dose, about 40% is excreted in 8 hours, which is increased to about 70% after tissue saturation. The amount of unchanged drug is dose dependent; in women the excretion of ascorbic acid appears to vary with the stage of the menstrual cycle and it is decreased when taking oral contraceptives. Oxalic acid and ascorbate - 2 - sulphate are excreted in the urine.<br /><em>Ascorbic Acid Injection 500mg/5ml UK Summary of Product Characteristics, UCB Pharma Limited, updated March 2009</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Asenapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Asenapine is metabolized by glucuronidation (UGT1A4) and oxidative metabolism (mainly CYP1A2, with minor contributions from CYP3A4 and CYP2D6).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Asparaginase</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolic profiles of both drugs, there is little potential for pharmacokinetic interaction. Acute pancreatitis is a relatively common adverse event in patients taking asparaginase. Pancreatitis, occasionally fatal, has been reported in up to 2-3% of patients enrolled in monotherapy clinical studies of stavudine, and in < 1% of patients in combination therapy studies including stavudine. Patients with a high risk of pancreatitis or those receiving products known to be associated with pancreatitis should be closely followed for symptoms of this condition.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Limited data suggest that asparaginase is likely to be eliminated by the reticuloendothelial system. Less than 0.1% of a total injected dose is recovered in urine.&nbsp; Uptake by receptor-mediated endocytosis has also been suggested as a mechanism of asparaginase elimination<br /><em>Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Narta UK, Kanwar SS, Azmi W. Crit Rev Oncol Hematol. 2007 Mar;61(3):208-21.<br />Comparative pharmacokinetic studies of three asparaginase preparations. Asselin BL, Whitin JC, Coppola DJ et al. J Clin Oncol. 1993 Sep;11(9):1780-6.<br />Elimination of l-asparaginase in children treated for acute lymphoblastic leukemia. Brueck M, Koerholz D, Nuernberger W et al. Dev Pharmacol Ther. 1989;12(4):200-4.</em></p>
<p>Acute pancreatitis occurs in &lt;10% of cases. There have been isolated reports of pseudocyst formation up to four months after last treatment, so appropriate testing (e.g. ultrasound) may need to be considered beyond last treatment. In very rare cases, haemorrhagic or necrotising pancreatitis occurs, with fatal consequences. <br /><em>Erwinase&#174; 10,000 Unit/vial, Lyophilisate for solution for injection (Asparaginase from Erwinia chrysanthemi) UK Summary of Product Characteristics, EUSA Pharma (Europe) Limited, updated March 2011<br />Erwinaze&#174; (asparaginase Erwinia chrysanthemi) for injection US Prescribing Information, EUSA Pharma (USA), Inc, updated November 2011</em></p>
<p>Pancreatitis, occasionally fatal, has been reported in up to 2-3% of patients enrolled in monotherapy clinical studies of stavudine, and in &lt; 1% of patients in combination therapy studies including stavudine. Patients with a history of pancreatitis had an incidence of approximately 5% on stavudine, as compared to approximately 2% in patients without such a history. Patients with a high risk of pancreatitis or those receiving products known to be associated with pancreatitis should be closely followed for symptoms of this condition.<br /><em>Zerit&#174; (stavudine) capsules, UK Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceutical Limited, updated April 2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Aspirin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aspirin is rapidly deacetylated to salicylic acid and then further metabolized mainly by glucuronidation (by several UGT, major UGT1A6). </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Astemizole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as astemizole is metabolized by CYPs 2D6, 2J2 and 3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Atazanavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration of single doses of stavudine (40 mg) atazanavir (400 mg) as part of pharmacokinetic study with didanosine resulted in no significant change in atazanavir or stavudine pharmacokinetics. Coadministration with atazanavir/ritonavir has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>The co-administration of atazanavir/ritonavir with stavudine is not expected to significantly alter the exposure of stavudine. <br /><em>Reyataz Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, April 2012.</em></p>
<p><div>Atazanavir did not have a significant effect on the exposure of stavudine. <br /><em>Reyataz Prescribing Information, Bristol-Myers Squibb Co, September 2015.</em></div></p>
<p>Coadministration of a single doses of stavudine (40 mg) atazanavir (400 mg) as part of pharmacokinetic study with ddI resulted in no significant change in atazanavir or stavudine pharmacokinetics (n=31). <br /><em>BMS-232632: a summary of multiple dose pharmacokinetic, food effect and drug interactions studies in healthy subjects. O&#8217;Mara E, Mummaneni V, Randal D, et al. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2000, abstract 504. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Atenolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as atenolol is mainly eliminated unchanged by the kidney, predominantly by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Atorvastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as atorvastatin is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Atovaquone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as atovaquone is mainly eliminated unchanged in the faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Atropine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for interaction when atropine is used either systemically or as eye drops. Up to 50% of a dose is excreted unchanged via the kidneys. There is therefore low potential for clinically significant interactions with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p><strong>Systemic use:</strong> Atropine is metabolised in the liver by oxidation and conjugation to give inactive metabolites. About 50% of the dose is excreted within 4 hours and 90% in 24 hours in the urine, about 30 to 50% as unchanged drug.<br /><em>Atropine Injection BP Minijet UK Summary of Product Characteristics, International Medication Systems (UK) Ltd, updated October 2005</em></p>
<p><strong>Ocular use:</strong> Atropine is also absorbed by mucous membranes but less readily from the eye and skin, although significant toxicity can sometimes occur through absorption of excessive eye drops. Atropine is metabolised by hepatic oxidation and conjugation to inactive metabolites, with about 2% undergoing hydrolysis to tropine and tropic acid. About 30% of the dose is excreted unchanged in the urine. Only trace amounts of the dose are eliminated in the faeces.<br /><em>Minims Atropine Sulphate 1%, Eye drops solution UK Summary of Product Characteristics, Bausch &amp; Lomb U.K Limited, updated July 2012</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Azathioprine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Azathioprine is metabolized to 6-mercaptopurine which is further inactivated by xanthine oxidase and thiopurine methyltransferase. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Azithromycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as azithromycin is mainly eliminated via biliary excretion.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Baclofen</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as baclofen is primarily eliminated by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Beclometasone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Beclometasone is a pro-drug which is not metabolised by CYP450 but is hydrolysed via esterase enzymes to the highly active metabolite beclometasone-17-monopropionate.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Bedaquiline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as bedaquiline is metabolised by CYP3A4 and mainly eliminated in faeces. There are no clinical data on the safety and efficacy of bedaquiline when coadministered with antiretroviral agents.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Bendroflumethiazide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on  metabolism and clearance a clinically significant interaction is unlikely. Bendroflumethiazide is eliminated by hepatic metabolism (70%) and excreted unchanged in the urine (30%) via OAT1 and OAT3. In vitro data indicate that bendroflumethiazide inhibits these renal transporters but a clinically relevant drug interaction is unlikely in the range of observed clinical concentrations.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Benserazide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as benserazide is hydrolysed to trihydroxybenzylhydrazine. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Benznidazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Renal elimination of unchanged benznidazole appears to be minimal, there is therefore little potential for interaction via competition with stavudine for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Benznidazole is absorbed from the gastrointestinal tract after oral doses (&gt; 90% bioavailability) and is widely distributed throughout the body. More than 40% of the drug is bound to plasma protein. The peak plasma concentration occurs after 3 to 4 hours and the half-life is about 12 hours. It is metabolised in the liver and more than 70% of the metabolites are excreted by the kidneys; about 30% of a dose is excreted in the faeces.<br /><em>Raaflaub J, Ziegler WH. Single-dose pharmacokinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung 1979; 29: 1611&#8211;14.</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Bepridil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as bepridil is mainly metabolized by CYP2D6 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Betamethasone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Betamethasone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Bexarotene</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Bexarotene is mainly metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Bezafibrate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug-drug interaction is unlikely. In vitro data suggest that bezafibrate inhibits the renal transporter OAT1 but a clinically relevant drug interaction with stavudine is unlikely in the observed range of clinical concentrations.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Biperiden</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as biperiden undergoes hydroxylation in the liver.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Bisacodyl</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisacodyl is converted to an active metabolite by intestinal and bacterial enzymes. Absorption from the gastrointestinal tract is minimal and the small amount absorbed is excreted in the urine as the glucuronide.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Bisoprolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisoprolol is partly metabolized by CYP3A4 and CYP2D6 and partly eliminated unchanged in the urine. There is no evidence that bisoprolol and stavudine are eliminated by the same renal transporters.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Bleomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bleomycin is inactivated by a cytosolic enzyme, bleomycin hydrolase, and two thirds of the administered drug is excreted unchanged in urine, probably by glomerular filtration. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Boceprevir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as boceprevir is metabolized by aldoketoreductase and CYP3A.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Bortezomib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Bortezomib is mainly metabolized by CYP3A4 and 2C19 and to a lesser extent by CYPs 1A2, 2D6 and 2C9. A pharmacokinetic interaction is unlikely, however, the risk of neurotoxicity may be potentially increased as both drugs can cause neuropathy.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Bosentan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as bosentan is metabolized by CYP3A4 and CYP2C9. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Bromazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as bromazepam undergoes oxidative biotransformation. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Budesonide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as budesonide is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Bupivacaine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Renal excretion of unchanged bupivacaine is thought to account for approximately 1% of a dose. There is therefore little potential for interaction with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Bupivacaine is extensively metabolised in the liver, predominately by aromatic hydroxylation to 4-hydroxy-bupivacaine and N-dealkylation to PPX, both mediated by cytochrome P4503A4. About 1% of bupivacaine is excreted in the urine as unchanged drug in 24 h and approximately 5% as PPX. The plasma concentrations of PPX and 4-hydroxy-bupivacaine during and after continuous administration of bupivacaine are low as compared to the parent drug. <br /><em>Marcain&#174; Polyamp Steripack 0.25% and 0.5% UK Summary of Product Characteristics, AstraZeneca UK Limited, updated May 2012</em></p>
<p>Bupivacaine is extensively metabolized in the liver predominantly by aromatic hydroxylation to 4-hydroxy-bupivacaine and N-dealkylation to 2,6-pipecoloxylidine (PPX), both mediated by cytochrome P450 3A4. The terminal half-life of bupivacaine in adults is 2.7 hours, and in neonates it is prolonged up to eight hours. The kidney is the main excretory organ for most local anaesthetics and their metabolites. About 1% of bupivacaine is excreted in the urine as unchanged drug in 24 h and approximately 5% as PPX. The plasma concentrations of PPX and 4-hydroxy-bupivacaine during and after continuous administration of bupivacaine are low as compared to the parent drug.<br /><em>Sensorcaine&#174; Bupivacaine Hydrochloride Injection USP Canadian Product Monograph, AstraZeneca Canada Inc, Last revised: February 2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Buprenorphine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Buprenorphine undergoes both N-dealkylation to form norbuprenorphine (via CYP3A4) and glucuronidation (via UGT2B7 and UGT1A1). Norbuprenorphine, an active metabolite, can further undergo glucuronidation (via UGT1A3 and UGT1A1).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Bupropion</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as bupropion is primarily metabolized by CYP2B6. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Buspirone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as buspirone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Caffeine citrate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as caffeine is mainly metabolized by CYP1A2. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Calcium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Calcium is eliminated through faeces, urine and sweat.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Candesartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as candesartan is mainly eliminated unchanged via urine and bile.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Cannabis</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. THC, the principal psychoactive constituent of cannabis, is metabolized mainly by CYP2C9 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Capecitabine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Capecitabine is activated by sequential enzyme reactions to fluorouracil. Dihydropyrimidine dehydrogenase plays a role in fluorouracil metabolism. Nucleoside analogues such as stavudine may compete for or inhibit this metabolism pathway, leading to increased fluorouracil toxicity. The clinical relevance of this interaction is unknown and clinical monitoring is recommended.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Capreomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Capreomycin is predominantly excreted in the urine as unchanged drug. As capreomycin may potentially compete with stavudine for renal elimination transport mechanisms, levels of either drug may hypothetically be raised. Monitoring of renal function may be warranted, particularly as there have been reports of renal toxicity with capreomycin use.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Capreomycin is excreted in the urine, essentially unaltered, and approximately 50% of a 1g intramuscular dose is excreted within 12 hours.<br /><em>Capreomycin Injection Summary of Product Characteristics King Pharmaceuticals Ltd, updated April 2010<br />Capastat&#174; (capreomycin) US Prescribing Information, Eli Lilly &amp;Co. updated January 2008</em></p>
<p>Renal injury, with tubular necrosis, elevation of the blood urea nitrogen (BUN) or serum creatinine, and abnormal urinary sediment, has been noted. Slight elevation of the BUN and serum creatinine has been observed in a significant number of patients receiving prolonged therapy. In 36% of 722 patients treated with Capastat Sulfate, elevation of the BUN above 20 mg/100 mL has been observed. Toxic nephritis was reported<br /><em>Capastat&#174; (capreomycin) US Prescribing Information, Eli Lilly &amp;Co. updated January 2008</em></p>
<p>Since stavudine is actively secreted by the renal tubules, interactions with other actively secreted medicinal products are possible, e.g. with trimethoprim.<br /><em>Zerit&#174; (stavudine) Hard Capsules UK Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceutical Ltd, updated April 2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Captopril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Captopril is largely excreted in the urine by OAT1 but stavudine does not inhibit this renal transporter.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Carbamazepine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on  metabolism and clearance a clinically significant interaction is unlikely. Carbamazepine is almost completely metabolized in the liver to carbamazepine 10,11 epoxide.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Carbidopa</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carbidopa is partly metabolized and partly eliminated unchanged (30% of the total urinary excretion). </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Carbimazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Carbimazole is a pro-drug which undergoes rapid and virtually complete metabolism to the active metabolite, thiamazole (also known as methimazole).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Carboplatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Carboplatin is excreted primarily by glomerular filtration, therefore there is little potential for interaction with stavudine via competition for active renal transport pathways. However, coadministration can increase the risk of peripheral neuropathy due to additive toxicity.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Carboplatin is excreted primarily by glomerular filtration in urine, with recovery of 65% of a dose within 24 hours. Most of the drug is excreted within the first 6 hours. Approximately 32% of a given dose of carboplatin is excreted unchanged.<br /><em>Carboplatin Summary of Product Characteristics, Hospira UK Ltd,&nbsp;June 2009.</em></p>
<p>The major route of elimination of carboplatin is renal excretion. Patients with creatinine clearances of approximately 60 mL/min or greater excrete 65% of the dose in the urine within 12 hours and 71% of the dose within 24 hours. All of the platinum in the 24-hour urine is present as carboplatin. Only 3% to 5% of the administered platinum is excreted in the urine between 24 and 96 hours. There are insufficient data to determine whether biliary excretion occurs. The primary determinant of carboplatin clearance is glomerular filtration rate<br /><em>Carboplatin Prescribing Information, Hospira Inc, August 2007.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Carvedilol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carvedilol undergoes glucuronidation via UGTs 1A1, 2B4 and 2B7, with additional metabolism via CYP2D6 and to a lesser extent 2C9 and 1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Caspofungin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Caspofungin undergoes spontaneous chemical degradation and metabolism via a non CYP-mediated pathway.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Cat&#39;s Claw (Uncaria tomentosa)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cats claw was demonstrated to strongly inhibit CYP3A4 in vitro, but stavudine does not undergo CYP3A4 metabolism.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Cefalexin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Cefalexin is predominantly eliminated unchanged renally by glomerular filtration and tubular secretion via OAT1 and MATE1. Thus, there is potential for competition with cefalexin for renal transporters, which could lead to increased concentrations of either drug.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Cefazolin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefazolin is predominantly excreted unchanged in the urine, mainly by glomerular filtration with some renal tubular secretion via OAT3, whereas stavudine is eliminated by other renal transporters.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Cefixime</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. As cefixime is renally excreted predominantly by glomerular filtration, with no significant active renal tubular secretion, there is little potential for interaction via competition with stavudine for active renal elimination transport mechanisms.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Cefixime is predominantly eliminated as unchanged drug in the urine. Glomerular filtration is considered the predominant mechanism. Metabolites of cefixime have not been isolated from human serum or urine.<br /><em>Suprax&#174; tablets (Cefixime) Summary of Product Characteristics, Sanofi-Aventis, updated November 2010</em></p>
<div>Approximately 50% of the absorbed dose is excreted unchanged in the urine in 24 hours. In animal studies, it was noted that cefixime is also excreted in the bile in excess of 10% of the administered dose. There is no evidence of metabolism of cefixime in vivo. <br /><em>Suprax&#174; (cefixime) US Prescribing Information, Lupin Pharmaceuticals INC, updated November 2011</em> 
<div>&nbsp;</div>
<div>In vitro studies using rat renal brush border membrane vesicles showed that the initial uptake rate of cefixime into an osmotically sensitive vesicular space showed concentration and ternperature dependencies, indicating the presence of a carrier mediated transport mechanism for cefixime. Organic anions such as probenecid and p-aminohippuric acid and anion transport inhibitors such as 4,4'-diisothiocyano-stilbene-2,2'-disulfonic acid and furosemide reduced the uptake significantly. These results indicate that cefixime is transported through the renal brush-border membrane via a carrier-mediated transport system which is common to organic anions. <br /><em>Carrier-mediated transport of cefixime, a new cephalosporin antibiotic, via an organic anion transport system in the rat renal brush-border membrane. Tamai I, Tsuji A, Kin Y. J Pharmacol Exp Ther. 1988; 246: 338-44.</em></div></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Cefotaxime</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Most of a dose of cefotaxime is excreted in the urine - about 60% as unchanged drug and a further 24% as desacetyl-cefotaxime, an active metabolite. In vitro studies have shown that cefotaxime dose-dependently inhibits organic anion uptake mediated by human-OAT2. Probenecid, an inhibitor of renal tubular excretion, interferes with renal tubular transfer of cefotaxime delaying its excretion. As stavudine is predominantly excreted by active renal tubular secretion, there is potential for competition for renal elimination pathways, which may increase levels of either drug.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Approximately 20-36% of an intravenously administered dose of 14C-cefotaxime is excreted by the kidney as unchanged cefotaxime and 15-25% as the desacetyl derivative, the major metabolite. The desacetyl metabolite has been shown to contribute to the bactericidal activity. Two other urinary metabolites (M2 and M3) account for about 20-25%. They lack bactericidal activity.<br /><em>Cefotaxime for injection US Prescribing Information, Pfizer Labs, updated December 2009</em></p>
<div>Cefotaxime is partially metabolised prior to excretion. The principal metabolite is the microbiologically active product, desacetyl-cefotaxime. Most of a dose of cefotaxime is excreted in the urine - about 60% as unchanged drug and a further 24% as desacetyl-cefotaxime. Plasma clearance is reported to be between 260 and 390ml/minute and renal clearance 145 to 217 ml/minute.<br />Probenecid interferes with renal tubular transfer of cefotaxime delaying its excretion and increasing the plasma concentration.<br /><em>Cefotaxime for injection Summary of Product Characteristics, Wockhardt UK Ltd, updated August 2008</em><br /></div>
<div>An in vitro study investigated the interaction of human-OAT2 and rat-OAT2 renal organic anion transporters with cephalosporin antibiotics using proximal tubule cells stably expressing human-OAT2 and rat-OAT2. Human-OAT2 is localized to the basolateral side of the proximal tubule, whereas rat-OAT2 is localized to the apical side of the proximal tubule. Cefotaxime dose-dependently inhibited organic anion uptake mediated by human-OAT2 and rat-OAT2. There was no species difference observed for the effects of OAT2 with cephalosporins between human and rat transporters. Kinetic analysis revealed that the inhibitory effects for human-OAT2 were competitive. In conclusion, human-OAT2 interacts with cephalosporins, and thus, human-OAT2 may mediate the uptake of cephalosporins on the basolateral side of the proximal tubule. <br /><em>Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics. Khamdang S, Takeda M, Babu E, Noshiro R, Onozato ML, Tojo A, Enomoto A, Huang XL, Narikawa S, Anzai N, Piyachaturawat P, Endou H. Eur J Pharmacol. 2003 Mar 28;465(1-2):1-7.<br /><br /></div></em>
<div>Since stavudine is actively secreted by the renal tubules, interactions with other actively secreted medicinal products are possible, e.g. with trimethoprim.<br /><em>Zerit&#174; (stavudine) Hard Capsules UK Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceutical Ltd, updated April 2011</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ceftazidime</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. As ceftazidime is excreted predominantly by renal glomerular filtration, with no significant active renal tubular secretion, there is little potential for interaction via competition with stavudine for active renal transport mechanisms.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Ceftazidime is not metabolised in the body and is excreted unchanged in the active form into the urine by glomerular filtration. Approximately 80 to 90% of the dose is recovered in the urine within 24 hours. Less than 1% is excreted via the bile, significantly limiting the amount entering the bowel.<br /><em>Fortum&#174; 500 injection (ceftazidime) Summary of Product Characteristics, GlaxoSmithKline UK, updated August 2009</em></p>
<p>Approximately 80% to 90% of an IM or IV dose of ceftazidime is excreted unchanged by the kidneys over a 24-hour period. After the IV administration of single 500-mg or 1-g doses, approximately 50% of the dose appeared in the urine in the first 2 hours. An additional 20% was excreted between 2 and 4 hours after dosing, and approximately another 12% of the dose appeared in the urine between 4 and 8 hours later. The calculated plasma clearance of approximately 115 mL/min indicated nearly complete elimination of ceftazidime by the renal route. Administration of probenecid before dosing had no effect on the elimination kinetics of ceftazidime, suggesting that ceftazidime is eliminated by glomerular filtration and is not actively secreted by renal tubular mechanisms.<br /><em>Fortaz&#174; (ceftazidime for injection) US Prescribing Information, GlaxoSmithKline, updated August 2010</em></p>
<p>In a study of 2 healthy subjects, ceftazidime was administered by i.v. infusion and 1 g probenecid was administered orally after steady state plasma concentrations were reached. In a second session, ceftazidime was administered at increasing infusion rates such that three different levels of plasma drug concentration were achieved. The renal clearance of ceftazidime was calculated based upon unbound plasma concentration, and tubular clearance was estimated by subtracting inulin clearance from the renal clearance of the antibiotic. Non-linear regression analysis was used to estimate parameters describing the saturability of tubular excretion and the effect of probenecid inhibition. Tubular excretion of ceftazidime was practically zero, and there was no significant inhibition of renal clearance when administered with probenecid.<br /><em>The renal clearance of cefuroxime and ceftazidime and the effect of probenecid on their tubular excretion. Verhagen CA, Mattie H, Van Strijen E. Br J Clin Pharmacol. 1994 Feb;37(2):193-7.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ceftriaxone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. As ceftriaxone is excreted predominantly by renal glomerular filtration with minimal active renal tubular secretion, there is little potential for interaction via competition with stavudine for active renal transport mechanisms. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Ceftriaxone is eliminated mainly as unchanged drug; approximately 60% of the dose being excreted in the urine (almost exclusively by glomerular filtration) and the remainder via the biliary and intestinal tracts. The elimination of ceftriaxone is not altered by probenecid<br /><em>Rocephin&#174; (ceftriaxone) 250mg, 1g and 2g vials Summary of Product Characteristics, Roche Products Limited, updated May 2011</em></p>
<p>Thirty-three percent to 67% of a ceftriaxone dose was excreted in the urine as unchanged drug and the remainder was secreted in the bile and ultimately found in the feces as microbiologically inactive compounds. The elimination of ceftriaxone is not altered by co-administration with probenecid.<br /><em>Rocephin&#174; (ceftriaxone sodium) for injection, US Prescribing Information, Genentech USA, Inc, updated November 2010</em></p>
<p>An in vitro study investigated the interaction of human-OAT2 and rat-OAT2 renal organic anion transporters with cephalosporin antibiotics using proximal tubule cells stably expressing human-OAT2 and rat-OAT2 . Human-OAT2 is localized to the basolateral side of the proximal tubule, whereas rat-OAT2 is localized to the apical side of the proximal tubule. Ceftriaxone dose-dependently inhibited organic anion uptake mediated by human-OAT2 and rat-OAT2. There was no species difference observed for the effects of OAT2 with cephalosporins between human and rat transporters. Kinetic analysis revealed that the inhibitory effects for human-OAT2 were competitive. In conclusion, human-OAT2 interacts with cephalosporins, and thus, human-OAT2 may mediate the uptake of cephalosporins on the basolateral side of the proximal tubule. <br /><em>Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics. Khamdang S, Takeda M, Babu E, Noshiro R, Onozato ML, Tojo A, Enomoto A, Huang XL, Narikawa S, Anzai N, Piyachaturawat P, Endou H. Eur J Pharmacol. 2003 Mar 28;465(1-2):1-7.</em></p>
<p>The kinetics and binding parameters of ceftriaxone were studied in eight healthy subjects who received, in sequence, 1.0 g ceftriaxone and 1.0 g ceftriaxone together with 250 and 500 mg probenecid. Probenecid increased the total systemic clearance (CLTS) from 0.244 to 0.312 ml/min/kg, whereas the terminal half-life (t1/2T (beta)) fell from 8.1 to 6.5 h. In contrast, the renal clearance of free ceftriaxone (CLFR) was decreased from 2.09 to 1.67 ml/min/kg, confirming a small but significant contribution of tubular secretion to the renal elimination of ceftriaxone. <br /><em>Effect of probenecid on the elimination and protein binding of ceftriaxone. Stoeckel K, Trueb V, Dubach UC, McNamara PJ. Eur J Clin Pharmacol. 1988;34(2):151-6.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Celecoxib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as celecoxib is metabolised mainly by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Cetirizine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cetirizine is only metabolised to a limited extent and is eliminated unchanged in the urine through both glomerular filtration and tubular secretion. In vitro data indicate that cetirizine inhibits OCT2 but this is not involved in the renal elimination of stavudine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Chlorambucil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorambucil is almost completely metabolized (little is known about chlorambucil metabolism in humans, most probably non CYP mediated) and has extremely low urinary excretion. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Chloramphenicol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Chloramphenicol is predominantly metabolised via UDP-glucuronyltransferases, in particular UGT2B7.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>The primary UGT enzymes responsible for chloramphenicol O-glucuronidation were evaluated in vitro. Reaction phenotyping for the glucuronidation of chloramphenicol with 12 expressed human liver UGT isoforms has identified UGT2B7 as having the highest activity for 3-O- and 1-O-chloramphenicol glucuronidation with minor contributions from UGT1A6 and UGT1A9. The formation of 1-O-chloramphenicol glucuronide by pooled HLM and expressed UGT2B7 exhibited substrate inhibition kinetics with apparent K(m) values of 408.2 and 115.0 microM, respectively. Azidothymidine (AZT) and hyodeoxycholic acid (substrates of UGT2B7) inhibited 3-O- and 1-O-chloramphenicol glucuronidation in pooled HLMs. In 10 donor HLM preparations, both chloramphenicol 3-O- and chloramphenicol 1-O-glucuronidation showed a significant correlation with AZT glucuronidation (UGT2B7) at 30 microM chloramphenicol. These results suggest that UGT2B7 is the primary human hepatic UDP-glucuronosyltransferase isoform catalyzing 3-O- and 1-O-chloramphenicol glucuronidation with minor contributions from UGT1A6 and UGT1A9.<br /><em>Identification of human UGT2B7 as the major isoform involved in the O-glucuronidation of chloramphenicol. Chen M, LeDuc B, Kerr S, Howe D, Williams DA. Drug Metab Dispos. 2010 Mar;38(3):368-75.</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Chlordiazepoxide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlordiazepoxide is extensively metabolized by hepatic microsomal enzymes.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Chloroquine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Chloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney (50%). Due to the multiple elimination pathways, a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Chlorphenamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Chlorphenamine is predominantly metabolized via CYP2D6, approximately 22% of a chlorphenamine dose is excreted unchanged in the urine. There is therefore little potential for interaction with  stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Chlorphenamine is metabolised to the monodesmethyl and didesmethyl derivatives. About 22% of an oral dose is excreted unchanged in the urine.<br /><em>Piriton&#174; (Chlorphenamine) Tablets&nbsp; UK Summary of Product Characteristics, GlaxoSmithKline Consumer Healthcare, updated May 2010</em></p>
<p>Eight healthy volunteers received a single 8mg oral dose of rac-chlorphenamine either given alone or following administration of quinidine 50mg every 6 h for 2 days prior to the study day and every 6 h thereafter until the end of the study. For (S)-(+)-chlorphenamine, administration of quinidine, an inhibitor of CYP2D6, resulted in an increase in Cmax to 13.94 (P&lt;0.01), a reduction in CLoral to 0.22 l h-1 kg-1 (P&lt;0.01), and a prolongation of elimination half-life from 18.0 h to 29.3 h (P&lt;0.001). Administration of quinidine decreased CLoral for (R)-(-)-chlorphenamine to 0.60+/-0.10 l h-1 kg-1 (P&lt;0.005). In CYP2D6 poor metabolizers, systemic exposure was greater after chlorphenamine alone than in extensive metabolizers, and administration of quinidine resulted in a slight increase in CLoral. Stereoselective elimination of chlorphenamine occurs in humans, with the most pharmacologically active (S)-(+)-enantiomer cleared more slowly than the (R)-(-)-enantiomer. CYP2D6 plays a role in the metabolism of chlorphenamine in humans.<br /><em>The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorphenamine. Yasuda SU, Zannikos P, Young AE et al. Br J Clin Pharmacol. 2002 May;53(5):519-25.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Chlorpromazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorpromazine is metabolized mainly by CYP2D6, but also CYP1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Chlortalidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as chlortalidone is mainly excreted unchanged in the urine and faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ciclosporin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as ciclosporin is mainly metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Cidofovir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but may decrease stavudine renal elimination as in vitro data suggest that cidofovir inhibits the renal transporter OAT1. Furthermore, as cidofovir is nephrotoxic renal function should be monitored and stavudine dosage adjusted accordingly.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Cilazapril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cilazapril is mainly eliminated unchanged by the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Cimetidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as in vitro data indicate that cimetidine inhibits OAT1 at concentrations much higher than the observed clinical concentrations. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ciprofloxacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciprofloxacin is primarily eliminated unchanged by the kidneys by glomerular filtration and tubular secretion via OAT3. It is also metabolized and partially cleared through the bile and intestine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Cisapride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cisapride is metabolised mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Cisatracurium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cisatracurium undergoes mainly (80% of overall elimination) spontaneous degradation in plasma and tissues at physiological pH and temperature (Hofmann elimination).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Cisplatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Cisplatin is eliminated renally via OCT2 and MATE1. A pharmacokinetic interaction is unlikely, however, the risk of neurotoxicity may be potentially increased as both drugs can cause neuropathy.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Citalopram</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Citalopram is metabolized by CYP2C19 (38%), 2D6 (31%) and 3A4 (31%).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Clarithromycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No significant interaction observed. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>The pharmacokinetics of stavudine were determined in 10 HIV-infected subjects following administration of stavudine (40 mg twice daily) alone and with single, double or triple combinations of clarithromycin (500 mg twice daily), fluconazole (200 mg once daily) and/or rifabutin (300 mg once daily). Stavudine exposure was not significantly altered by multiple concomitant medications. The greatest difference in AUC between stavudine administered alone or with any other regimen was an 18% decrease when given with the rifabutin/clarithromycin combination. <br /><em>A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus-infected patients. Piscitelli SC, et al. Antimicrob Agents Chemother, 1999, 43: 647-650. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Clavulanic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Clavulanic acid is extensively metabolized (likely by a non CYP mediated pathway) and excreted in the urine by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Clindamycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Clindamycin is metabolized by CYP3A4 with some metabolites having antibacterial activity.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Clobetasol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely with the topical use of clobetasol.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Clofazimine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. As renal excretion has a minor role in clofazimine elimination, interaction with stavudine via competition for renal elimination pathways is unlikely. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)<br /><em></em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Clofibrate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clofibrate is hydrolyzed to an active metabolite, clofibric acid. Excretion of clofibric acid glucuronide is possibly performed via OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Clomifene</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Renal excretion of clomifene is thought to account for approximately 8% of an oral dose. There is therefore little potential for interaction with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Orally administered 14C labelled Clomifene citrate was readily absorbed when administered to humans. Cumulative excretion of the 14C label by way of urine and faeces averaged about 50% of the oral dose after 5 days in 6 subjects, with mean urinary excretion of 7.8% and mean faecal excretion of 42.4%. A mean rate of excretion of 0.73% per day of the 14C dose after 31 days to 35 days and 0.45% per day of the 14C dose after 42 days to 45 days was seen in faecal and urine samples collected from 6 subjects for 14 to 53 days after Clomifene citrate 14C administration. The remaining drug/metabolites may be slowly excreted from a sequestered enterohepatic recirculation pool.<br /><em>Clomid&#174; (clomifene Tablets) UK Summary of Product Characteristics, sanofi-aventis, updated September 2010</em></p>
<p>Based on early studies with 14C-labeled clomiphene citrate, the drug was shown to be readily absorbed orally in humans and excreted principally in the feces. Cumulative urinary and fecal excretion of the 14C averaged about 50% of the oral dose and 37% of an intravenous dose after 5 days. Mean urinary excretion was approximately 8% with fecal excretion of about 42%.<br /><em>Clomid&#174; (clomiphene citrate tablets USP) US Prescribing Information, Sanofi-aventis U.S. revised June 2006</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Clomipramine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clomipramine is metabolized by CYPs 3A4, 1A2 and 2C19 to desmethylclomipramine, an active metabolite which has a higher activity than the parent drug. In addition, clomipramine and desmethylclomipramine are metabolized by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Clonazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clonazepam is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Clonidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 70% of administered clonidine is excreted in the urine, mainly in form of the unchanged parent drug (40-60% of the dose). Clonidine is a weak inhibitor of OCT2 but is unlikely to affect stavudine which is eliminated by different renal transporters.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Clopidogrel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clopidogrel is a prodrug that is converted to its active metabolites via CYPs 3A4, 2B6, 2C19 and 1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Clorazepate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clorazepate is rapidly converted to nordiazepam which is then metabolized to oxazepam by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Cloxacillin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Cloxacillin is metabolised to a limited extent, and the unchanged drug and metabolites are excreted via renal glomerular filtration and tubular secretion. As total renal elimination is approximately 35% of a dose, there is little potential for significant interactions with stavudine via competition for renal transport. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Cloxacillin is metabolised to a limited extent, and the unchanged drug and metabolites are excreted in the urine by glomerular filtration and renal tubular secretion. About 35% of an oral dose is excreted in the urine and up to 10% in the bile. <br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete) last reviewed 03/11/11</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Clozapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clozapine is metabolized by CYPs 1A2, 2C19, 3A4, and to a lesser extent by CYPs 2C9 and 2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Cobicistat (with ATV or DRV)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Cocaine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cocaine is metabolized by several pathways (non CYP and CYP mediated), with metabolism to norcocaine by CYP3A4 being less than 10% of the overall metabolic clearance.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Codeine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Codeine undergoes predominantly direct glucuronidation with CYP3A4 mediated metabolism accounting for only 10-15% of the overall metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Colchicine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely as colchicine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Colecalciferol (Vitamin D3)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Metabolism of vitamin D to active metabolites occurs in the liver and kidneys, and is thought to involve CYP3A4 and CYP24A1. There is little potential for interaction with stavudine via modulation of, or competition for, metabolic pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Cubeb pepper (Piper cubeba)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Cyanocobalamin (Vitamin B12)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Cyclophosphamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cyclophosphamide is activated (major pathway) to 4-hydroxycyclophosphamide by CYPs 2B6 (major), 2C9 and 3A4. Inactivation (minor, 10%) to the neurotoxic chloroacetaldehyde metabolite is performed mainly by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Cycloserine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Cycloserine is predominantly excreted renally via glomerular filtration. There is therefore little potential for interaction via competition with stavudine for active renal transport mechanisms.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Cycloserine is excreted into the urine, levels appearing within half an hour of oral ingestion. Approximately 66 per cent of a dose appears unchanged in the urine in 24 hours. A further 10 per cent is excreted over the next 48 hours. It is not significantly excreted in the faeces. Approximately 35 per cent is metabolised, but the metabolites have not yet been identified.<br /><em>Cycloserine UK Summary of Product Characteristics, King Pharmaceuticals Ltd,&nbsp; updated November 2007</em></p>
<p>Cycloserine is excreted largely unchanged by glomerular filtration. About 50% of a single 250-mg dose is excreted unchanged in the urine within 12 hours and about 70% is excreted within 72 hours. <br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 20-August-2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Cyproterone acetate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cyproterone acetate is metabolized by CYP3A4.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Cytarabine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cytarabine is metabolized by cytidine deaminase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Dabigatran</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dabigatran is not metabolized by CYP450 isoenzymes and is mainly cleared by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Dacarbazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dacarbazine undergoes activation to MTIC primarily via CYP1A2 and to a lesser extent by CYP2E1, with CYP1A1 having a role in extrahepatic metabolism. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Daclatasvir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. No dose adjustment of daclatasvir or stavudine is required. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Dactinomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for pharmacokinetic interaction. There have been reports that dactinomycin may induce viral resistance to stavudine via a modification of cellular factors. The clinical relevance of this is unknown.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Actinomycin D (ActD) is a transcription inhibitor and has been used in the treatment of certain forms of cancer. ActD has been reported to be a potential inhibitor of human immunodeficiency virus type 1 (HIV-1) replication due to its ability to inhibit reverse transcription. In contrast to what was expected, low concentrations of ActD (1 to 10 nM) upregulated HIV-1 replication 8- to 10-fold in MT-2 cells and had no effect on HIV-2 replication or on HIV-1 replication in MT-4, Jurkat, or peripheral blood mononuclear cells. The upregulation of HIV-1 replication was associated with an increase in HIV-1 transcription and a decrease in CD4 and CXCR4 expression. To further evaluate the effects of ActD on emergence of drug resistance in HIV-1 replication, a series of drug resistance assays were performed. Of interest, treatment of MT-2 cells with ActD also led to a high level of resistance to thymidine analogs (&gt;1,000-fold increase in resistance to zidovudine and &gt;250-fold to stavudine) but not to other nucleoside reverse transcriptases (RT), nonnucleoside RT, or protease inhibitors. This resistance appeared to be due to a suppression of host cell thymidine kinase-1 (TK-1) expression. These results indicate that ActD leads to a novel form of thymidine analog resistance by suppressing host cell TK-1 expression. These results suggest that administration of combination drugs to HIV-1-infected patients may induce resistance to antiretroviral compounds via a modification of cellular factors.<br /><em>Actinomycin D induces high-level resistance to thymidine analogs in replication of human immunodeficiency virus type 1 by interfering with host cell thymidine kinase expression. Imamichi T, Murphy MA, Adelsberger JW et al. J Virol. 2003 Jan;77(2):1011-20.</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Dalteparin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but a clinically significant pharmacokinetic interaction is unlikely. Dalteparin is excreted largely unchanged by the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Dapsone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. However, coadministration of both drugs may increase the risk of peripheral neuropathy (additive toxicity).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Darifenacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Darifenacin is metabolized by CYP3A4 and CYP2D6.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Darunavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Based on the different elimination pathways (stavudine is primarily renally excreted), no significant interactions are expected with darunavir/ritonavir. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>This interaction has not been studied. Based on the different elimination pathways of the other NRTIs zidovudine, emtricitabine, stavudine, lamivudine, that are primarily renally excreted, and abacavir for which metabolism is not mediated by CYP450, no interactions are expected for these medicinal compounds and darunavir coadministered with low dose ritonavir. <br /><em>Prezista Summary of Product Characteristics, Janssen-Cilag Ltd, <em>June 2012</em>.</em></p>
<p>Based on the different elimination pathways of the NRTIs (zidovudine, zalcitabine, emtricitabine, stavudine, lamivudine and abacavir) that are primarily renally excreted, no drug interactions are expected for these drugs and darunavir/ritonavir. <br /><em>Prezista Prescribing Information, Tibotec Inc, June 2012.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Dasatinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely.  Dasatinib is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Daunorubicin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. A clinical study reported that antiretroviral regimens containing stavudine had no effect on the pharmacokinetics of liposomal daunorubicin.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Daunorubicin hydrochloride is mainly metabolized in the liver; each accompanying medication influencing liver function may also influence the metabolism or pharmacokinetics of daunorubicin hydrochloride and as a consequence influence efficacy and/or toxicity. Daunorubicin is rapidly taken up by tissues, especially by the kidneys, spleen, liver and heart. It does not cross the blood-brain barrier, subsequent release of drug and its metabolites from the tissues is slow (t&#189; = 55 hours). Daunorubicin is rapidly metabolised in the liver. The major metabolite daunorubicinol is also active. Daunorubicin is excreted slowly in the urine, mainly as metabolites with 25% excreted in the first 5 days. Biliary excretion also makes a significant (40%) contribution to elimination. <br /><em>Daunorubicin 20mg Powder for Injection UK Summary of Product Characteristics, Zentiva, updated March 2012</em></p>
<div>The plasma pharmacokinetics of DaunoXome(daunorubicin citrate liposome injection) differ significantly from the results reported for conventional daunorubicin hydrochloride. DaunoXome has a small steady-state volume of distribution of 6.4 L, (probably because it is confined to vascular fluid volume), and clearance of 17 mL/min. These differences in the volume of distribution and clearance result in a higher daunorubicin exposure (in terms of plasma AUC) from DaunoXome than with conventional daunorubicin hydrochloride. The apparent elimination half-life of DaunoXome is 4.4 hours, far shorter than that of daunorubicin, and probably represents a distribution half-life. Daunorubicinol, the major active metabolite of daunorubicin, was detected at low levels in the plasma following intravenous administration of DaunoXome.<br /><em>DaunoXome&#174; (daunorubicin citrate liposome injection) US Prescribing Information, Galen Limited, updated December 2011</em> 
<div>&nbsp;</div>
<div>A study investigated the pharmacokinetics of liposomal daunorubicin (DaunoXome) administered alone or in combination with antiviral therapy including protease inhibitors (PI) to HIV-positive patients affected by Kaposi's sarcoma (KS). Patients with extensive or rapidly progressing AIDS-related KS (n=18) received DaunoXome at a dose of 40mg/m2 alone or with triple combination therapy consisting of one PI plus two nucleoside reverse transcriptase inhibitors (stavudine, didanosine, lamivudine, or zidovudine). Daunorubicin pharmacokinetics were determined in a total of 23 cycles, 6 with DaunoXome alone, 9 in combination with indinavir, 6 with ritonavir and 2 with saquinavir. Plasma samples were obtained at different times during the 72 h after DaunoXome administration. Daunorubicin and daunorubicinol plasma levels were determined by high-performance liquid chromatography. There were no significant differences in the pharmacokinetic parameters of daunorubicin in patients receiving DaunoXome in combination with indinavir and ritonavir compared with those in patients not receiving PIs. Therefore in patients affected by AIDS-related KS treated with Highly Active AntiRetroviral Therapy (HAART) there is no pharmacokinetic justification for reducing the doses of DaunoXome<br /><em>The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma. Fumagalli L, Zucchetti M, Parisi I et al. Cancer Chemother Pharmacol. 2000;45(6):495-501.</em></div></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green outline">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Delavirdine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Not Available</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Not Available</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Denosumab</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Denosumab is not eliminated via hepatic metabolism but follows the immunoglobulin clearance pathway.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Desflurane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desflurane is almost exclusively eliminated unchanged by the lungs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Desipramine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as desipramine is metabolized by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Desogestrel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desogestrel is a prodrug which is activated to etonogestrel by CYP2C9 (and possible CYP2C19); the metabolism of etonogestrel is mediated by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Dexamethasone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dexamethasone is metabolized mainly in the liver but also in the kidney. Dexamethasone and its metabolites are excreted in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Dexmedetomidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dexmedetomidine undergoes extensive hepatic metabolism through direct glucuronidation (mainly via UGT1A4, 2B10) and cytochrome P450 (mainly CYP2A6). </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Dextropropoxyphene</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as dextropropoxyphene is mainly metabolized by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Diamorphine (diacetylmorphine)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diamorphine is rapidly metabolized by sequential deacetylation to morphine which is then mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Diazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diazepam is metabolized to nordiazepam (by CYP3A4 and 2C19) and to temazepam (mainly by CYP3A4). </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Diclofenac</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diclofenac is partly glucuronidated by UGT2B7 and partly oxidized by CYP2C9. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Didanosine (ddI)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No significant PK interaction observed. However, coadministration not recommended due to increased risk of peripheral neuropathy, pancreatitis and lactic acidosis. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Coadministration is not recommended. Fatal hepatic failure, as well as peripheral neuropathy, pancreatitis and symptomatic hyperlactatemia/lactic acidosis have been reported in patients receiving didanosine and ribavirin with or without stavudine. Pancreatitis (fatal and nonfatal) and peripheral neuropathy (severe in some cases) have been reported in HIV infected patients receiving didanosine in association with hydroxyurea and stavudine. Specific interaction studies have been conducted with stavudine without evidence of interaction. <br /><em>Videx Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, June 2009.</em></p>
<p>Patients treated with didanosine in combination with stavudine may be at increased risk for pancreatitis. Fatal lactic acidosis has been reported in pregnant women who received the combination of didanosine and stavudine with other antiretroviral agents. The combination of didanosine and stavudine should be used with caution during pregnancy and is recommended only if the potential benefit clearly outweighs the potential risk. Peripheral neuropathy has occurred more frequently in patients with advanced HIV disease, in patients with a history of neuropathy, or in patients being treated with neurotoxic drug therapy, including stavudine. Fatal hepatic events were reported most often in patients treated with the combination of hydroxyurea, didanosine, and stavudine. Patients treated with didanosine in combination with stavudine, with or without hydroxyurea, may be at increased risk for pancreatitis and hepatotoxicity, which may be fatal, and severe peripheral neuropathy. The combination of didanosine and hydroxyurea, with or without stavudine, should be avoided. When the buffered formulation of ddI (100 mg twice daily for 4 days) was coadministered with stavudine (40 mg twice daily for 4 days) to 10 HIV-negative subjects, there was no change in ddI AUC or Cmax. When the same doses were studied in 10 HIV-infected subjects, there was no change in stavudine AUC and a 17% increase in Cmax. <br /><em>Videx Prescribing Information, Bristol-Myers Squibb Company, November 2011.</em></p>
<p>Coadministration is not recommended. Pancreatitis (fatal and nonfatal) and peripheral neuropathy (severe in some cases) have been reported in HIV infected patients receiving stavudine in association with hydroxyurea and didanosine. Hepatotoxicity and hepatic failure resulting in death were reported during postmarketing surveillance in HIV infected patients treated with antiretroviral agents and hydroxyurea; fatal hepatic events were reported most often in patients treated with stavudine, hydroxyurea and didanosine. In vitro studies indicate that the activation of stavudine is inhibited by doxorubicin and ribavirin but not by other medicinal products used in HIV infection which are similarly phosphorylated, e.g. didanosine, zalcitabine, ganciclovir and foscarnet. <em>Zerit Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, March 2011.</em></p>
<p>Fatal and nonfatal pancreatitis have occurred during therapy when stavudine was part of a combination regimen that included didanosine in both treatment-naive and treatmentexperienced patients, regardless of degree of immunosuppression. The combination of stavudine and didanosine and any other agents that are toxic to the pancreas should be suspended in patients with suspected pancreatitis. Reinstitution of stavudine after a confirmed diagnosis of pancreatitis should be undertaken with particular caution and<br />close patient monitoring; avoid use in combination with didanosine. Patients treated with stavudine in combination with didanosine, with or without hydroxyurea, may be at increased risk for pancreatitis and hepatotoxicity, which may be fatal, and severe peripheral neuropathy. The combination of stavudine and hydroxyurea, with or without didanosine, should be avoided.. Coadministration of stavudine (40 mg twice daily for 4 days) and didanosine (100 mg twice daily for 4 days) was studied in 10 HIV-infected subjects. There was no change in stavudine AUC and a 17% increase in Cmax. Didanosine AUC and Cmax were unaltered. <br /><em>Zerit Prescribing Information, Bristol-Myers Squibb Company, January 2012.</em></p>
<p>The pharmacokinetics of single and coadministered doses of didanosine (100 mg) and stavudine (40 mg) were evaluated in 10 HIV-positive subjects. No significant changes in Cmax, AUC, elimination half life or renal clearance of didanosine and stavudine were observed when the drugs were administered simultaneously. Cmax and AUC values for didanosine (alone vs. combination) were 422&#177;184 vs. 419&#177;153 mg/ml and 615&#177;170 vs. 637&#177;155 ng/ml.h, respectively. Cmax and AUC values obtained for stavudine were 603&#177;160 vs. 726&#177;188 and 1246&#177;230 vs. 1326&#177;267 ng/ml.h, respectively. <br /><em>Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients. Seifert RD, et al. Br J Clin Pharmacol, 1994, 38: 405-410. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Diethylcarbamazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on limited data concerning the metabolism/elimination and toxicity profile of diethylcarbamazine, there is little potential for interaction with stavudine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Diethylcarbamazine is readily absorbed from the gastrointestinal tract and also through the skin and conjunctiva. It is widely distributed in tissues and is mainly excreted in the urine unchanged and as the N-oxide metabolite. Urinary excretion and hence plasma half-life is dependent on urinary pH. About 5% of a dose is eliminated in the faeces. Results in patients with chronic renal impairment and in healthy subjects, given a single 50-mg oral dose of diethylcarbamazine citrate, indicated that the plasma half-life of diethylcarbamazine is prolonged and its 24-hour urinary excretion considerably reduced in those with moderate and severe degrees of renal impairment<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification 14-May-2011</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Digoxin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Digoxin is eliminated unchanged in the kidney via the renal transporters OATP4C1 and P-gp, whereas stavudine is excreted by different renal transporters.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Dihydrocodeine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dihydrocodeine undergoes predominantly direct glucuronidation, with CYP3A4 mediated metabolism accounting for only 5-10% of the overall metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Dihydroergotamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as dihydroergotamine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Diloxanide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Diloxanide furoate is largely hydrolysed under the combined action of bacterial and gut esterases and consequently glucuronidated. No clinically-significant drug interactions are known, and significant interactions with antiretrovirals are unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>In the gut, diloxanide furoate is largely, if not wholly, hydrolysed into diloxanide and furoic acid under the combined action of bacterial and gut esterases. After absorption, diloxanide is very rapidly conjugated to form a glucuronide. In circulating blood, it is present to about 99% as a glucuronide and 1% as free diloxanide. Diloxanide is predominantly excreted in the urine. It is believed that the unabsorbed diloxanide is the active anti-amoebic substance, up to 10% remaining in the gut which is subsequently excreted as diloxanide in the faeces. No clinically-significant drug interactions are known<br /><em>Diloxanide Tablets 500mg UK Summary of Product Characteristics, Sovereign Medical, updated September 2007</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Diltiazem</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as diltiazem is metabolized by CYP3A4 and CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Diphenhydramine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Diphenhydramine is mainly metabolized by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Dipyridamole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dipyridamole is glucuronidated by many UGTs, specifically those of the UGT1A subfamily.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Disopyramide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Disopyramide is metabolized by CYP3A4 (25%) and 50% of the drug is eliminated unchanged in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Disulfiram</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Disulfiram is reduced to diethyldithiocarbamic acid, is conjugated with glucuronic acid, oxidised to sulphate, methylated and decomposed to diethylamine and carbon disulphide.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Docetaxel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a pharmacokinetic interaction is unlikely. However, coadministration of both drugs may increase the risk of peripheral neurotoxicity due to additive toxicity.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Dolasetron</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Dolasetron is converted by carbonyl reductase to its active metabolite, hydrodolasetron, which is mainly glucuronidated (60%) and metabolized by CYP2D6 (10-20%) and CYP3A4 (<1%). </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Dolutegravir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Domperidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as domperidone is mainly metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Dopamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Renal elimination of unchanged dopamine is minimal. There is therefore little potential for interaction with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Orally administered dopamine is rapidly metabolised in the G.I. tract. Following IV administration, the onset of action of dopamine occurs within 5 minutes, and the drug has a duration of action of less than 10 minutes. Dopamine is metabolised in the liver, kidneys, and plasma by monoamine oxidase (MAO) and catechol-0-methyltransferase to the inactive compounds homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid. About 25% of a dose of dopamine is metabolised to norepinephrine within the adrenergic nerve terminals. Dopamine is excreted in urine principally as HVA and its sulphate and glucuroide conjugates and as 3,4-dihydroxyphenylacetic acid. A very small fraction of a dose is excreted unchanged. <br /><em>Dopamine 40 mg/ml Sterile Concentrate UK Summary of Product Characteristics, Hospira UK Ltd, updated August 2010</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Doxazosin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as doxazosin is metabolized mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Doxepin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxepin is metabolized mainly by CYP2C19 to nordoxepin, an active metabolite. In addition, doxepin and nordoxepin are metabolized by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Doxorubicin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Potential interaction that may inhibit the activation of stavudine. Concomitant use should be undertaken with caution. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>In vitro studies indicate that the activation of stavudine is inhibited by doxorubicin and ribavirin. Therefore coadministration of stavudine with either doxorubicin or ribavirin should be undertaken with caution. <br /><em>Zerit Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, March 2011.</em></p>
<p>In vitro data indicate that the phosphorylation of stavudine is inhibited at clinically relevant concentrations by doxorubicin. The clinical significance of this in vitro interaction is unknown; therefore, concomitant use of stavudine should be undertaken with caution. <br /><em>Zerit Prescribing Information, Bristol-Myers Squibb Company, January 2012.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Doxycycline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Doxycycline is excreted in the urine and faeces as unchanged active substance. Between 40%- 60% of an administered dose can be accounted for in the urine. Studies have indicated that administration of doxycycline at the usual recommended doses does not lead to excessive accumulation in patients with renal impairment. There is therefore little potential for a clinically significant interaction with stavudine via completion for renal elimination transport mechanisms.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Doxycycline is almost completely absorbed and is not subject to presystemic metabolism, the mean bioavailability being approximately 93%. No significant metabolism occurs and Doxycycline is cleared intact by renal and biliary mechanisms. Studies to date have indicated that administration of doxycycline at the usual recommended doses does not lead to excessive accumulation of the antibiotic in patients with renal impairment.<br /><em>Doxycycline Capsules BP 100mg, UK Summary of Product Characteristics, Actavis UK Ltd, updated June 2011</em></p>
<p>Doxycycline is excreted in the urine and faeces as unchanged active substance. Between 40% and 60% of an administered dose can be accounted for in the urine by 92 hours, and approximately 30% in the faeces. <br /><em>Efracea&#174; 40mg Modified Release Hard Capsules, Summary of Product Characteristics, Galderma (U.K) Ltd, updated November 2011</em></p>
<p>The pharmacokinetics as well as erythrocyte and plasma protein binding of doxycycline were studied in fifteen patients with various renal function impairments after oral doxycycline polyphosphate single administration. Plasma half-life (t 1/2), area under the plasma concentration-time curve (AUC), urinary excretion, renal clearance, erythrocyte and plasma protein binding (%) were regressed vs creatinine clearance. No significant correlations were observed between t 1/2 or AUC and renal function nor plasma protein binding and plasma albumin concentrations. Significant correlations were obtained between urinary excretion, renal clearance, erythrocyte binding, plasma protein binding and creatinine clearance. Constancy of overall elimination parameters in renal failure is due to parallel increase in plasma free fraction of doxycycline.<br /><em>The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man. Houin G, Brunner F, Nebout T, Cherfaoui M, Lagrue G, Tillement JP. Br J Clin Pharmacol. 1983 Sep;16(3):245-52.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Droloxifene</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as droloxifene is mainly glucuronidated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Dronabinol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dronabinol is mainly metabolized by CYP2C9 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Drospirenone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Duloxetine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Dutasteride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as dutasteride is mainly metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Dydrogesterone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Echinacea</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Edoxaban</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Edoxaban is minimally metabolised by hydrolysis (mediated by carboxylesterase 1), conjugation, or oxidation by CYP3A4/5 (&lt;10%). Edoxaban is eliminated primarily as unchanged drug in urine.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Efavirenz</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Specific interaction studies have not been performed. Clinically significant interactions would not be expected with stavudine since the NRTIs are metabolised via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Specific interaction studies have not been performed with efavirenz and NRTIs other than lamivudine, zidovudine, and tenofovir disoproxil fumarate. Clinically significant interactions are not expected since the NRTIs are metabolised via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways. No dosage adjustment is necessary for either medicinal product. <br /><em>Sustiva Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, April 2015.<br />Sustiva Prescribing Information, Bristol-Myers Squibb Company, March 2015.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Eflornithine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Approximately 80% of oral/intravenous doses of eflornithine are excreted unchanged via the kidneys. As there are no available data determining whether excretion is via active tubular secretion or glomerular filtration, there is potential for competition with stavudine for active renal transport mechanisms, which may lead to increased levels of either drug. As <1% of topically applied eflornithine is systemically absorbed, clinically significant interactions are not expected with topical preparations.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>After intravenous doses about 80% is excreted unchanged in the urine in 24 hours. The terminal elimination half-life is about 3 hours. It is distributed to the CSF. <br />Less than 1% of a dose is absorbed after topical application. <br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 23-Sep-2011</em></p>
<div>Eflornithine was administered to six healthy men in single intravenous doses of 5 and 10 mg/kg and oral doses of 10 and 20 mg/kg. Peak plasma concentrations were reached within 6 hr after oral doses. The decay of the plasma concentrations followed first-order kinetics with a mean half-life (t 1/2) for all four doses studied of 199 +/- 6 min (+/- SD). Mean renal clearance was determined as 0.99 +/- 0.03 ml . min-1 . kg-1, accounting for 83% of drug elimination. Mean apparent volume of distribution (aVD) was 0.337 +/- 0.031 l/kg-1, corresponding to 24 l for 70 kg of body weight. The amount of unchanged drug in 24-hr urine samples was 47 +/- 7% and 40 +/- 11% after 10 and 20 mg/kg orally, and 78% and 81 +/- 8% after 5 and 10 mg/kg intravenously. Twenty-four-hour urinary recovery of unchanged drug was 46.9% of the 10mg/kg and 40.3% of the 20 mg/kg oral doses. &gt;86% of the oral doses were cleared from the body by renal filtration. In the case of intravenous dosing, 81% of the drug was eliminated by the kidneys. <br /><em>Kinetics of alpha-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase. Haegele KD, Alken RG, Grove J et al. Clin Pharmacol Ther. 1981 Aug;30(2):210-7.</em> 
<div>&nbsp;</div>
<div>Since stavudine is actively secreted by the renal tubules, interactions with other actively secreted medicinal products are possible, e.g. with trimethoprim.<br /><em>Zerit&#174; (stavudine) Hard Capsules UK Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceutical Ltd, updated April 2011</em></div></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Elbasvir/Grazoprevir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as stavudine is predominantly eliminated unchanged via the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Eltrombopag </p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Eltrombopag is metabolised by cleavage conjugation (UGTs 1A1 and 1A3) and oxidation (CYPs 1A2 and 2C8).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Elvitegravir/Cobi/FTC/TAF</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div><div><div>Genvoya should not be co-administered with other antiretroviral medicinal products. <br /><em>Genvoya Summary of Product Characteristics, Gilead Sciences International Ltd, November 2015.</em></div><br /></div><div>Genvoya  is a complete regimen for the treatment of HIV-1 infection;  therefore,  coadministration of Genvoya with other antiretroviral  medications for  treatment of HIV-1 infection should be avoided.</div><div><em>Genvoya US Prescribing Information, Gilead Sciences Inc, November 2015.</em></div></div><em></em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Elvitegravir/Cobi/FTC/TDF</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Stribild is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div> <div>Stribild is indicated for use as a complete regimen for the  treatment of HIV 1 infection and must not be administered with other  antiretroviral products.<br /><em>Stribild Summary of Product Characteristics, Gilead Sciences<br />International Ltd, May 2015.</em><br /><br /></div><div>Stribild  is a complete regimen for the treatment of HIV-1 infection; therefore,  Stribild should not be administered with other antiretroviral  medications for treatment of HIV-1 infection.</div><div><em>Stribild Prescribing Information, Gilead Sciences Inc, July 2015.</em></div><div>&nbsp;</div><div>Healthy  volunteers (n=32) were administered a single dose of stavudine (40 mg)  and elvitegravir/ritonavir (200/100 mg once daily) alone and in  combination. Elvitegravir/ritonavir did not have significant effects on  the kinetics of stavudine (no change in Cmax, 7% increase in AUC).  Elvitegravir AUC and Cmax decreased by 1% and 4%, with Cmin increasing  by 24%.</div><div><em>Pharmacokinetics of coadministered  ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or  abacavir. Ramanathan S, Shen G, Hinkle J, et al. J Acquir Immune Defic  Syndr, 2007, 46(2):160-6.</em></div> </div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Empagliflozin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Empagliflozin is mainly glucuronidated by UGTs 1A3, 1A8, 1A9 and 2B7. It is a substrate of P-gp and BCRP, and also a substrate of the renal transporter OAT3 and the hepatic transporters OATP1B1 and OATP1B3.&nbsp;</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Emtricitabine (FTC)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No significant interaction. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>There are no clinically significant interactions when emtricitabine is co-administered with indinavir, zidovudine, stavudine, famciclovir or tenofovir disoproxil fumarate. <br /><em>Emtriva Summary of Product Characteristics, Gilead Sciences International Limited, July 2011.</em></p>
<p>No significant interactions were observed between emtricitabine and stavudine. Coadministration of emtricitabine (200 mg single dose) and stavudine (40 mg single dose) was studied in 6 HIV-negative subjects. There was no change in the AUC or Cmax values for emtricitabine or stavudine. <br /><em>Emtriva Prescribing Information, Gilead Sciences Inc, November 2011.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Emtricitabine/TAF</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Enalapril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.  Enalapril is hydrolysed to enalaprilat which is eliminated renally, possibly via OATs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Enflurane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as enflurane is predominantly metabolized by CYP2E1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green outline">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Enfuvirtide (T20)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Not Available</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Not Available</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Enoxaparin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enoxaparin does not undergo cytochrome metabolism but is desulphated and depolymerised in the liver, and is excreted predominantly renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Entecavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Entecavir is eliminated renally via glomerular filtration and active renal secretion by both organic anion and cation transporters.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ephedrine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Ephedrine is predominantly excreted unchanged via renal pathways. There are no clear data to suggest whether elimination of ephedrine occurs via active renal transport or glomerular filtration, therefore competition for active renal elimination pathways with stavudine can not be ruled out. As levels of either drug may potentially be increased, monitoring for adverse events and renal function may be warranted. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Ephedrine is rapidly and completely absorbed after oral administration and extensively distributed throughout the body with accumulation in the liver, lungs, kidneys, spleen and brain. The plasma half-life is reported to be between 3-11 hours, with up to 95% being excreted in the urine.<br /><em>Ephedrine Hydrochloride Tablets UK Summary of Product Characteristics, Wockhardt UK Ltd, updated November 2008</em></p>
<div>A pharmacokinetic model was developed based on the simultaneous modelling using plasma samples gathered from two clinical trials. Treatments consisted of single-doses of pharmaceutical caffeine and ephedrine, given alone or together, and an herbal formulation containing both caffeine and ephedrine. A mixed-effect statistical model and the program NONMEM was used to take account of intersubject variability. Three hundred and seventy-nine ephedrine, 352 norephedrine, 417 caffeine plasma concentrations and 40 ephedrine urine concentrations were obtained from 24 subjects. Ephedrine is mostly excreted unchanged in the urine, but is also metabolized to norephedrine to a small and variable extent, involving enzymatic N-demethylation and oxidative deaminiation of the side chain. The variance in Km was relatively large, indicating substantial variation in the extent of metabolism of ephedrine to norephedrine. This pathway, however, is minor compared with the renal elimination of ephedrine and, even after repeated drug intake, significant drug accumulation would not be expected. Although a saturable metabolism of ephedrine to norephedrine was observed, this was thought to represent a minor path of ephedrine elimination.<br /><em>Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. Csajka C, Haller CA, Benowitz NL, Verotta D. Br J Clin Pharmacol. 2005 Mar;59(3):335-45.</em></div>
<div>&nbsp;</div>
<div>Since stavudine is actively secreted by the renal tubules, interactions with other actively secreted medicinal products are possible, e.g. with trimethoprim.<br /><em>Zerit&#174; (stavudine) Hard Capsules UK Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceutical Ltd, updated April 2011</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Epirubicin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as epirubicin is glucuronidated by UGT2B7.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Eprosartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as eprosartan is largely excreted in bile and urine as unchanged drug.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ergometrine (Ergonovine)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Ergometrine is extensively metabolized, most likely by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ergotamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Ergotamine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Erlotinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Erlotinib is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ertapenem</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied significant drug interaction is unlikely. Ertapenem is mainly eliminated through the kidneys by glomerular filtration with tubular secretion playing a minor role.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Erythromycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Erythromycin is extensively metabolized in the liver.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Escitalopram</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Esomeprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as esomeprazole is mainly metabolized by CYP2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Estazolam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Estazolam is metabolized to its major metabolite 4-hydroxyestazolam via CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Estradiol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as estradiol is metabolized by CYP1A2 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Estramustine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Estramustine phosphate undergoes rapid dephosphorylation to estramustine which is then oxidized by 17beta-hydroxysteroid dehydrogenases to estromustine. Estramustine and estromustine are subsequently hydrolyzed to estradiol and estrone, respectively. Estradiol is then hydroxylated by CYPs 1A1, 1A2 and 3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ethambutol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethambutol is partly metabolized by alcohol dehydrogenase (20%) and partly eliminated unchanged in the faeces (20%) and in the urine (50%).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ethinylestradiol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethinylestradiol is mainly metabolized by hydroxylation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ethionamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Less than 1% of the oral dose is excreted as ethionamide in urine, there is therefore little potential for interaction with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Ethionamide is extensively metabolized to active and inactive metabolites. Metabolism is presumed to occur in the liver and 6 metabolites have been isolated: 2-ethylisonicotinamide, carbonyl-dihydropyridine, thiocarbonyl-dihydropyridine, S-oxocarbamoyl dihydropyridine, 2-ethylthioiso-nicotinamide, and ethionamide sulphoxide. The sulphoxide metabolite has been demonstrated to have antimicrobial activity against Mycobacterium tuberculosis. Less than 1% of the oral dose is excreted as ethionamide in urine.<br /><em>Trecator&#174; US Prescribing Information, Wyeth Pharmaceuticals Inc. (now Pfizer) revised November 2007</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ethosuximide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as ethosuximide is mainly oxidized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Etonogestrel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etonogestrel undergoes hepatic metabolism by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Etoposide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etoposide is partly glucuronidated by UGT1A1 and partly metabolized by CYP3A4 to reactive catechol metabolites. Conversion to reactive metabolites can also be mediated by prostaglandin synthase or myeloperoxidase. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Etravirine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but no interaction is expected. Etravirine can be used without dose adjustment. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Coadministration has not been studied, but no interaction is expected based on the primary renal elimination route for abacavir, emtricitabine, lamivudine, stavudine and zidovudine. Etravirine can be used with these NRTIs without dose adjustment. <br /><em>Intelence Summary of Product Characteristics, Janssen-Cilag Ltd, March 2012.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Eucalpytus globulus</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. There is no evidence to suggest that eucalyptus impacts UGTs or P-gp.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Everolimus</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely.  Everolimus is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Exemestane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Exemestane is metabolized by CYP3A4 and aldoketoreductase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Exenatide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as exenatide is primarily eliminated by glomerular filtration. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ezetimibe</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ezetimibe is glucuronidated by UGTs 1A1 and 1A3 and to a lesser extent by UGTs 2B15 and 2B7.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Famciclovir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Famciclovir is converted to penciclovir by aldehyde oxidase. Penciclovir is secreted in the urine possibly by OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Famotidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Famotidine is eliminated by renal excretion via OAT3 (65-70%) and by metabolic routes (30-35%).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Felodipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as felodipine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Fenofibrate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fenofibrate is metabolised to an active metabolite, fenofibric acid: in vitro data suggest that fenofibric acid inhibits OAT3. A clinically relevant drug interaction is unlikely as stavudine is excreted via OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Fentanyl</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fentanyl undergoes extensive CYP3A4 metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Fesoterodine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fesoterodine is rapidly hydrolysed to its active metabolite which is subsequently metabolized by CYP2D6 and CYP3A4.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Fexofenadine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fexofenadine undergoes negligible metabolism and is mainly eliminated unchanged in the faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Finasteride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Finasteride is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Fish oils</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Flecainide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flecainide is metabolized mainly via CYP2D6, with a proportion (approximately 30%) of the parent drug also eliminated unchanged renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Flibanserin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flibanserin is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Flucloxacillin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flucloxacillin is mainly eliminated renally partly by glomerular filtration and partly by active secretion via OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Fluconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No clinically significant interaction observed. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>The pharmacokinetics of stavudine were determined in 10 HIV-infected subjects following administration of stavudine (40 mg twice daily) alone and with single, double or triple combinations of clarithromycin (500 mg twice daily), fluconazole (200 mg once daily) and/or rifabutin (300 mg once daily). Stavudine exposure was not significantly altered by multiple concomitant medications. The greatest difference in AUC between stavudine administered alone or with any other regimen was an 18% decrease when given with the rifabutin/clarithromycin combination. <br /><em>A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus-infected patients. Piscitelli SC, et al. Antimicrob Agents Chemother, 1999, 43: 647-650. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Flucytosine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Flucytosine is metabolised to 5-flurouracil which is further metabolised by dihydropyrimidine dehydrogenase. This enzyme is also involved in the catabolic pathway of pyrimidine analogs and competition could potentially increase haematological toxicity. Monitor haematological parameters and consider dose reduction if required.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Fludarabine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Fludarabine phosphate is rapidly hydrolyzed (non-CYP mediated) to 2F-ara-A, the principal metabolite, which is then eliminated renally. However, use with caution due to the risk of peripheral neuropathy associated with both drugs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Fludrocortisone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fludrocortisone is metabolized in the liver to inactive metabolites, possibly via CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Flunitrazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunitrazepam is metabolized mainly via CYP3A4 and CYP2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Fluocinolone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely with the topical use of fluocinolone.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Fluorouracil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Dihydropyrimidine dehydrogenase plays a role in fluorouracil metabolism. Nucleoside analogues such as stavudine may compete for or inhibit this metabolism pathway, leading to increased fluorouracil toxicity. The clinical relevance of this interaction is unknown, however clinical monitoring is necessary.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>A clinically significant interaction between the antiviral sorivudine and fluorouracil prodrugs, resulting from inhibition of dihydropyrimidine dehydrogenase by sorivudine or chemically related analogues. Caution should be taken when using fluorouracil in conjunction with medications which may affect dihydropyrimidine dehydrogenase activity.<br /><em>Fluorouracil 50 mg/ml Injection UK Summary of Product Characteristics, Hospira UK Ltd, updated August 2011</em></p>
<p>The disposition and metabolic fate of 3'-deoxy-2',3'-didehydrothymidine (D4T) were evaluated both in isolated hepatocytes and in nonhuman primates. Rapid formation of thymine and beta-aminoisobutyric acid (BAIBA) occurred following incubation of hepatocytes with 10 microM [5(-3)H]D4T. Substantial levels of tritiated water were also detected. Exposure of cells to D4T in the presence of either 1 mM thymine or 10 microM benzyloxybenzyluracil, an inhibitor of dihydropyrimidine dehydrogenase, decreased intracellular BAIBA levels by approximately 89 and 63%, respectively. Concurrently, [3H]thymine levels increased two- to fivefold. These results are consistent with D4T being cleaved to thymine, which is then degraded to BAIBA. A similar metabolic disposition was observed in monkeys following administration of 25 mg of [5(-3)H]D4T per kg of body weight. Approximately 50% of the administered dose was recovered in urine within 24 h, with the majority of the radioactivity representing unchanged drug. <br /><em>Cretton EM, Zhou Z, Kidd LB, In vitro and in vivo disposition and metabolism of 3'-deoxy-2',3'-didehydrothymidine. Antimicrob Agents Chemother. 1993 Sep;37(9):1816-25</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Fluoxetine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluoxetine is metabolized by CYPs 2D6 and 2C9 and to a lesser extent by 2C19 and 3A4 to form norfluoxetine. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Fluphenazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Fluphenazine is predominantly metabolised via CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Fluphenazine is metabolised by P450 2D6 and is itself an inhibitor of this drug metabolising enzyme. The plasma concentrations and the effects of fluphenazine may therefore be increased and prolonged by drugs that are either the substrates or inhibitors of this P450 isoform, possibly resulting in severe hypotension, cardiac arrhythmias or CNS side effects.<br /><em>Modecate&#174; (fluphenazine) Concentrate Injection 100mg/ml UK Summary of product Characteristics, sanofi-aventis, updated December 2011</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Flurazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as the metabolism of flurazepam is most likely CYP-mediated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Fluticasone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as fluticasone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Fluvastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as fluvastatin is metabolised mainly by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Fluvoxamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Folic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Folic acid is metabolized to dihydrofolic acid and tetrahydrofolic acid with the aid of reduced diphosphopyridine nucleotide and folate reductases.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Fondaparinux</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fondaparinux does not undergo cytochrome metabolism but is eliminated predominantly renally.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Formestane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Formestane undergoes reductive metabolism by hepatic hydroxysteroid dehydrogenase and glucuronidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Formoterol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Formoterol is eliminated primarily by direct glucuronidation, with O-demethylation (by CYPs 2D6, 2C19, 2C9, and 2A6) followed by further glucuronidation being another pathway. As multiple CYP450 and UGT enzymes catalyze the transformation the potential for a pharmacokinetic interaction is low.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green outline">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Fosamprenavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Not Available</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Not Available</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Foscarnet</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No interaction observed in vitro. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>In vitro studies indicate that the activation of stavudine is inhibited by doxorubicin and ribavirin but not by other medicinal products used in HIV infection which are similarly phosphorylated, e.g. didanosine, zalcitabine, ganciclovir and foscarnet. <br /><em>Zerit Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, March 2011.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Furosemide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Furosemide is glucuronidated mainly in the kidney (UGT1A9) and to a lesser extent in the liver (UGT1A1). A large proportion of furosemide is also eliminated unchanged renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Gabapentin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant interaction is unlikely as gabapentin is cleared mainly by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Gamma-hydroxybutyrate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant interaction is unlikely. Gamma-hydroxybutyrate undergoes first pass metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ganciclovir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No significant interaction observed. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>In vitro studies indicate that the activation of stavudine is inhibited by doxorubicin and ribavirin but not by other medicinal products used in HIV infection which are similarly phosphorylated, e.g. didanosine, zalcitabine, ganciclovir and foscarnet. <br /><em>Zerit Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, March 2011.</em></p>
<p>Coadministration of ganciclovir (1000 mg three times daily) and stavudine (40 mg twice daily) was studied in 11 HIV-infected subjects. There was considerable interindividual variation in ganciclovir pharmacokinetics, but there were no statistically significant differences between pharmacokinetic parameters for ganciclovir when administered alone or in combination. The 19% increase in ganciclovir renal clearance in the presence of stavudine was not statistically significant. Ganciclovir had no statistically significant effects on the pharmacokinetics of stavudine. <br /><em>The pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV- and CMV-seropositive patients. Jung D, et al. J Clin Pharmacol, 1999, 39:505-512. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Garlic</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although garlic has been shown to induce intestinal CYP3A4 and/or P-gp, this is not expected to impact stavudine exposure.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Gefitinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely.  Gefitinib is metabolized by CYP3A4 and 2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Gemcitabine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gemcitabine is metabolized in the liver by cytidine deaminase to an inactive metabolite.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Gemfibrozil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as gemfibrozil is metabolised mainly by UGT2B7.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Gentamicin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Gentamicin is excreted unchanged via renal glomerular filtration. As little active renal secretion is thought to occur, there is low potential for interaction with stavudine via competition for active renal elimination mechanisms.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Gentamicin is not metabolized in the body but is excreted unchanged in microbiologically active form predominantly via the kidneys.<br /><em>Gentamicin 40 mg/ml Injection Summary of Product Characteristics, Hospira UK Ltd, updated August 2011</em></p>
<p>Little, if any, metabolic transformation occurs; the drug is excreted principally by glomerular filtration.&nbsp; After several days of treatment, the amount of gentamicin excreted in the urine approaches, but does not equal, the daily dose administered.&nbsp; As with other aminoglycosides, a small amount of the gentamicin dose may be retained in the tissues, especially in the kidneys.&nbsp; Minute quantities of aminoglycosides have been detected in the urine of some patients weeks after drug administration was discontinued.&nbsp; Renal clearance of gentamicin is similar to that of endogenous creatinine. Probenecid does not affect renal tubular transport of gentamicin.<br /><em>Gentamicin Injection USP, US Prescribing Information, APP Pharmaceuticals, revised August 2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Gestodene</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely as gestodene is metabolized by CYP3A4 and to a lesser extent by CYP2C9 and CYP2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ginger (Zingiber officinale)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely.&nbsp;</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ginkgo biloba</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Glibenclamide (Glyburide)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glibenclamide is mainly metabolized by CYP3A4 and to a lesser extent by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Gliclazide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as gliclazide is metabolised by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Glimepiride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as glimepiride is metabolised by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Glipizide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as glipizide is mainly metabolized by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Goldenseal root (Hydrastis canadensis)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.&nbsp;</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See&nbsp;Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Goserelin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Goserelin is mainly hydrolyzed.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Granisetron</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as granisetron is metabolized by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Grapefruit juice</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although grapefruit juice inhibits CYP3A4, this is not expected to alter exposure of stavudine as its metabolism is not CYP-mediated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Griseofulvin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied.  Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Less than 1% of a griseofulvin dose is excreted unchanged via the kidneys. There is therefore little potential for competition with stavudine for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Griseofulvin undergoes metabolism to inactive metabolites, principally 6-desmethylgriseofulvin or its glucuronide conjugate, the majority of which are excreted in the urine, with less than 1% of the administered dose being excreted as unchanged drug. The remainder of the dose, principally as metabolites, is excreted in bile and faeces. <br /><em>Griseofulvin 500mg Tablets Summary of Product Characteristics, Morningside Healthcare Ltd, May 2010.</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Halofantrine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Halofantrine is extensively metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Haloperidol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Haloperidol undergoes glucuronidation (UGT2B7>1A4, 1A9), carbonyl reduction as well as oxidative metabolism (CYP3A4, 2D6).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Halothane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Halothane undergoes both oxidative and reductive metabolism by cytochromes. In vitro data have shown that oxidation occurs mainly via CYP2E1 and to a lesser extent CYP2A6 and reduction via CYP2A6 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Heparin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Heparin does not undergo elimination via renal tubular secretion, therefore there is little potential for interaction with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>After intravenous or subcutaneous injection heparin is extensively bound to plasma proteins. The half-life of heparin depends on its dose and route as well as the method of calculation and is subject to wide inter- and intra-individual variation; a range of 1 to 6 hours with an average of 1.5 hours has been cited. It may be slightly prolonged in renal impairment, decreased in patients with pulmonary embolism, and either increased or decreased in patients with liver disorders. Heparin is taken up by the reticuloendothelial system. It is excreted in the urine, mainly as metabolites, although after large doses up to 50% may be excreted unchanged.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), last reviewed 2011-11-15</em></p>
<p>Heparin is not eliminated enzymatically nor by glomerular filtration or renal tubular secretion. In all likelihood, the anticoagulant is transferred to reticuloendothelial cells, which may also provide the means for its degradation.<br /><em>Estes JW. Clinical pharmacokinetics of heparin. Clin Pharmacokinet 1980; 5: 204&#8211;20.</em></p>
<p>After either subcutaneous or intravenous injection heparin is distributed primarily within the intravascular space. A short distribution phase is seen which is thought to correspond to endothelial cell binding and internalisation. The disposition curve for unfractionated heparin has a unique concave-convex shape which is the result of combined saturable and nonsaturable elimination mechanisms. The nonsaturable elimination mechanism is renal and is the primary route of elimination for low molecular weight heparins.<br /><em>Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1992; 22: 359&#8211;74.</em></p> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Heroin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically relevant drug interaction is unlikely. When used illicitly, heroin is mainly injected or inhaled through the nose and goes directly in the bloodstream. Heroin is then rapidly deacetylated to 6-monoacetylmorhine (6-MAM) and subsequently to morphine by plasma and liver esterase, respectively. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Stavudine does not affect these metabolic pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Hops (Humulus lupulus)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro data indicate that extracts of hops activate PXR and thereby induce the expression of CYP3A4, CYP2B6 and MDR1. However, this is not expected to alter exposure of stavudine as its metabolism is not CYP-mediated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Hydralazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Hydralazine is metabolised via primary oxidative metabolism and acetylation. Renal elimination of unchanged hydralazine is minimal, therefore there is little potential for interaction with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Hydralazine is rapidly absorbed from the gastrointestinal tract and peak plasma concentrations have been reported to occur in the plasma after about one hour. It is metabolised by hydroxylation of the ring system and conjugation with glucuronic acid, and by N-acetylation.<br /><em>Hydralazine Tablets BP 50mg UK Summary of Product Characteristics, Actavis UK Ltd, updated April 2011</em></p>
<p>Hydralazine is rapidly absorbed after oral administration, and peak plasma levels are reached at 1 to 2 hours. Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours. Binding to human plasma protein is 87%. Plasma levels of hydralazine vary widely among individuals. Hydralazine is subject to polymorphic acetylation; slow acetylators generally have higher plasma levels of hydralazine and require lower doses to maintain control of blood pressure. Hydralazine undergoes extensive hepatic metabolism; it is excreted mainly in the form of metabolites in the urine.<br /><em>Hydralazine hydrochloride tablets USP US Prescribing Information, TEVA Pharmaceuticals USA, updated March 2012</em></p>
<p>Pharmacokinetic data indicate hydralazine is absorbed well from the gastrointestinal tract, and has an extensive and complex metabolism depending on acetylator status: slow acetylators undergo primary oxidative metabolism, while rapid acetylators are acetylated.<br /><em>Mulrow JP, Crawford MH. Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure. Clin Pharmacokinet. 1989 Feb;16(2):86-9</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Hydrochlorothiazide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Hydrochlorothiazide is not metabolised and is cleared by the kidneys via OAT1. In vitro data indicate that hydrochlorothiazide is unlikely to inhibit OAT1 in the range of clinically relevant drug concentrations and therefore is unlikely to affect the renal elimination of stavudine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Hydrocodone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Hydrocodone is metabolised by CYP2D6 to hydromorphone and by CYP3A4 to norhydrocodone, both of which have analgesic effects.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Hydrocortisone (oral)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrocortisone is metabolized by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Hydrocortisone (topical)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but no clinically relevant drug interactions are expected with the topical use of hydrocortisone.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Hydromorphone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Hydromorphone is eliminated via glucuronidation, mainly by UGT2B7. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Hydroxyurea (Hydroxycarbamide)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration not recommended due to increased risk of hepatotoxicity, peripheral neuropathy and pancreatitis. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Coadministration is not recommended. Pancreatitis (fatal and nonfatal) and peripheral neuropathy (severe in some cases) have been reported in HIV infected patients receiving stavudine in association with hydroxyurea and didanosine. Hepatotoxicity and hepatic failure resulting in death were reported during postmarketing surveillance in HIV infected patients treated with antiretroviral agents and hydroxyurea; fatal hepatic events were reported most often in patients treated with stavudine, hydroxyurea and didanosine. Hence, hydroxyurea should not be used in the treatment of HIV infection. <br /><em>Zerit Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, March 2011.</em></p>
<div>Hepatotoxicity and hepatic failure resulting in death were reported during postmarketing surveillance in HIV-infected patients treated with hydroxyurea and other antiretroviralagents. Fatal hepatic events were reported most often in patients treated with the combination of hydroxyurea, didanosine, and stavudine. Patients treated with stavudine in combination with didanosine, with or without hydroxyurea, may be at increased risk for pancreatitis and hepatotoxicity, which may be fatal, and severe peripheral neuropathy. The combination of stavudine and hydroxyurea, with or without didanosine, should be avoided.<br /><em>Zerit Prescribing Information, Bristol-Myers Squibb Company, January 2012.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Hydroxyzine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxyzine is partly metabolized by alcohol dehydrogenase and partly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ibandronic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Ibandronic acid should be taken after an overnight fast (at least 6 hours) and before the first food or drink of the day. Medicinal products and supplements should be similarly avoided prior to taking ibandronic acid. Fasting should be continued for at least 30 minutes after taking ibandronic acid. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary) </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ibuprofen</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ibuprofen is metabolized mainly by CYP2C9 and to a lesser extent by CYP2C8 and direct glucuronidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ifosfamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for pharmacokinetic interaction. Ifosfamide is predominantly metabolized by CYP3A4 and CYP2B6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>The pharmacokinetics of ifosfamide exhibit considerable interindividual variation. It is a prodrug that is extensively metabolised, chiefly by cytochrome P450 isoenzymes such as CYP3A4 and CYP2B6 in the liver, to both active and inactive metabolites; there is some evidence that metabolism is saturated at very high doses. Although licensed product information states that a mean terminal elimination half-life is about 15 hours after a single high-dose intravenous bolus, most studies at lower doses recorded elimination half-lives of 4 to 8 hours. After repeated doses there is a decrease in the elimination half-life, apparently due to autoinduction of metabolism. It is excreted largely in urine, as unchanged drug and metabolites. <br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 20-Aug-2010<br />Wagner T. Clin Pharmacokinet 1994; 26: 439&#8211;56; Boddy AV, Yule SM. Clin Pharmacokinet 2000; 38: 291&#8211;304; Kerbusch T, et al. Clin Pharmacokinet 2001; 40: 41&#8211;62.</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Iloperidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Iloperidone is metabolised by CYP3A4 and CYP2D6. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Imatinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied.  Imatinib is primarily metabolized by CYP3A4 and to a lesser extent by CYPs 1A2, 2D6, 2C9 and 2C19. In vitro data indicate that imatinib inhibits CYPs 3A4, 2D6, 2C9 and 2C19. A pharmacokinetic interaction is unlikely. However, hepatitis and occasionally fatal liver failure, has been reported with stavudine. Hepatotoxicity, occasionally severe, may occur with imatinib. Close monitoring of liver function is warranted.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Imipenem/Cilastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Renal clearance is by glomerular filtration and to a lesser extent, active tubular secretion for both imipenem and cilastatin. Probenecid, an inhibitor of renal tubular excretion, had minimal effect on plasma levels of imipenem. There is therefore little potential for interaction via competition for renal transport mechanisms when imipenem/cilastatin is administered with stavudine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>When administered alone, imipenem is metabolised in the kidneys by dehydropeptidase-I. Individual urinary recoveries ranged from 5 to 40%, with an average recovery of 15-20% in several studies. Cilastatin is a specific inhibitor of dehydropeptidase-I enzyme and effectively inhibits metabolism of imipenem so that concomitant administration of imipenem and cilastatin allows therapeutic antibacterial levels of imipenem to be attained in both urine and plasma.<br />Approximately 70% of the administered antibiotic was recovered intact in the urine within ten hours, and no further urinary excretion of imipenem was detectable. Urine concentrations of imipenem exceeded 10 &#956;g/ml for up to eight hours after a 500 mg/500 mg dose of imipenem/cilastatin. The remainder of the administered dose was recovered in the urine as antibacterially inactive metabolites, and faecal elimination of imipenem was essentially nil.<br /><em>Primaxin&#174; IV Injection Summary of Product Characteristics, Merck Sharp &amp; Dohme Limited, updated October 2011<br />Primaxin&#174; I.V. (Imipenem and cilastatin for injection) US Prescribing Information, Merck&amp;Co Inc, Issued February 2010</em><br /><br />Approximately 70-80% of the dose of cilastatin was recovered unchanged in the urine as cilastatin within 10 hours of administration of imipenem/cilastatin. No further cilastatin appeared in the urine thereafter. Approximately 10% was found as the N-acetyl metabolite, which has inhibitory activity against dehydropeptidase comparable to that of cilastatin. Activity of dehydropeptidase-I in the kidney returned to normal levels shortly after the elimination of cilastatin from the blood stream.<br /><em>Primaxin&#174; IV Injection Summary of Product Characteristics, Merck Sharp &amp; Dohme Limited, updated October 2011<br />Primaxin&#174; I.V. (Imipenem and cilastatin for injection) US Prescribing Information, Merck&amp;Co Inc, Issued February 2010</em></div>
<p>Since it is hydrolysed by dehydropeptidase-I, a zinc metallo-enzyme resident in the brush border of the renal tubule, imipenem is co-administered with cilastatin, a reversible inhibitor of this enzyme. This provides clinically relevant concentrations of imipenem in the urine for 8-10 h after a 500 mg dose. Renal clearance of unchanged imipenem accounts for 60-70% of plasma clearance when the imipenem is given with cilastatin. Administration of radiolabelled drugs results in recovery of over 99% of the radiolabel in the urine for both imipenem and cilastatin. With increasing renal dysfunction, the half-life of imipenem is controlled by a metabolic clearance pathway which is unaffected by cilastatin. Renal clearance is by glomerular filtration and active tubular secretion for both imipenem and cilastatin. <br /><em>An overview of the pharmacology of imipenem/cilastatin. Drusano GL. J Antimicrob Chemother. 1986 Dec;18 Suppl E:79-92</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Imipramine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Indapamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Indapamide is extensively metabolized by CYP P450. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Indinavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration with indinavir alone showed no clinically significant interactions. Coadministration with indinavir/ritonavir (800/200 mg twice daily) increased stavudine AUC by 24% but had no effect on Cmax. Stavudine may be administered with indinavir and/or ritonavir without dose modification, but further investigation is required. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Indinavir and NRTIs can be co-administered without dose adjustment. Coadministration of stavudine (40 mg twice daily) and indinavir (800 mg three times daily) had no effect on indinavir AUC or Cmin; stavudine AUC increased by 21%. <br /><em>Crixivan Summary of Product Characteristics, Merck Sharp &amp; Dohme Ltd, <em>February 2012</em>.</em> 
<p>
<p>Coadministration of stavudine (40 mg twice daily for 7 days) and indinavir (800 mg three times daily for 7 days) to 11 HIV+ subjects resulted in a 5% decrease in indinavir Cmax and AUC and a 13% increase in indinavir Cmin. Data from 13 HIV+ subjects receiving the same dose showed a 14% decrease in stavudine Cmax and a 21% increase in AUC. <br /><em>Crixivan Prescribing Information, Merck &amp; Co Inc, <em>April 2012</em>.</em></p>
<p>A cross over study was performed in 24 healthy volunteers to investigate the interaction between stavudine (40 mg single dose) and indinavir alone and in the presence of ritonavir. Indinavir alone (800 mg single dose) had no effect on the pharmacokinetics of stavudine. Indinavir plus ritonavir (800/200 mg twice daily) resulted in no change in stavudine Cmax, but increased stavudine AUC by 24%. Stavudine may be administered with indinavir and/or ritonavir without dose modification, but further investigation is required to assess the long term effects. <br /><em>The effect of coadminsitration of indinavir and ritonavir on the pharmacokinetics of stavudine. Kaul S, Agarwala H, Hess H, et al, 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 2002, abstract A-1825.</em></p>
<p>Stavudine concentrations were assessed in paired samples of blood and CSF in the 050, ADAM, Prometheus and ERA studies. Unexpectedly, it was found that d4T concentrations were 3-6 fold higher in regimens containing indinavir and/or ritonavir. <br /><em>Increased stavudine concentrations in plasma and cerebrospinal fluid: a possible interaction with ritonavir and/or indinavir. Reijers MHE, Gisolf EH, Van Praag RME, et al. 13th International AIDS Conference, Durban, July 2000, asbstract TuPeB3299.</em></p>
<p>Coadministration of indinavir (800 mg every 8 h) and stavudine (40 mg every 12 h) to HIV+ individuals showed no clinically significant interaction. No dose modification is required. <br /><em>Indinavir (MK639) drug interaction studies. The Indinavir (MK 639) Pharmacokinetic Study Group. 11th International Conference on AIDS, 1996, abstract Mo.B.174.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Insulin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Interferon alpha</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Potential interaction. Monitor for treatment-associated toxicities, especially hepatic decompensation. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Hepatic decompensation (some fatal) has occurred in HIV/HCV co-infected patients receiving combination antiretroviral therapy for HIV and interferon and ribavirin. Patients receiving interferon with or without ribavirin and stavudine should be closely monitored for treatment-associated toxicities, especially hepatic decompensation. Discontinuation of stavudine should be considered as medically appropriate. Dose reduction or discontinuation of interferon, ribavirin, or both should also be considered if worsening clinical toxicities are observed, including hepatic decompensation (eg, Child-Pugh &gt;6). <br /><em>Zerit Prescribing Information, Bristol-Myers Squibb Company, January 2012.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Interleukin 2 (Aldesleukin)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic  interaction is unlikely as interleukin-2 is mainly eliminated by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Inula racemosa</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely.&nbsp;</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Iodine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Iodine is converted to iodide, which is trapped in the thyroid gland. Iodides are excreted mainly in the urine with smaller amounts excreted in the faeces, sweat and saliva.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Iodine is converted to iodide, which is trapped in the thyroid gland. Iodides are excreted mainly in the urine with smaller amounts excreted in the faeces, sweat and saliva.<br /><em>Aqueous Iodine Oral Solution BP UK Summary of Product Characteristics, Thornton &amp; Ross Ltd, updated November 2011</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ipratropium bromide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Renal elimination of unchanged ipratropium is minimal, therefore there is little potential for interaction with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>After intravenous administration approximately 60% of the dose is metabolised, mainly by conjugation (40%), wheras after inhalation about 77% of the systemically available dose is metabolised by ester hydrolysis (41%) and conjugation (36%). After inhalation of ipratropium bromide either with HFA 134a or CFC propellant, cumulative renal excretion over 24 hours was approximately 12% and 10%, respectively.&nbsp; In an excretion balance study cumulative renal excretion (6 days) of drug-related radioactivity (including parent compound and all metabolites) accounted for 72.1% after intravenous administration, 9.3% after oral administration and 3.2% after inhalation. The main urinary metabolites bind poorly to the muscarinic receptor and have to be regarded as ineffective.<br /><em>Atrovent&#174; (Ipratropium bromide) 20 micrograms/actuation Inhaler CFC-Free UK Summary of Product Characteristics, Boehringer Ingelheim Limited, updated August 2011</em></p>
<p>After inhalation, around 10 to 30% of a dose is deposited in the lungs where it exerts its therapeutic effect. Only a small amount of ipratropium reaches the systemic circulation. The majority of a dose is swallowed but is poorly absorbed from the gastrointestinal tract. Following oral administration, the apparent systemic availability was around 2%, and after inhalation it was 6.9%. Ipratropium and its metabolites are eliminated in the urine and faeces.<br /><em>Ensing K, et al. Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. Eur J Clin Pharmacol 1989; 36: 189&#8211;94.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Irbesartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as irbesartan is metabolized by via glucuronidation and oxidation (mainly CYP2C9).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Irinotecan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Irinotecan is converted to its active metabolite SN38 via tissue carboxylesterase and to inactive metabolites (APC, NPC) via CYP3A4. SN38 is further inactivated by several UGTs. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Iron supplements</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Isoflurane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as isoflurane is almost exclusively eliminated unchanged by the lungs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Isoniazid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>There may be an increased risk of distal sensory neuropathy when isoniazid is used with stavudine (d4T). </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>There may be an increased risk of distal sensory neuropathy when isoniazid is used in patients taking stavudine (d4T). <br /><em>Isoniazid Summary of Product Characteristics, UCB Pharma Ltd, April 2007.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Isosorbide dinitrate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Isosorbide dinitrate undergoes extensive first past metabolism, predominantly in the liver. As renal elimination of unchanged drug is a minor pathway, there is little potential for interaction with stavudine via competion for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Isosorbide dinitrate is readiliy absorbed from the oral mucosa and also following oral administration. It undergoes extensive first pass metabolism, mainly in the liver. <br /><em>Isosorbide Dinitrate Tablets BP 20mg UK Summary of Product Characteristics, Actavis UK Ltd, updated October 2011</em></p>
<p>Isosorbide dinitrate (ISDN) is eliminated from plasma with a short half-life (about 0.7h). The metabolic degradation of ISDN occurs via denitration and glucuronidation, like all organic nitrates. The rate of formation of the metabolites has been calculated for isosorbide-5-mononitrate (IS-5-MN) with 0.27 h -1, and isosorbide (IS) with 0.16 h-1. IS-5-MN and IS-2-MN are the primary metabolites which are also pharmacologically active. IS-5-MN is metabolised to isosorbide 5-mononitrate-2-glucuronide (IS-5-MN-2-GLU). The half-life of this metabolite (about 2.5h) is shorter than that of IS-5-MN (about 5.1h). The half-life of ISDN is the shortest of all and that of IS-2-MN (about 3.2h) lies in between. <br /><em>Isoket&#174; (Isosorbide dinitrate) 1mg/ml injection/infusion UK Summary of Product Characteristics, UCB Pharma Limited, updated July 2010</em></p>
<p>The bioavailabilities of a conventional and two slow release 20 mg isosorbide dinitrate (ISDN) formulations were compared after oral administration in a three way cross-over study in 8 male volunteers. In a further group of 6 male volunteers the pharmacokinetics and metabolism of ISDN were investigated after intravenous infusion of a median dose of 14.1 mg for 2.5 h. The median elimination half-lives of ISDN, IS-5-MN, IS-2-MN and IS-5-MN-2-Glu were 0.7, 5.1, 3.2 and 2.5 h, respectively. Apart from IS-5-MN-2-Glu, with a renal clearance of 5.9 l/min which suggested substantial glucuronidation in the kidney, the renal clearances of ISDN, IS-5-MN, IS-2-MN and the corresponding amounts excreted were negligible. 27.8% of the administered ISDN was excreted as IS-5-MN-2-Glu (8.7%) and IS (19.1%). Calculations based on the two mononitrate metabolites formed from ISDN showed an incomplete recovery of 84.1%, leading to the assumption that a simultaneous denitration to IS must have occurred. <br /><em>Abshagen U, Betzien G, Endele R et al. Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration. Eur J Clin Pharmacol. 1985;27(6):637-44.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Isotretinoin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Isotretinoin is metabolised mainly by CYP2C8 and CYP3A4 with the participation of CYP2B6 and CYP2C9. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Itraconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as itraconazole is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ivabradine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction as ivabradine is metabolised by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ivermectin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. In vitro studies suggest that ivermectin is predominantly metabolised via CYP3A4, so there is little potential for interactions with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Ivermectin is metabolized in the liver, and ivermectin and/or its metabolites are excreted almost exclusively in the feces over an estimated 12 days, with less than 1% of the administered dose excreted in the urine.<br />In vitro studies using human liver microsomes and recombinant CYP450 enzymes have shown that ivermectin is primarily metabolized by CYP3A4. Depending on the in vitro method used, CYP2D6 and CYP2E1 were also shown to be involved in the metabolism of ivermectin but to a significantly lower extent compared to CYP3A4. The findings of in vitro studies using human liver microsomes suggest that clinically relevant concentrations of ivermectin do not significantly inhibit the metabolizing activities of CYP3A4, CYP2D6, CYP2C9, CYP1A2, and CYP2E1.<br /><em>Stromectol&#174; US Prescribing Information, Merck Sharp &amp; Dohme BV Issued May 2010</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Kanamycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. As kanamycin is eliminated unchanged predominantly via glomerular filtration, there is little potential for interaction with stavudine via competition for active renal transport mechanisms.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Kanamycin is rapidly excreted by glomerular filtration and most of a parenteral dose appears unchanged in the urine within 24 hours.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 20-August-2011</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ketamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Ketamine is mainly metabolized by CYP3A4 and to a lesser extent by CYP2B6 and CYP2C9 in the range of concentrations used in anaesthesia.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ketoconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as ketoconazole is metabolized by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Labetalol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Labetalol is mainly glucuronidated by UGTs 1A1 and 2B7.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Lacidipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as lacidipine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Lacosamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lacosamide is metabolized to O-desmethyl-lacosamide mainly by CYP2C19 (~30% of the dose) and is eliminated unchanged through the kidneys (~40% of the dose).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Lactulose</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of lactulose to lactic acid occurs via gastro-intestinal microbial flora only.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Lamivudine (3TC)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No significant interaction observed. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Since stavudine is actively secreted by the renal tubules, interactions with other actively secreted medicinal products are possible. No clinically relevant pharmacokinetic interaction has, however, been seen with lamivudine. <br /><em>Zerit Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, March 2011.</em></p>
<p>Coadministration of stavudine (40 mg single dose) and lamivudine (150 mg single dose) was studied in 18 HIV-infected subjects. There was no change in stavudine AUC and a 12% increase in Cmax. Lamivudine AUC and Cmax were unaltered. <br /><em>Zerit Prescribing Information, Bristol-Myers Squibb Company, January 2012.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Lamotrigine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lamotrigine is mainly glucuronidated by UGT1A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Lansoprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lansoprazole is mainly metabolized by CYP2C19 and 3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Lapatinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Lapatinib is metabolized by CYP3A4 and does not significantly inhibit renal transporters (OAT, OCT).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ledipasvir/Sofosbuvir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as stavudine is primarily renally eliminated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Lercanidipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lercanidipine is mainly metabolized by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Letrozole </p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Letrozole is metabolised by CYP3A4 and CYP2A6 to carbinol, an inactive metabolite.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Leuprorelin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Leuprorelin acetate is a peptide that is primarily degraded by peptidases.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See&nbsp;Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Levamisole (Ergamisol)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Metabolism and elimination of levamisole has not been well characterized. Renal elimination of unchanged levamisol apprears to be minimal, therefore interactions via competition for renal elimination pathways are not considered likely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Levamisole is rapidly absorbed from the gastrointestinal tract and peak plasma concentrations occur within 1.5 to 2 hours. It is extensively metabolised in the liver. The plasma half-life for levamisole is 3 to 4 hours and for the metabolites is 16 hours. It is excreted mainly in the urine as metabolites and a small proportion in the faeces. About 70% of a dose is excreted in the urine over 3 days, with about 5% as unchanged levamisole.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification 14-May-2011</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Levetiracetam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Levetiracetam undergoes enzymatic hydrolysis (non CYP) and is eliminated unchanged in the urine by glomerular filtration. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Levocetirizine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as less than 14% of a dose of levocetirizine is metabolised. Levocetirizine is mainly eliminated unchanged in the urine through both glomerular filtration and tubular secretion.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Levodopa</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. In the presence of a peripheral dopa-decarboxylase inhibitor (carbidopa or benserazide) levodopa is metabolised mainly to 3-O-methyldopa by catechol-O-methyltransferase. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Levofloxacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely as levofloxacin is metabolised to a very small extent.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Levomepromazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely as levomepromazine is metabolised by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Levonorgestrel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is hydroxylated in the liver and the metabolites are excreted as glucuronide conjugates.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Levonorgestrel (Emergency Contraception)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Levothyroxine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Levothyroxine is metabolized by deiodination (by enzymes of deiodinase family) and glucuronidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Lidocaine (Lignocaine)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. CYP1A2 is the predominant enzyme involved in lidocaine metabolism in the range of therapeutic concentrations with a minor contribution from CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Linagliptin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as linagliptin is mainly eliminated as parent compound in faeces. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Linezolid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Linezolid undergoes non-CYP mediated metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Liquorice (Glycyrrhiza glabra)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Liraglutide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as liraglutide is degraded by endogenous endopeptidases. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Lisinopril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Lithium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Lithium is mainly eliminated unchanged through the kidneys. Lithium is freely filtered at a rate that is dependent upon the glomerular filtration rate therefore no pharmacokinetic interaction is expected. However, since lithium is nephrotoxic, renal function should be monitored periodically and stavudine dosage adjusted accordingly.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Loperamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loperamide is mainly metabolized by CYP3A4 and CYP2C8.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Lopinavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No change in the pharmacokinetics of lopinavir was observed when Kaletra was given alone or in combination with stavudine and lamivudine in clinical studies. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>No change in the pharmacokinetics of lopinavir. No dose adjustment necessary. <br /><em>Kaletra Summary of Product Characteristics, Abbott Laboratories Ltd, February 2012.</em></p>
<p>Drug interaction studies revealed no clinically significant interaction between lopinavir and stavudine.<br /><em>Kaletra Prescribing Information, Abbott Laboratories, May 2012.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Loratadine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loratadine is metabolized mainly by CYP3A4 and to a lesser extent by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Lorazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely as lorazepam is mainly glucuronidated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Lormetazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely as lormetazepam is mainly glucuronidated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Losartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Losartan is converted to its active metabolite mainly by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Lovastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as lovastatin is metabolised mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Lumefantrine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as lumefantrine is metabolized predominantly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Lysergic acid diethylamide (LSD)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. LSD (lysergic acid diethylamide) is metabolized to O-H-LSD and N-desmethyl-LSD partly by CYP (unknown isoenzyme).</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Macitentan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Macitentan is metabolized mainly by CYP3A4 and to a lesser extent by CYPs 2C19, 2C9 and 2C8.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Magnesium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Magnesium is eliminated in kidney, mainly by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Malabar nut tree (Justicia adhatoda, Adhatoda vasica)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on the limited data available on the effect of malabar nut tree leaf extracts on drug metabolism, a clinically significant interaction is unlikely.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Mannitol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Mannitol is predominantly eliminated via renal glomerular filtration and does not undergo active renal transport. There is therefore little potential for interaction with stavudine via competition for active renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Mannitol is metabolized only very slightly, if at all, to glycogen in the liver. The drug is freely filtered by the glomeruli, with less than 10% tubular reabsorption; it is not secreted by tubular cells. The elimination half-life in adults is about 100 minutes. Approximately 80% of a 100-g dose is excreted unchanged in urine within 3 hours. When large dose are given as in forced diuresis, retention of the drug may occur. In the presence of renal disease in which glomerular function is impaired or in conditions that impair small vessel circulation, such as congestive heart failure, cirrhosis with ascitic accumulation, shock, or dehydration, mannitol clearance is lower than normal.<br /><em>AHFS Drug Information (via Medicines Complete), published by the American Society of Health-System Pharmacists Inc, December 2008</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Maprotiline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Maraviroc</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No significant interaction expected. Maraviroc and NRTIs can be co-administered without dose adjustment. The US Prescribing Information recommends maraviroc should be reduced to 150 mg twice daily in patients with creatinine clearance less than 30 ml/min or on haemodialysis if there are any symptoms of postural hypotension. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>No significant interaction expected. Maraviroc 300 mg twice daily and NRTIs can be co-administered without dose adjustment. <br /><em>Celsentri Summary of Product Characteristics,&nbsp;</em><em>ViiV Healthcare, October 2013</em><em>.</em></p>
<p>The recommended dose of maraviroc when coadministered with NRTIs is 300 mg twice daily. Maraviroc should be reduced to 150 mg twice daily in patients with creatinine clearance &lt;30 ml/min or on haemodialysis if there are any symptoms of postural hypotension.<br /><em>Selzentry Prescribing Information,&nbsp;</em><em>ViiV Healthcare, September 2013</em><em>.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>MDMA (Ecstasy)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. MDMA is metabolized mainly by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Mebendazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Renal excretion of unchanged mebendazole appears to be minimal. There is therefore little potential for interaction with stavudine via competition for active renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Orally administered mebendazole is extensively metabolized primarily by the liver. Plasma concentrations of its major metabolites (amino and hydroxylated amino forms of mebendazole) are substantially higher than those of mebendazole. Impaired hepatic function, impaired metabolism, or impaired biliary elimination may lead to higher plasma levels of mebendazole. <br />Mebendazole, the conjugated forms of mebendazole, and its metabolites likely undergo some degree of enterohepatic recirculation and are excreted in the urine and bile. The apparent elimination half-life after an oral dose ranges from 3 to 6 hours in most patients.<br /><em>Ovex&#174; Summary of Product Characteristics, McNeil Products Ltd. Updated April 2011</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Medroxyprogesterone (IM depot injection)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Medroxyprogesterone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Medroxyprogesterone (oral)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction as medroxyprogesterone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Mefenamic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mefenamic acid is metabolized by CYP2C9 and glucuronidated by UGT2B7 and UGT1A9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Mefloquine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mefloquine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Megestrol acetate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as megestrol acetate is mainly eliminated in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Meglumine antimoniate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profile of both drugs, there is little potential for pharmacokinetic interaction. Pancreatitis has been described as a relatively common serious adverse effect of meglumine antimoniate therapy. Pancreatitis, occasionally fatal, has been reported in up to 2-3% of patients enrolled in monotherapy clinical studies of stavudine, and in < 1% of patients in combination therapy studies including stavudine. Patients with a high risk of pancreatitis or those receiving products known to be associated with pancreatitis should be closely followed for symptoms of this condition.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>A study analysed 25 visceral leishmaniasis (VL) episodes in human immunodeficiency virus (HIV)-infected patients who were treated with meglumine antimoniate (MA) at the Centers for Disease Control and Prevention (CDC, Atlanta, GA)-recommended dose. Adverse effects were observed in 14 (56%) VL episodes. In 7 (28%), treatment with MA was permanently discontinued due to serious adverse effects that included acute pancreatitis, acute renal failure, and leukopenia. Three (12%) patients died during therapy due to severe acute pancreatitis attributable to MA. MA used at the doses studied was associated with a high rate of serious side effects in HIV-1-infected patients.<br /><em>High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Delgado J, Mac&#237;as J, Pineda JA et al. Am J Trop Med Hyg. 1999 Nov;61(5):766-9</em></p>
<p>The medical charts of 54 Ethiopian visceral leishmaniasis patients treated with meglumine antimoniate were reviewed to assess the effectiveness and safety profile in a routine healthcare setting. None of the patients from south Ethiopia (n=24) and 46.4% of the patients from north Ethiopia (n=30) were HIV co-infected. 33 non-serious and 6 serious adverse events (two pancreatitis, one renal failure and three deaths) were observed in 26 patients. One-third of the non-serious adverse events were due to biochemical pancreatitis. During treatment, a case-fatality rate of 10.0% in north Ethiopia and 0.0% in south Ethiopia was noted. These data point to clinical pancreatitis as a safety concern, especially in patients with HIV co-infection.<br /><em>Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection. Hailu W, Weldegebreal T, Hurissa Z et al. Trans R Soc Trop Med Hyg. 2010 Nov;104(11):706-12</em></p>
<p>Pancreatitis, occasionally fatal, has been reported in up to 2-3% of patients enrolled in monotherapy clinical studies of stavudine, and in &lt; 1% of patients in combination therapy studies including stavudine. Patients with a history of pancreatitis had an incidence of approximately 5% on stavudine, as compared to approximately 2% in patients without such a history. Patients with a high risk of pancreatitis or those receiving products known to be associated with pancreatitis should be closely followed for symptoms of this condition.<br /><em>Zerit&#174; (stavudine) capsules, UK Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceutical Limited, updated April 2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Melarsoprol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This Interaction has not been studied. Based on limited data concerning metabolism, elimination and toxicity of melarsoprol, there is little potential for interaction, although due to the lack of data, vigilance is required if administering melarsoprol with antiretrovirals. It is unknown whether urinary metabolites of melarsoprol, such as arsenic, are excreted via active renal mechanisms, however a clinical study has reported that urinary pharmacokinetic parameters are not predictive of toxicity or therapeutic efficacy. Therefore stavudine has little potential to effect melarsoprol treatment via competition for renal elimination mechanisms.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>The pharmacokinetics of melarsoprol have not been fully evaluated. Using biological assay and atomic absorption spectrometry, the terminal half-life of melarsoprol was originally calculated to be 35 hours and low trypanocidal activity was detected in the CSF. When the terminal half-life was calculated by high-performance liquid chromatography (HPLC), melarsoprol was found to be eliminated from the plasma within 1 hour. Based on these findings it is thought that melarsoprol is rapidly eliminated from the plasma and transformed into metabolites with trypanocidal activity. Melarsen oxide has been identified by HPLC as a metabolite; the peak plasma concentration was reached 15 minutes after a dose and the half-life of free melarsen oxide was 3.9 hours.<br /><em>Bronner U, et al. Discrepancy in plasma melarsoprol concentrations between HPLC and bioassay methods in patients with T. gambiense sleeping sickness indicates that melarsoprol is metabolized. Trop Med Int Health 1998; 3: 913&#8211;7.</em></p>
<p>The half-life of melarsoprol determined by HPLC was &lt;1 hour compared with 35 hours determined by bioassay and atomic absorption spectroscopy, indicating the existence of active metabolites. One metabolite, melarsen oxide, was identified by ultraviolet HPLC after incubation of melarsoprol with microsomes. Melarsen oxide could also be detected at the same concentration range in the control run without NaDPH. This indicates that melarsen oxide might not be formed only in a microsomal reaction but also by hydrolysis. The maximum plasma concentration of melarsen oxide was reached 15 minutes after administration; the clearance was 21.5 mL/min/kg and the half-life of free melarsen oxide was 3.9 hours. Either melarsen oxide or a yet-undiscovered active metabolite is irreversibly bound to proteins, as shown by ultrafiltration, precipitation experiments, and atomic absorption spectroscopy. <br /><em>Investigations of the metabolites of the trypanocidal drug melarsoprol. Keiser J, Ericsson O, Burri C. Clin Pharmacol Ther. 2000 May;67(5):478-88.</em></p>
<p>This study enrolled 28 CNS-involved patients with Trypanosoma brucei rhodesiense at the Kenya Trypanosomiasis Research Institute (Alupe, Kenya) to examine treatment efficacy and toxicity of melarsoprol in relation to renal excretion/dose relationships. This study complied with World Health Organization treatment recommendations, initially treating with suramin followed by three courses of melarsoprol. Traced study patients had a relapse rate of 4.1%. The toxicity and crude death rate was 7.1%. Total urine arsenic output was measured between 24 and 48 hr after the last dose for each course. The range of means of total urine arsenic output between the three treatment courses was 356-511 micrograms. There was no correlation comparing melarsoprol dose, estimated creatine clearance, or urine arsenic output. Urinary pharmacokinetic parameters are not predictive of toxicity or therapeutic efficacy.<br /><em>Attempt to correlate urine arsenic excretion with clinical course during melarsoprol therapy of patients with Rhodesian trypanosomiasis. Harrison SM, Harris RW, Bales JD Jr. Am J Trop Med Hyg. 1997 Jun;56(6):632-6.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Menthol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. There is no evidence to suggest that menthol impacts UGTs or P-gp.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See&nbsp;Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Mephedrone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction as mephedrone is metabolized mainly by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Mercaptopurine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolic/toxicity profiles of both drugs, there is little potential for interaction. Mercaptopurine is predominantly metabolised by xanthine oxidase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>The main route of elimination for 6-mercaptopurine is by metabolic alteration. The kidneys eliminate approximately 7% of 6-mercaptopurine unaltered within 12 hours of the drug being administered. Xanthine oxidase is the main catabolic enzyme of 6-mercaptopurine and it converts the drug into the inactive metabolite, 6-thiouric acid. This is excreted in the urine.<br /><em>Puri-Nethol&#174; (Mercaptopurine) 50 mg Tablets UK Summary of Product Characteristics, Aspen, updated May 2012</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Meropenem</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Meropenem is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporters OAT3/OAT1. A clinically relevant drug interaction is unlikely as meropenem has a higher affinity for OAT3 whereas OAT1 is involved in the elimination of stavudine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Mesalazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mesalazine is metabolized to N-acetyl-mesalazine by N-acetyltransferase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Mesna</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Stavudine is predominantly eliminated by active renal transport mechanisms. Co-administration with other drugs which are predominantly eliminated by active renal transport may lead to competition for renal transporters and may raise exposure to either drug. Administration of renal organic anion transporter inhibitor probenecid to healthy subjects significantly increased combined mesna and dimesna plasma exposure, while decreasing the renal clearance. This may decrease the efficacy of mesna as a chemoprotectant, increasing the risk of ifosfamide- and cisplatin-induced toxicities.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Analagous to the physiological cysteine system, following intravenous administration, mesna is rapidly oxidised to its only metabolite, mesna disulphide. Mesna disulphide remains in the intravascular compartment and is rapidly eliminated by the kidneys. In the kidney, mesna disulphide is reduced to the free thiol compound, mesna, which acts to detoxify ifosfamide metabolites. Approximately 32% and 33% of the administered dose was eliminated in the urine in 24 hours as mesna and mesna disulphide respectively.<br /><em>Mesna Tablets/Injection US Prescribing Information, Baxter Healthcare Corporation, updated February 2009</em></p>
<p>Mesna and its dimer, dimesna, are coadministered for mitigation of ifosfamide- and cisplatin-induced toxicities, respectively. Dimesna is selectively reduced to mesna in the kidney, producing its protective effects. In vitro screens of uptake and efflux transporters revealed saturable uptake by renal organic anion transporters OAT1, OAT3, and OAT4. Efflux transporters breast cancer resistance protein; multidrug and toxin extrusion 1 (MATE1); multidrug resistance proteins MRP1, MRP2, MRP4, and MRP5; and P-glycoprotein (Pgp) significantly reduced dimesna accumulation. Further investigation demonstrated that renal apical efflux transporters MATE1, MRP2, and Pgp were also capable of mesna efflux. Administration of OAT inhibitor probenecid to healthy subjects significantly increased combined mesna and dimesna plasma exposure (91% &#177; 34%) while decreasing the renal clearance due to net secretion (67.0% &#177; 12.7%) and steady-state volume of distribution (45.2% &#177; 13.4%). Thus, the kidney represents a significant sink of total mesna, whereas function of renal drug transporters facilitates clearance in excess of glomerular filtration rate and likely the presence of active mesna in the urine. Loss of renal transporter function due to genetic variability or drug-drug interactions may decrease the efficacy of chemoprotectants, increasing the risk of ifosfamide- and cisplatin-induced toxicities.<br /><em>In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. Cutler MJ, Urquhart BL, Velenosi TJ et al. J Clin Pharmacol. 2012 Apr;52(4):530-42.</em></p>
<p>Since stavudine is actively secreted by the renal tubules, interactions with other actively secreted medicinal products are possible, e.g. with trimethoprim.<br /><em>Zerit&#174; (stavudine) Hard Capsules UK Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceutical Ltd, updated April 2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Metformin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metformin is mainly eliminated unchanged in the urine via the renal transporter OCT2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Methadone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Methadone coadministration reduced stavudine AUC and Cmax by 23% and 44%, respectively. The clinical significance of a change in drug exposure of this magnitude is not certain. No effect of stavudine on methadone trough concentrations. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Pharmacokinetics of stavudine (40 mg twice daily) were determined in 17 subjects stable on methadone maintenance therapy (9 HIV-infected, 8 HIV-negative) and compared those obtained in 10 control subjects not receiving methadone (5 HIV-infected, 5 HIV-negative). Methadone treatment reduced stavudine AUC by 23% and Cmax by 44%. The clinical significance of a change in drug exposure of this magnitude is not certain. Trough levels of methadone did not differ significantly from controls. <br /><em>Interaction of methadone with didanosine and stavudine. Rainey PM, et al. J Acquir Immun Def Syndr, 2000, 24:241-248. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Methamphetamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methamphetamine is mainly metabolized by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Methotrexate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance there is little potential for a pharmacokinetic interaction. However, due to the potentially toxic effect on the liver, additional hepatotoxic medications should not be given during treatment with methotrexate unless clearly necessary; close monitoring of liver enzymes should be undertaken. Note, some methotrexate product labels contraindicate its use or advise caution in immunodeficiency and some contraindicate its use in HIV infection.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Methyldopa</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied.  Pancreatitis has been observed as a serious adverse effect of methyldopa therapy. Pancreatitis, occasionally fatal, has been reported in up to 2-3% of patients enrolled in monotherapy clinical studies of stavudine, and in <1% of patients in combination therapy studies including stavudine. Patients with a high risk of pancreatitis or those receiving products known to be associated with pancreatitis should be closely followed for symptoms of this condition.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Increases in serum- and urinary-amylase activity accompanied by fever and suggestive of pancreatitis have been associated with methyldopa in various case reports. Symptoms reappeared on rechallenge in 3 patients. In contrast to the acute form, chronic pancreatitis is not generally attributable to drug use.3 However, a case of florid chronic pancreatitis, with exocrine and endocrine insufficiency and heavy calcification over 30 months, associated with 2 periods of methyldopa treatment, has been reported. <br /><em>van der Heide H, et al Pancreatitis caused by methyldopa. BMJ 1981; 282: 1930&#8211;1; Anderson JR, et al. Drug-associated recurrent pancreatitis. Dig Surg 1985; 2: 24&#8211;6; Banergee AK, et al. Drug-induced acute pancreatitis. Med Toxicol Adverse Drug Exp 1989; 4: 186&#8211;98; Ramsay LE, et al. Methyldopa-induced chronic pancreatitis. Practitioner 1982; 226: 1166&#8211;9</em></p>
<p>Pancreatitis, occasionally fatal, has been reported in up to 2-3% of patients enrolled in monotherapy clinical studies of stavudine, and in &lt; 1% of patients in combination therapy studies including stavudine. Patients with a history of pancreatitis had an incidence of approximately 5% on stavudine, as compared to approximately 2% in patients without such a history. Patients with a high risk of pancreatitis or those receiving products known to be associated with pancreatitis should be closely followed for symptoms of this condition.<br /><em>Zerit&#174; (stavudine) capsules, UK Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceutical Limited, updated April 2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Methylphenidate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Methylphenidate is not metabolized by cytochrome P450s to a clinically relevant extent and does not inhibit cytochrome P450s.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Methylprednisolone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Methylprednisolone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Metoclopramide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoclopramide is partially metabolized by CYP450 system (mainly CYP2D6).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Metolazone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely as metolazone is largely excreted unchanged in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Metoprolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Metronidazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Mexiletine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mexiletine is metabolized mainly by CYP2D6 and to a lesser extent by CYP1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Mianserin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Miconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Midazolam (oral)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Midazolam is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Midazolam (parenteral)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Midazolam is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Mifepristone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Renal excretion of mifepristone is thought to account for approximately 10% of an oral dose. There is therefore little potential for interaction with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>N-Demethylation and terminal hydroxylation of the 17-propynyl chain are primary metabolic pathways of hepatic oxidative metabolism. Mifepristone is mainly excreted in faeces. After administration of a 600 mg labelled dose, 10% of the total radioactivity is eliminated in the urine and 90% in the faeces. No interaction studies have been performed. <br /><em>Mifegyne&#174; (Mifepristone) 200mg Tablets UK Summary of Product Characteristics, Nordic Pharma Limited, updated July 2011<br />Mifeprex&#174; (Mifepristone) Tablets 200mg US Prescribing Information, Danco Laboratories LLC, updated April 2009</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Milk thistle</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Drug-drug interaction studies suggest that milk thistle has limited clinical impact on substrates of CYP3A, P-gp, UGT and OATP.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Milnacipran</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Milnacipran is mainly eliminated unchanged (50%), and as glucuronides (30%) and oxidative metabolites (20%).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Miltefosine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on limited data concerning metabolism, elimination and toxicity of miltefosine, there is little potential for interaction. Only a very small proportion of an administered dose of miltefosine is excreted in the unchanged form, therefore there is little potential for interaction with stavudine via competition for renal elimination pathways. A case report describes two patients who were taking a regimen of stavudine, lamivudine and nevirapine who were safely and effectively treated with miltefosine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>In vitro studies have shown that interactions between miltefosine and drugs which are metabolised by cytochrome P450, glucuronidated or otherwise conjugated are unlikely, however the possibility of interactions with commonly used drugs can not be totally excluded. No oxidative metabolism of miltefosine was observed in in vitro studies with 15 CYP450 Isozymes. No CYP3A induction was observed in animal studies. A slow metabolic degradation in human hepatocytes was demonstrated, in which a phospholipase D-like cleavage of miltefosine causes the release of choline. Preclinical and clinical studies suggest that only a very small proportion of the administered dose is excreted in the unchanged form. The most likely excreted products are choline and choline-containing products.<br /><em>Impavido&#174; (Miltefosine) Capsules German Product Information, Paladin Labs Ltd, updated September 2009</em></p>
<p>A case report describes the first two patients to be treated with miltefosine for post-kala-azar dermal leishmaniasis (PKDL). One was a 26-year-old Ethiopian man who had been treated with sodium stibogluconate, for relapsing visceral leishmaniasis (VL), four times between August 2002 and March 2004. In January 2004 this patient was found to be seropositive for HIV and began antiretroviral treatment with stavudine, lamivudine and nevirapine. Five months later he developed clinical PKDL, with extensive cutaneous, conjunctival and oral mucosal involvement. The second patient was a 42-year-old Ethiopian man who was treated for relapsing VL in November 2003. He too was subsequently found to be seropositive for HIV and was treated with stavudine, lamivudine and nevirapine from May 2004. He developed a nodular rash of PKDL over his face and upper body 2 weeks after starting the antiretroviral therapy. Treatment of both patients with oral miltefosine, at 100 mg/day for 28 days, led to the complete regression of their PKDL lesions. When checked 3-6 months after the end of the miltesofine treatment, neither patient showed any signs of VL, PKDL or other HIV-associated disease. Significant adverse events were not observed.<br /><em>Successful miltefosine treatment of post-kala-azar dermal leishmaniasis occurring during antiretroviral therapy. Belay AD, Asafa Y, Mesure J, Davidson RN. Ann Trop Med Parasitol. 2006 Apr;100(3):223-7.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Mirabegron</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mirabegron is metabolized by multiple pathways including hydrolysis, glucuronidation and oxidation by CYP2D6 and CYP3A4.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Mirtazapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mirtazapine is metabolised to 8-hydroxymirtazapine by CYP2D6 and CYP1A2, and to N-desmethylmirtazapine mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Misoprostol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Misoprostol is predominantly metabolised via fatty acid oxidising systems, there is therefore little potential for interaction via competition with stavudine for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Misoprostol is predominantly metabolised via fatty acid oxidising systems and has shown no adverse effect on the hepatic microsomal mixed function oxidase (P450) enzyme system. In specific studies no clinically significant pharmacokinetic interaction has been demonstrated with antipyrine or diazepam. A modest increase in propranolol concentrations (mean approximately 20% in AUC, 30% in Cmax) has been observed with multiple dosing of misoprostol. In extensive clinical studies no drug interactions have been attributed to Misoprostol. <br /><em>Cytotec&#174; (Misoprostol) Tablets UK Summary of Product Characteristics, Pharmacia Limited updated November 2010</em></p>
<p>Misoprostol is extensively absorbed, and undergoes rapid deesterification to its free acid, which is responsible for its clinical activity and, unlike the parent compound, is detectable in plasma. The alpha side chain undergoes beta oxidation and the beta side chain undergoes omega oxidation followed by reduction of the ketone to give prostaglandin F analogs. Maximum plasma concentrations of misoprostol acid are diminished when the dose is taken with food and total availability of misoprostol acid is reduced by use of concomitant antacid. Clinical trials were conducted with concomitant antacid, however, so this effect does not appear to be clinically important. Drug interaction studies between misoprostol and several nonsteroidal anti-inflammatory drugs showed no effect on the kinetics of ibuprofen or diclofenac, and a 20% decrease in aspirin AUC, not thought to be clinically significant. Pharmacokinetic studies also showed a lack of drug interaction with antipyrine and propranolol when these drugs were given with misoprostol. Misoprostol given for 1 week had no effect on the steady state pharmacokinetics of diazepam when the two drugs were administered 2 hours apart.<br /><em>Cytotec&#174; (Misoprostol) tablets US Prescribing Information, Pfizer Inc, Revised September 2009</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Mitoxantrone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Mitoxantrone is metabolized to inactive carboxylic acid derivatives possibly by CYP450.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Modafinil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Modafinil is largely metabolized by hydrolysis (esterase mediated) and to a lesser extent by CYP3A4 mediated oxidative metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Mometasone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mometasone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Montelukast</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Montelukast is mainly metabolized by CYP2C8 and to a lesser extent by CYPs 3A4 and 2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Morphine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically relevant drug interaction is unlikely. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Stavudine does not affect this metabolic pathway. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Moxifloxacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Moxifloxacin is predominantly glucuronidated by UGT1A1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Mycophenolate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Mycophenolate is mainly glucuronidated by UGT1A9 and UGT2B7.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Naftidrofuryl</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naftidrofuryl is metabolized to 3 major metabolites primarily by plasma pseudo-choline esterases</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Naltrexone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies have shown that neither naltrexone, nor its main metabolite (6-beta-naltrexol), is metabolized by CYP450 enzymes.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Nandrolone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance there is little potential for pharmacokinetic interaction. Nandrolone is metabolized in the liver.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Naproxen</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naproxen is mainly glucuronidated by UGT2B7 (major) and demethylated to desmethylnaproxen by CYP2C9 (major) and CYP1A.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Nateglinide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nateglinide is metabolized mainly by CYP2C9 (70%) and to a lesser extent by CYP3A4 (30%).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Nebivolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as nebivolol metabolism involves CYP2D6</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Nefazodone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as nefazodone is metabolized mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Nelfinavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Drug interaction studies reveal no clinically significant drug interactions and no dose adjustments are needed. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Clinically significant interactions of stavudine or stavudine plus didanosine with nelfinavir have not been observed. <br /><em>Zerit Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, March 2011.</em></p>
<p>Coadministration of stavudine (30-40 mg twice daily for 56 days) and nelfinavir(750 mg three times daily for 56 days) was studied in 8 HIV-infected subjects. There was no change in the AUC and Cmax of stavudine or nelfinavir. <br /><em>Zerit Prescribing Information, Bristol-Myers Squibb Company, January 2012.</em></p>
<p>Clinically significant interactions have not been observed between nelfinavir and nucleoside analogues. <br /><em>Viracept Summary of Product Characteristics, Roche Products Ltd, September 2011.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Neostigmine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Up to 50% of a neostigmine dose is excreted unchanged via the kidneys. As other non-renal elimination mechanisms  are involved, significant interaction via competition with stavudine for active renal transport are unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Neostigmine undergoes hydrolysis by cholinesterase and is also metabolized by microsomal enzymes in the liver. Protein binding to human serum albumin ranges from 15 to 25 percent. Following intramuscular administration, Neostigmine is rapidly absorbed and eliminated. In a study of five patients with myasthenia gravis, peak plasma levels were observed at 30 minutes, and the half-life ranged from 51 to 90 minutes. Approximately 80 percent of the drug was eliminated in urine within 24 hours; approximately 50% as the unchanged drug and 30 percent as metabolites.<br /><em>Neostigmine Methylsulfate Injection USP UA Prescribing Information, American Reagent Inc, updated January 2009</em></p>
<p>Neostigmine kinetics and metabolism were studied after intracellular administration to 8 patients with myasthenia gravis. The plasma neostigmine level declined monoexponentially from 21 +/- 2 to 9 +/- 1 ng/ml between 30 and 120 min. Approximately 80% of the drug was eliminated in urine within 24 hr either as unchanged neostigmine or its metabolites. Approximately 50% of the dose was eliminated as the unchanged drug, 15% as 3-hydroxyphenyltrimethylammonium, and 15% as other unidentified metabolites. The neostigmine t1/2, based on the urinary excretion of the unchanged drug, ranged from 90.2 to 118.7 min. It was concluded that neostigmine was eliminated by renal and extrarenal mechanisms.<br /><em>Somani SM, Chan K, Dehghan A, Calvey TN. Kinetics and metabolism of intramuscular neostigmine in myasthenia gravis. Clin Pharmacol Ther. 1980 Jul;28(1):64-8.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Nevirapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration of nevirapine (200 mg twice daily) with stavudine (30-40 mg twice daily) caused no alteration in stavudine AUC or Cmax, and the effect on nevirapine pharmacokinetics was not significant. Stavudine and nevirapine can be coadministered without dose adjustments. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Coadministration of nevirapine and stavudine (30-40 mg twice daily) decreased stavudine AUC and Cmax by 4% and 6% respectively. Compared to historical controls, nevirapine levels appeared to be unchanged. Stavudine and nevirapine can be coadministered without dose adjustments. <br /><em>Viramune Summary of Product Characteristics, Boehringer Ingelheim International GmbH, January 2012.</em></p>
<p>Coadministration of nevirapine (200 mg once daily for 2 weeks then 200 mg twice daily for 2 weeks) with stavudine (30-40 mg twice daily), in 22 HIV+ patients, caused no alteration in stavudine AUC or Cmax. Stavudine Cmin was below the limit of detection for that assay. The effect on nevirapine pharmacokinetics was not significant. <br /><em>Viramune Prescribing Information, Boehringer Ingelheim Pharmaceuticals Inc, November 2011.</em></p>
<p>The effect of nevirapine (200 mg twice daily) on the pharmacokinetics of stavudine (30-40 mg twice daily) in the presence of nelfinavir was studied in 25 HIV-infected subjects. No statistically significant changes in stavudine AUC or Cmax were observed. The effect of nevirapine on stavudine Cmin could not be determined as Cmin was below the limit of quantification in 77% of subjects (this was as expected because although the intracellular half-life is long, the plasma half life is short). Nevirapine AUC, Cmax and Cmin values were consistent with historical data. <br /><em>Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine and nelfinavir therapy in HIV-1-infected adults. Skowron G, et al. J Acquir Immune Defic Syndr, 2004, 35:351-358. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Nicardipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as nicardipine is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6 and CYP2C8.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Niclosamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. After oral administration, absorption of niclosamide is considered minimal.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>After oral administration, 2-25% of the administered dose is detected in urine. Absorption is considered minimal<br /><em>Yomesan&#174; Summary of Product Characteristics (Germany), Bayer Vital, Updated January 2011</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Nicorandil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of nicorandil takes place mainly via denitration with the denitrated product then merging into the nicotinamide pathway.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Nicotinamide (Niacinamide)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Renal elimination of unchanged nicotinamide is minimal. There is therefore little potential for interaction with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Nicotinic acid and nicotinamide are readily absorbed from the gastrointestinal tract after oral doses and widely distributed in the body tissues. The main route of metabolism is their conversion to N-methylnicotinamide and the 2-pyridone and 4-pyridone derivatives; nicotinuric acid is also formed. Small amounts of nicotinic acid and nicotinamide are excreted unchanged in urine after therapeutic doses; however the amount excreted unchanged is increased with larger doses.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via medicines Complete), last modified 2006-01-26</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Nifedipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nifedipine is metabolised mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Nifurtimox</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on limited data concerning metabolism, elimination and toxicity of nifurtimox, there is little potential  for interaction. Nifurtimox appears to be biotransformed partially at a cytochrome P450 level but mostly by NADPH P450 reductase, with <1% of a dose excreted unchanged via the kidneys. There is therefore little potential for interaction with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Oral nifurtimox is well absorbed and peak serum concentrations occur after 4 hours. It is rapidly and extensively metabolised and relatively low concentrations of nifurtimox appear in the plasma and tissues. It is presumed to cross the blood-brain barrier. Less than 1% of an oral dose is excreted unchanged in the urine. <br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), last reviewed 2011-03-03</em></p>
<p>Nifurtimox (Nfx) has serious toxic effects including mutagenic, reproductive and carcinogenic actions. Its toxicity has been linked to NADPH dependent nitroreductive metabolic biotransformation with production of oxygen reactive species. Rat liver nuclei exhibit Nfx-nitroreductase activity (Nfx-ase). This activity is null under oxygen and partially inhibited under CO. Results suggest that Nfx is biotransformed partially at a cytochrome P450 level but mostly by NADPH P450 reductase. Formation of reactive metabolites nearby DNA and nuclear proteins might be related to long term deleterious effects of this drug.<br /><em>Rat liver nuclear nifurtimox nitroreductase activity. de Toranzo EG, Herrera DM, Castro JA. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):249-54.</em></p>
<p>Liver microsomal (mic); nuclei (N) and mitochondria (mit) anaerobically nitroreduce Nifurtimox (Nfx) in the presence of NADPH generating system. Simultaneous formation of small amounts of nitrite was observed in microsomes and nuclei but not in mitochondria. The microsomal nitroreductase activity was enhanced by the presence of flavine-adenine-dinucleotide disodium salt (FAD), was not inhibited by CO and was significantly inhibited by diphenyleneiodonium (DPI). In the microsomal NADPH-dependent fraction nitrite formation was null in the presence of FAD, DPI and under air and was partially inhibited by pure CO. Pure human cytochrome P450 reductase in the presence of NADPH significantly nitroreduced Nfx and produced small amounts of nitrite. The nitroreductive process was significantly enhanced by FAD but the nitrite formation became null. FAD itself was able to chemically nitroreduce Nfx without production of nitrite. NADPH generating system enhanced the FAD nitroreductive effect and led to small production of nitrite. Formation of reactive metabolites and nitric oxide during Nfx metabolism might contribute to its toxicity.<br /><em>Nifurtimox biotransformation to reactive metabolites or nitrite in liver subcellular fractions and model systems. Montalto de Mecca M, Diaz EG, Castro JA. Toxicol Lett. 2002 Nov 15;136(1):1-8</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Nilotinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Nilotinib is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Nimesulide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as nimesulide is extensively metabolized in the liver following multiple pathways including CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Nisoldipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as nisoldipine is metabolised mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Nitrendipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrendipine is extensively metabolized mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Nitrofurantoin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for pharmacokinetic interaction. As both nitrofurantoin and stavudine can cause peripheral neuropathy, patients should be monitored for symptoms if nitrofurantoin and stavudine are coadministered.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Peripheral neuropathy and susceptibility to peripheral neuropathy which may become severe or irreversible has occurred and may be life threatening. Therefore, treatment should be stopped at the first signs of neural involvement<br /><em>Macrodantin&#174; Capsules 100mg B.P. UK Summary of Product Characteristics, Goldshield Group Limited, updated June 2011</em></p>
<p>Peripheral neuropathy, which may become severe or irreversible, has occurred. Fatalities have been reported.<br /><em>Macrodantin&#174; Capsules US Prescribing Information, Norwich Pharmaceuticals Inc, revised January 2009</em></p>
<p>Up to 20% of patients treated with stavudine will develop peripheral neuropathy, often starting after some months of treatment. Patients with a history of neuropathy, or with other risk factors (for example alcohol, medicines such as isoniazid) are at particular risk. Patients should be monitored for symptoms (persistent numbness, tingling or pain in feet/hands) and if present patients should be switched to an alternate treatment regimen<br /><em>Zerit&#174; UK Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceutical Limited, updated April 2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Nitrous oxide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Most inhaled nitrous oxide is rapidly eliminated unchanged through the lungs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Nitrous oxide is rapidly absorbed on inhalation. The blood/gas partition coefficient is low and most of the inhaled nitrous oxide is rapidly eliminated unchanged through the lungs though small amounts diffuse through the skin.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 05-Dec-2011</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Norelgestromin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as norelgestromin is metabolized to norgestrel (possibly by CYP3A4).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Norethisterone (Norethindrone)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction as norethisterone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Norgestimate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely as norgestimate is rapidly deacetylated to the active metabolite which is further metabolized via CYP450.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Norgestrel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Norgestrel is a racemic mixture with levonorgestrel being biologically active. Levonorgestrel is mainly metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Nortriptyline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as nortriptyline is metabolized mainly by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Nystatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Systemic absorption of nystatin from oral or topical dosage forms is not significant, therefore no drug interactions are expected.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Nystatin is formulated in oral and topical dosage forms and is not systemically absorbed from any of these preparations. Interaction with other medicinal products and other forms of interaction: None known<br /><em>Nystan oral suspension&#174; Summary of product Characteristics, E. R. Squibb &amp; Sons Limited, updated February 2010</em></p>
<p>Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.<br /><em>Nystatin oral suspension USP US Prescribing Information, Taro Pharmaceuticals U.S.A., Inc., updated March 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ofloxacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Ofloxacin is primarily eliminated by the kidney. In vitro data suggest that ofloxacin weakly inhibits the renal transporter OAT3 whereas stavudine is partly excreted via OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Olanzapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Olanzapine is metabolized mainly by CYP1A2, but also by glucuronidation (UGT1A4).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Olmesartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Olmesartan medoxomil is de-esterified to the active metabolite olmesartan which is eliminated in the faeces and urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ombitasvir/Paritaprevir/r</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as stavudine is predominantly eliminated unchanged by the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ombitasvir/Paritaprevir/r + Dasabuvir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as stavudine is predominantly eliminated unchanged by the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Omeprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Omeprazole is mainly metabolized by CYP2C19 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ondansetron</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ondansetron is metabolized mainly by CYP1A2 and CYP3A4 and to a lesser extent by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Orlistat</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as orlistat is mainly eliminated unchanged in the faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Oseltamivir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oseltamivir is converted to oseltamivir carboxylate by esterases which is then excreted in the urine by glomerular filtration and tubular secretion by OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Oxaliplatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Oxaliplatin undergoes non-enzymatic biotransformation and is eliminated renally via OCT2 and MATE2-K. A pharmacokinetic interaction is unlikely. However, the risk of neurotoxicity may be potentially increased as both drugs can cause neuropathy.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Oxamniquine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Oxamniquine is extensively metabolised to inactive metabolites. As renal excretion of unchanged drug is minimal, there is little potential for interaction with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Oxamniquine is extensively metabolised to inactive metabolites, mainly the 6-carboxy derivative, which are excreted in the urine. About 70% of a dose of oxamniquine is excreted as the 6-carboxy metabolite within 12 hours of a dose; traces of the 2-carboxy metabolite have also been detected in the urine. <br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification 12-March-2011</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Oxandrolone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Oxazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxazepam is mainly glucuronidated by UGTs 2B15, 1A9 and 2B7.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Oxcarbazepine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Oxcarbazepine is rapidly reduced by cytosolic arylketone reductases to its active metabolite, 10-hydroxycarbazepine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Oxprenolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as oxprenolol is largely metabolised by glucuronidation. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Oxybutynin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxybutynin is metabolized by CYP3A4.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Oxycodone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Oxytocin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Renal excretion of unchanged oxytocin is thought to be minimal. There is therefore little potential for interaction with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>The plasma half-life of oxytocin is of the order of five minutes, hence the need for continuous iv infusion. Elimination is via the liver, kidney, functional mammary gland and oxytocinase.<br /><em>Syntocinon&#174; (Oxytocin) Ampoules 10 IU/ml UK Summary of Product Characteristics, Alliance Pharmaceuticals, updated March 2007</em></p>
<p>Oxytocin has a plasma half-life of about 1 to 6 minutes which is decreased in late pregnancy and during lactation. Following intravenous administration of oxytocin, uterine response occurs almost immediately and subsides within 1 hour. Following intramuscular injection of the drug, uterine response occurs within 3 to 5 minutes and persists for 2 to 3 hours. Its rapid removal from plasma is accomplished largely by the kidney and the liver. Only small amounts are excreted in urine unchanged.<br /><em>Pitocin&#174; (Oxytocin Injection, USP, synthetic) US Prescribing Information, JHP Pharmaceuticals LLC, updated December 2007</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Paclitaxel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paclitaxel is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Paliperidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paliperidone is primarily eliminated renally (possibly via OCT) with minimal metabolism occurring via CYP2D6 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Pantoprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pantoprazole is mainly metabolized by CYP2C19 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Para-aminosalicylic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. As para-aminosalicylic acid and stavudine are predominantly renally eliminated, including active tubular secretion, there is potential for competition for elimination via renal transport proteins, which may lead to increased concentrations of either drug.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Aminosalicylic acid and its metabolites are excreted in urine by glomerular filtration and tubular secretion. Following a single 4-g dose of aminosalicylic acid in adults with normal renal function, approximately 77% of the dose is excreted in urine within 24 hours; 56% is excreted as the acetylated metabolite. Aminosalicylic acid and its acetyl metabolite accumulate in patients with severe renal disease. Continued acetylation of the parent drug leads exclusively to accumulation of the inactive acetylated form; deacetylation, if it occurs, is minor. <br /><em>Paser&#174; granules (aminosalicylic acid granules) US prescribing information, Jacobus Pharmaceutical Co.&nbsp; Last updated August 1996</em> 
<div>&nbsp;</div>
<div>Since stavudine is actively secreted by the renal tubules, interactions with other actively secreted medicinal products are possible, e.g. with trimethoprim.<br /><em>Zerit&#174; (stavudine) Hard Capsules UK Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceutical Ltd, updated April 2011</em></div></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Paracetamol (Acetaminophen)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paracetamol is mainly metabolized by glucuronidation (UGT1A9 (major), UGT1A6, UGT1A1, UGT2B15), sulfation and, to a lesser extent, by oxidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Paromomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Pancreatitis has been described in a patient with HIV infection receiving paromomycin treatment. Pancreatitis, occasionally fatal, has been reported in up to 2-3% of patients enrolled in monotherapy clinical studies of stavudine, and in < 1% of patients in combination therapy studies including stavudine. Patients with a high risk of pancreatitis or those receiving products known to be associated with pancreatitis should be closely followed for symptoms of this condition.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Pancreatitis was associated with use of paromomycin during treatment of cryptosporidiosis in a patient with HIV infection. <br /><em>Paromomycin-associated pancreatitis in HIV-related cryptosporidiosis. Tan WW, et al.&nbsp; Ann Pharmacother 1995; 29: 22&#8211;4.</em> </p>
<p>Pancreatitis, occasionally fatal, has been reported in up to 2-3% of patients enrolled in monotherapy clinical studies of stavudine, and in &lt; 1% of patients in combination therapy studies including stavudine. Patients with a history of pancreatitis had an incidence of approximately 5% on stavudine, as compared to approximately 2% in patients without such a history. Patients with a high risk of pancreatitis or those receiving products known to be associated with pancreatitis should be closely followed for symptoms of this condition.<br /><em>Zerit&#174; (stavudine) capsules, UK Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceutical Limited, updated April 2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Paroxetine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paroxetine is mainly metabolized by CYP2D6 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Pazopanib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Pazopanib is metabolized by CYP3A4 and to a lesser extent 1A2 and 2C8.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Peginterferon alfa-2a</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>In study NR15961, patients concurrently treated with stavudine and interferon therapy with or without ribavirin, the incidence of pancreatitis and/or lactic acidosis was 3% (12/398).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>In study NR15961, patients concurrently treated with stavudine and interferon therapy with or without ribavirin, the incidence of pancreatitis and/or lactic acidosis was 3% (12/398).<br /><em>Pegasys Summary of Product Characteristics, Roche Products Ltd, July 2010.</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Penicillamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for interaction. Up to 80% of a dose is excreted via the kidneys, predominantly as metabolites and rarely as unchanged drug. There is therefore low potential for clinically significant interactions with stavudine via competition for active renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Penicillamine is not extensively metabolised in man. The drug is rapidly excreted in urine; however traces remain in the plasma after a single dose for up to 48 hours due to extensive protein binding. Penicillamine is eliminated primarily by metabolism to the disulphide which is excreted in the urine together with a small proportion of unchanged drug. Some of the dose is excreted as a penicillamine copper complex and some as the S-methyl derivative.<br /><em>Penicillamine 250mg Tablets UK Summary of Product Characteristics, Kent Pharmaceuticals Ltd, updated April 2012</em></p>
<p>About 80% of the absorbed dose is excreted rapidly in the urine, mostly as mixed disulphides. Some of the dose is excreted as a penicillamine copper complex and some as the S-methyl derivative.<br /><em>Distamine&#174; (Penicillamine) 250mg Film-coated tablets UK Summary of Product Characteristics, Alliance Pharmaceuticals, updated June 2010</em></p>
<p>Very little information is available on the metabolism of the penicillamine that is not excreted as part of a metal or cysteine complex. The drug is believed to be metabolized in the liver and excreted in urine and feces, principally as inactive disulfides: penicillamine disulfide, penicillamine-cysteine disulfide, and small amounts of S-methyl-d-penicillamine. The manufacturers report that penicillamine is rarely excreted unchanged in urine. In one study, about 50% of a dose of penicillamine was excreted in urine, about 20% in feces, and about 30% was unaccounted for after 24 hours.<br /><em>AHFS Drug Information (via Medicines Complete), published by the American Society of Health-System Pharmacists Inc, updated April 2009</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Penicillins</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Penicillins are mainly eliminated in the urine (20% by glomerular filtration and 80% by tubular secretion via OAT) whereas stavudine is partly eliminated renally by OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Pentamidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but may increase the risk of pancreatitis. Avoid combination if possible. Due to the prolonged half-life of pentamidine, stavudine should not be started until 1 week after pentamidine therapy is concluded.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Pentoxifylline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on limited data for metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pentoxifylline has not been well described but some studies indicate oxidation by CYP1A2, reduction by carbonyl reductase, and oxidation by carboxylase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Perazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perazine is demethylated by CYP3A4 and to a lesser extent by CYP2C9, and oxidated by FMO3.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Pericyazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pericyazine has not been well characterized but is likely to involve CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Perindopril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perindopril is hydrolysed to the active metabolite perindoprilat and is metabolized to other inactive metabolites. Elimination occurs predominantly via the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Perphenazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as perphenazine is metabolized by CYP2D6. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Pethidine (Meperidine)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pethidine is metabolized mainly by CYP2B6 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Phencyclidine (PCP)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Phencyclidine is extensively metabolized to inactive metabolites by a variety of metabolic routes (mainly CYP3A4).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Phenelzine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenelzine is primarily metabolized by oxidation via monoamine oxidase and to a lesser extent by acetylation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Phenobarbital (Phenobarbitone)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenobarbital undergoes CYP-mediated metabolism. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Phenprocoumon</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenprocoumon is metabolized by CYP2C9 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Phenytoin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenytoin undergoes CYP-mediated metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Phytomenadione (Vitamin K)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Renal elimination of unchanged phytomenadione is minimal. There is therefore little potential for interaction with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Vitamin K1 is converted to more polar metabolites, such as phytomenadione-2,3-epoxide. The half-life of vitamin K1 in plasma is about 1.5 to 3 hours. Vitamin K1 is excreted in the bile and urine as glucuronide and sulphate conjugates.<br /><em>Konakion MM&#174; (phytomenadione) 2mg/0.2ml paediatric ampoules Product Information, Hoffmann-La Roche Ltd, updated November 2006</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Pilocarpine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for interaction when pilocarpine is used either orally or as eye drops. Renal elimination of unchanged pilocarpine is minimal. There is therefore little potential for interaction with stavudine via competition for renal elimination pathways. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p><strong>Systemic use:</strong> Pilocarpine is primarily metabolized by CYP2A6 and has demonstrated a capacity to inhibit CYP2A6 in vitro. Serum esterases are also involved in the biotransformation of pilocarpine to pilocarpic acid. Approximately 35% of dose is eliminated as 3-hydroxypilocarpine in urine and 20% of dose is excreted unchanged in the urine. Mean elimination half-lives for pilocarpine is 0.76 and 1.35 hours after repeated oral doses of 5 and 10 mg of pilocarpine hydrochloride, respectively.<br /><em>Salagen&#174; (Pilocarpine) 5mg Film Coated Tablets UK Summary of Product Characteristics, Novartis Pharmaceuticals UK Ltd, updated November 2011</em></p>
<p><strong>Ocular use:</strong> Systemic reactions rarely occur when treating chronic simple glaucoma at normal doses. However, in the treatment of acute closed-angle glaucoma the possibility of systemic reactions must be considered because of the higher doses given. Pilocarpine has a low ocular bioavailability when topically applied and this has been attributed to extensive pre-corneal drug loss in conjunction with the resistance to normal corneal penetration. Further, pilocarpine appears to bind to the eye pigments from which it is gradually released to the muscles. Inactivation of pilocarpine in the eye is thought to occur by a hydrolysing enzyme. The amount of this enzyme is not changed by the prolonged use of pilocarpine by glaucoma patients, nor is it changed in patients poorly controlled by glaucoma therapy.<br /><em>Minims Pilocarpine Nitrate 2% w/v Eye drops solution UK Summary of Product Characteristics, Bausch &amp; Lomb U.K Limited, updated July 2012</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Pimozide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pimozide is metabolized mainly by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Pindolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pindolol is partly metabolized to hydroxymetabolites (possibly by CYP2D6) and partly eliminated unchanged in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Pioglitazone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pioglitazone is metabolized by mainly CYP2C8 and to a lesser extent by CYPs 3A4, 1A2 and 2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Pipotiazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pipotiazine has not been well described but may involve CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Piroxicam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as piroxicam is primarily metabolized by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Pitavastatin </p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pitavastatin is metabolised by UGTs 1A3 and 2B7 with minimal metabolism by CYPs 2C9 and 2C8.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Posaconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Posaconazole is eliminated mainly unchanged in the faeces and only a minimal amount undergoes biotransformation (mainly glucuronidation by UGT1A4).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Potassium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as potassium is eliminated renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Pramipexole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pramipexole is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporter OCT2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Prasugrel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prasugrel is a prodrug and is converted to its active metabolite mainly by CYP3A4 and CYP2B6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Pravastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Praziquantel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Renal excretion of unchanged praziquantel appears to be minimal, therefore there is little potential for interaction with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Praziquantel is metabolised via various cytochrome P450 isoenzymes, mainly CYP2B1 and CYP3A4, and therefore has the potential to interact with drugs that are inhibitors or inducers of such enzymes. Enzyme-inducing drugs such as carbamazepine, dexamethasone, phenobarbital, and phenytoin may decrease plasma concentrations of praziquantel. Conversely, enzyme inhibitors such as cimetidine, erythromycin, itraconazole, and ketoconazole may increase plasma concentrations of praziquantel. It is excreted in the urine, mainly as metabolites which are thought to be inactive.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification 14-May-2011</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Prazosin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Prazosin undergoes extensive hepatic metabolism primarily by demethylation and conjugation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Prednisolone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednisolone undergoes hepatic metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Prednisone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednisone is converted to the active metabolite prednisolone by 11-B-hydroxydehydrogenase. Prednisolone is then metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Pregabalin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as pregabalin is cleared mainly by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Primaquine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Primaquine is metabolised mainly through a non-CYP mediated mechanism and only a small fraction of the drug is believed to be metabolised through CYP450.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Probenecid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. In vitro data suggest that probenecid is a substrate and inhibitor of OAT. Coadministration could increase stavudine concentrations as OAT is involved in the excretion of stavudine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Procarbazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction.  Procarbazine is metabolized to azoprocarbazine by CYP450 (mainly CYP2B and 1A) and monoamine oxidase. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Prochlorperazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prochlorperazine is metabolised by CYP2D6 and CYP2C19. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Proguanil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Proguanil is partly excreted unchanged and partly metabolized to its more active metabolite cycloguanil by CYP2C19 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Promethazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Promethazine is metabolized mainly by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Propafenone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propafenone is metabolized mainly by CYP2D6 and to a lesser extent by CYP1A2 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Propofol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propofol is glucuronidated via UGT1A9, UGT1A8 and is oxidized mainly via CYP2B6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Propranolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propranolol is metabolized by 3 routes (aromatic hydroxylation by CYP2D6, N-dealkylation followed by side chain hydroxylation via CYPs 1A2, 2C19, 2D6, and direct glucuronidation).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Propylthiouracil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Renal elimination of unchanged propylthiouracil is minor, therefore there is little potential for interaction with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Propylthiouracil is readily absorbed and is extensively metabolized. Approximately 35% of the drug is excreted in the urine, in intact and conjugated forms, within 24 hours.<br /><em>Propylthiouracil tablets US Prescribing Information, DAVA Pharmaceuticals Inc. updated February2010</em></p>
<p>Although the exact metabolic fate of propylthiouracil has not been fully established, the drug is extensively metabolized to its glucuronide conjugate and other minor metabolites. The drug and its metabolites are excreted in urine, with about 35% of a dose excreted within 24 hours<br /><em>AHFS Drug Information (via Medicines Complete), published by the American Society of Health-System Pharmacists Inc, updated October 2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Protamine sulphate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on very limited data concerning the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. The metabolism of protamine has not been fully elucidated, however protamine complexed with heparin is thought to be partially metabolised by fibrinolysin. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Protamine sulphate has a rapid onset of action. Following intravenous administration, neutralisation of heparin occurs within 5 minutes. Although the metabolic fate of the protamine-heparin complex is not known, it appears that the complex is partially degraded, thus freeing heparin. No interactions are known.<br /><em>Protamine Sulphate Injection BP 1% UK Summary of Product Characteristics, Sovereign Medical, updated September 2007<br />Prosulf&#174; (protamine sulphate)10mg/ml Solution for Injection UK Summary of Product Characteristics, Wockhardt UK Ltd updated September 2010</em></p>
<p>Although the metabolic fate of the protamine-heparin complex has not been elucidated, it appears that the protamine in the heparin-protamine complex may be partially metabolized or attacked by fibrinolysin, thus freeing heparin<br /><em>AHFS Drug Information (via Medicines Complete), published by the American Society of Health-System Pharmacists Inc, December 2008</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Prucalopride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prucalopride is minimally metabolised and mainly eliminated renally, partly by active secretion by renal transporters. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Pyrantel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Less than half of a pyrantel dose is absorbed from the gastrointestinal tract. Renal excretion of unchanged pyrantel is minimal (<7%), therefore there is little potential for interaction with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Only a small proportion of a dose of pyrantel embonate is absorbed from the gastrointestinal tract. Up to about 7% is excreted as unchanged drug and metabolites in the urine but over half of the dose is excreted unchanged in the faeces.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification 14-May-2011</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Pyrazinamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pyrazinamide is mainly metabolized by xanthine oxidase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Pyridostigmine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Pyridostigmine is predominantly excreted unchanged via the kidneys, with up to 74% of renal clearance attributed to active tubular secretion. There is therefore potential for competition with stavudine for active renal transport mechanisms, which may lead to increased levels of either drug.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>To assess the contribution of tubular secretion to the renal excretion of pyridostigmine, and its modification by other cationic drugs, six volunteers were given single oral doses of 60mg pyridostigmine bromide with and without co-administration of ranitidine or pirenzepine. In patients with myasthenia receiving continuous pyridostigmine therapy, renal clearance values were obtained in the same manner with and without ranitidine (10 patients) or pirenzepine (nine patients) co-medication. Pyridostigmine renal clearance averaged 6.65 ml/min per kg (350% of the creatinine clearance) in all subjects, 74% being due to net tubular secretion. Mean values for pyridostigmine renal clearance and for clearance by secretion were decreased in the presence of pirenzepine, but plasma concentrations were not affected significantly. Ranitidine caused a small non-significant decrease of the pyridostigmine clearance in patients. The renal clearance of creatinine was slightly increased by pyridostigmine in volunteers and slightly decreased by pirenzepine in the total group of subjects.<br /><em>Eiermann B, Sommer N, Winne D, Schumm F, Maier U, Breyer-Pfaff U. Renal clearance of pyridostigmine in myasthenic patients and volunteers under the influence of ranitidine and pirenzepine. Xenobiotica. 1993 Nov;23(11):1263-75.</em></div>
<div>&nbsp;</div>
<div>Since stavudine is actively secreted by the renal tubules, interactions with other actively secreted medicinal products are possible, e.g. with trimethoprim.<br /><em>Zerit&#174; (stavudine) Hard Capsules UK Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceutical Ltd, updated April 2011</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Pyridoxine (Vitamin B6)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Pyridoxine is absorbed from the GI tract and is converted to the active form pyridoxal phosphate. It is excreted in the urine as 4-pyridoxic acid.<br /><em>Vitamin B Compound Strong Tablets, UK Summary of Product Characteristics, Actavis UK Ltd, updated July 2012</em></p>
<p>Pyridoxine, pyridoxal, and pyridoxamine are readily absorbed from the gastrointestinal tract after oral doses and are converted to the active forms pyridoxal phosphate and pyridoxamine phosphate. They are stored mainly in the liver where there is oxidation to 4-pyridoxic acid and other inactive metabolites which are excreted in the urine. As the dose increases, proportionally greater amounts are excreted unchanged in the urine.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), last modified 2006-07-17</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Pyrimethamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant pharmacokinetic interaction is unlikely. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Quercetin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Quetiapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quetiapine is primarily metabolised by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Quinapril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinapril is de-esterified to the active metabolite quinaprilat which is eliminated primarily by renal excretion via OAT3.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Quinidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinidine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Quinine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as quinine is extensively metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Rabeprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rabeprazole is mainly metabolized by CYP2C19 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green outline">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Raltegravir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Not Available</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Not Available</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ramipril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ramipril is hydrolysed to the active metabolite ramiprilat, and is metabolized to the diketopiperazine ester, diketopiperazine acid and the glucuronides of ramipril and ramiprilat.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ranitidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ranitidine is excreted via the kidney, partially by the cationic system.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ranolazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ranolazine is primarily metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Rasagiline </p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely as rasagiline is metabolised predominantly by CYP1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Reboxetine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as reboxetine is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Repaglinide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Repaglinide is metabolized by CYP2C8 and CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Retinol (Vitamin A)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Vitamin A esters are hydrolysed by pancreatic enzymes to retinol, which is then absorbed and re-esterified. Some retinol is stored in the liver. Retinol not stored in the liver undergoes glucuronide conjugation and subsequent oxidation to retinal and retinoic acid.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Vitamin A substances are readily absorbed from the gastrointestinal tract but absorption may be reduced in the presence of fat malabsorption, low protein intake, or impaired liver or pancreatic function. Vitamin A esters are hydrolysed by pancreatic enzymes to retinol, which is then absorbed and re-esterified. Some retinol is stored in the liver. It is released from the liver bound to a specific &#945;1-globulin (retinol-binding protein) in the blood. The retinol not stored in the liver undergoes glucuronide conjugation and subsequent oxidation to retinal and retinoic acid; these and other metabolites are excreted in urine and faeces.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 05-Dec-2011</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ribavirin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No pharmacokinetic interaction observed in vivo. Monitor for treatment-associated toxicities, especially hepatic decompensation. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>In vitro studies indicate that the activation of stavudine is inhibited by doxorubicin and ribavirin. Therefore coadministration of stavudine with either doxorubicin or ribavirin should be undertaken with caution. <br /><em>Zerit Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, March 2011.</em></p>
<p>In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine. The clinical significance of the interaction with stavudine is unknown; therefore, concomitant use of stavudine with ribavirin should be undertaken with caution. No pharmacokinetic (eg, plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (eg, loss of HIV/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n=18), stavudine (n=10), or zidovudine (n=6) were coadministered as part of a multi-drug regimen to HIV/HCV co-infected patients. Although no evidence of a pharmacokinetic or pharmacodynamic interaction was seen when ribavirin was coadministered with stavudine in HIV/HCV co-infected patients, hepatic decompensation (some fatal) has occurred in HIV/HCV co-infected patients receiving combination antiretroviral therapy for HIV and interferon and ribavirin. Patients receiving interferon with or without ribavirin and stavudine should be closely monitored for treatment-associated toxicities, especially hepatic decompensation. Discontinuation of stavudine should be considered as medically appropriate. Dose reduction or discontinuation of interferon, ribavirin, or both should also be considered if worsening clinical toxicities are observed, including hepatic decompensation (eg, Child-Pugh &gt;6). <br /><em>Zerit Prescribing Information, Bristol-Myers Squibb Company, January 2012.</em></p>
<p>The effect of ribavirin (800 mg/day) on the plasma and intracellular PK of zidovudine, lamivudine and stavudine was studied HIV/HCV co-infected subjects receiving zidovudine plus lamivudine, or stavudine plus lamivudine. Plasma zidovudine, lamivudine and stavudine and intracellular drug and endogenous triphosphates were measured at baseline without ribavirin and after 8-12 weeks of ribavirin co-administration. Plasma results showed no impact of ribavirin on nucleoside concentrations and ribavirin levels were consistent with previous data measured in the absence of the three NRTIs. Similar findings were observed for the deoxycytidine and deoxythymidine triphosphate analogues, when given with or without ribavirin, suggesting that ribavirin does not perturb the intracellular metabolism of zidovudine, lamivudine or stavudine.<br /><em>Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with HCV/HIV co-infection: final results of a randomized clinical study. Gries JM, et al. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2004, abstract 136LB. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Riboflavin (Vitamin B2)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Riboflavin is absorbed from the GI tract and in the circulation is bound to plasma proteins. Although widely distributed, little is stored in the body, and amounts in excess of requirements are excreted in the urine.<br /><em>Vitamin B Compound Strong Tablets UK Summary of Product Characteristics, Actavis UK Ltd, updated July 2012</em></p>
<p>Riboflavin is readily absorbed from the gastrointestinal tract. Although riboflavin is widely distributed to body tissues little is stored in the body. Riboflavin is converted in the body to the coenzyme flavine mononucleotide (FMN; riboflavin 5&#8242;-phosphate) and then to another coenzyme flavine adenine dinucleotide (FAD). About 60% of FMN and FAD are bound to plasma proteins. Riboflavin is excreted in urine, partly as metabolites. As the dose increases, larger amounts are excreted unchanged.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 05-Dec-2011</em> </p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Rifabutin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No clinically significant interaction observed. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>The pharmacokinetics of stavudine were determined in 10 HIV-infected subjects following administration of stavudine (40 mg twice daily) alone and with single, double or triple combinations of clarithromycin (500 mg twice daily), fluconazole (200 mg once daily) and/or rifabutin (300 mg once daily). Stavudine exposure was not significantly altered by multiple concomitant medications. The greatest difference in AUC between stavudine administered alone or with any other regimen was an 18% decrease when given with the rifabutin/clarithromycin combination. <br /><em>A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus-infected patients. Piscitelli SC, et al. Antimicrob Agents Chemother, 1999, 43: 647-650. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Rifampicin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as rifampicin is deacetylated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Rifapentine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely as rifapentine is deacetylated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Rifaximin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Rifaximin is mainly excreted in faeces, almost entirely as unchanged drug.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Rilpivirine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. No clinically relevant drug-drug interaction is expected when rilpivirine is co-administered with stavudine. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration with stavudine has not been studied. No clinically relevant drug-drug interactions are expected. No dose adjustment is required.</div>
<div><em>Edurant Summary of Product Characteristics, Janssen-Cilag Ltd, November 2011.</em>
<div>&nbsp;</div>No clinically relevant drug-drug interaction is expected when rilpivirine is co-administered with stavudine.</div>
<div><em>Edurant Prescribing Information, Tibotec Inc, May 2011.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Rilpivirine/FTC/TAF</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Odefsey is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be co-administered with other antiretroviral medicinal products.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Odefsey is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be co-administered with other antiretroviral medicinal products.<br><em>Odefsey Summary of Product Characteristics, Gilead Sciences Ltd, June 2016.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Rimantadine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rimantadine is both hydroxylated and glucuronidated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Risperidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely. Risperidone is metabolized by CYP2D6 and to a lesser extent by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ritonavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Specific drug interaction studies have not been performed. Based on the different elimination pathways (stavudine is primarily renally excreted), no clinically significant interaction is expected. Stavudine concentrations were assessed in paired samples of blood and CSF from various studies. Unexpectedly, higher stavudine concentrations (3-6 fold higher) were found in regimens containing indinavir and/or ritonavir. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p><em><strong>LHPG Comment</strong>: Specific drug interaction studies have not been performed. Based on the different elimination pathways (stavudine is primarily renally excreted), no clinically significant interaction is expected.</em></p>
<p>d4T concentrations were assessed in paired samples of blood and CSF in the 050, ADAM, Prometheus and ERA studies. Unexpectedly, it was found that d4T concentrations were 3&#8211;6 fold higher in regimens containing indinavir and/or ritonavir. <br /><em>Increased stavudine concentrations in plasma and cerebrospinal fluid: a possible interaction with ritonavir and/or indinavir. Reijers MHE, Gisolf EH, Van Praag RME, et al. 13th International AIDS Conference, Durban, July 2000, abstract TuPeB3299. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Rituximab</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rituximab is a monoclonal IgG antibody. Elimination is similar to endogenous IgG and occurs primarily via proteolytic catabolism throughout the body.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Rivaroxaban</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely. Rivaroxaban is partly metabolized in the liver (by CYP3A4, CYP2J2 and hydrolytic enzymes) and partly eliminated unchanged in urine (by P-gp and BCRP).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Rizatriptan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rizatriptan is metabolized by oxidative deamination by monoamine oxidase-A (MAO-A).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Rocuronium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely. Rocuronium is mostly cleared in the bile although up to 30% may be excreted renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ropinirole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as ropinirole is metabolised predominantly by CYP1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Rosiglitazone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely. Rosiglitazone is metabolized mainly by CYP2C8 and to a lesser extent by CYP2C9. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Rosuvastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely as rosuvastatin is largely excreted unchanged via the faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Sacubitril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sacubitril is rapidly converted to LBQ657 (active metabolite) by carboxylesterases and the active metabolite is not further metabolized to a significant extent.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Salbutamol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salbutamol is metabolized to the inactive salbutamol-4-O-sulphate. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Salmeterol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salmeterol is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green outline">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Saquinavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Not Available</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Not Available</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Saw palmetto (Serenoa repens)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Saxagliptin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Saxagliptin is mainly metabolized by CYP3A4/5 but does not inhibit or induce this enzyme. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary) </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Senna</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Senna glycosides are hydrolysed by colonic bacteria in the intestinal tract and the active anthraquinones liberated into the colon. Excretion occurs in the urine and the faeces and also in other secretions. No clinically significant drug interactions are known.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>There is some absorption of anthraquinone laxatives following administration by mouth. Senna glycosides are hydrolysed by colonic bacteria in the intestinal tract and the active anthraquinones liberated into the colon. Excretion occurs in the urine and the faeces and also in other secretions including breast milk. No clinically significant drug interactions are known.<br /><em>Senna Laxative Tablets, UK Summary of Product Characteristics, The Boots Company PLC, updated February 2008</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Sertraline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sertraline is mainly metabolized by CYP2B6 and to a lesser extent by CYPs 2C9, 2C19, 2D6 and 3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Seville orange juice</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Sevoflurane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as sevoflurane is almost exclusively eliminated unchanged by the lungs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Sildenafil (Erectile Dysfunction)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sildenafil is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Sildenafil (Pulmonary Arterial Hypertension)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sildenafil is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Simeprevir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but no clinically relevant drug-drug interaction is expected. No dose adjustment is required.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration has not been studied. No clinically relevant drug drug interaction is expected. No dose adjustment is required.</div><div><em>Olysio Summary of Product Characteristics, Janssen-Cilag, May 2014. </em></div><div>&nbsp;</div><div>No clinically relevant drug-drug interaction is expected when simeprevir is co-administered with stavudine. </div><div><em>Olysio US Prescribing Information, Janssen, December 2013.&nbsp;</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Simvastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Simvastatin is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Sirolimus</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sirolimus is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Sitagliptin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sitagliptin is primarily eliminated in urine as unchanged drug (active secretion by OAT3, OATP4C1, P-gp) and metabolism by CYP3A4 represents a minor elimination pathway. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Sodium nitroprusside</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Sodium nitroprusside is extensively metabolized, with little or no renal elimination of unchanged drug. There is therefore little potential for interaction with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Sodium nitroprusside is rapidly metabolized, probably by interaction with sulfhydryl groups in the erythrocytes and tissues. Cyanogen (cyanide radical) is produced which is converted to thiocyanate in the liver by the enzyme thiosulfate sulfurtransferase (rhodanase). This mitochondrial enzyme normally is present in excess quantities such that the rate-limiting step in the conversion of cyanogen to thiocyanate usually is the availability of sulfur donors (e.g., thiosulfate, cystine, cysteine). Sodium nitroprusside is excreted entirely as metabolites, principally thiocyanate. In animals, sodium nitroprusside metabolites are excreted mainly in urine, exhaled air, and probably in feces. The elimination half-life of thiocyanate is 2.7&#8211;7 days when renal function is normal but is longer in patients with impaired renal function or hyponatremia.<br /><em>AHFS Drug Information (via Medicines Complete), published by the American Society of Health-System Pharmacists Inc, 01/2009</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Sodium stibogluconate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for pharmacokinetic interaction. Pancreatitis has been described as a relatively common serious adverse effect of sodium stibogluconate therapy. Pancreatitis, occasionally fatal, has been reported in up to 2-3% of patients enrolled in monotherapy clinical studies of stavudine, and in < 1% of patients in combination therapy studies including stavudine. Patients with a high risk of pancreatitis or those receiving products known to be associated with pancreatitis should be closely followed for symptoms of this condition.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Transient rises in serum lipase and amylase usually occur during treatment with sodium stibogluconate. Symptomatic pancreatitis has also been reported<br /><em>Pentostam&#174; (sodium stibogluconate) injection UK Summary of Product Characteristics, GlaxoSmithKline UK, updated August 2007</em></p>
<p>Various case studies and trials of efficacy/tolerability of sodium stibogluconate describe pancreatitis during treatment, particularly in immunosuppressed individuals. Several authors recommend monitoring of serum amylase and consideration of pancreatitis in patients experiencing abdominal pain.<br /><em>Donovan KL et al. J Infect. 1990 Jul;21(1):107-10; McCarthy AE et al. Clin Infect Dis. 1993 Nov;17(5):952-3; McBride MO et al. Clin Infect Dis. 1995 Sep;21(3):710; Aronson NE et al. Clin Infect Dis. 1998 Dec;27(6):1457-64; Aronson NE et al. PLoS Negl Trop Dis. 2010 Mar 9;4(3):e628.</em></p>
<p>Pancreatitis, occasionally fatal, has been reported in up to 2-3% of patients enrolled in monotherapy clinical studies of stavudine, and in &lt; 1% of patients in combination therapy studies including stavudine. Patients with a history of pancreatitis had an incidence of approximately 5% on stavudine, as compared to approximately 2% in patients without such a history. Patients with a high risk of pancreatitis or those receiving products known to be associated with pancreatitis should be closely followed for symptoms of this condition.<br /><em>Zerit&#174; (stavudine) capsules, UK Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceutical Limited, updated April 2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Sofosbuvir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Based on metabolism and elimination there is little potential for interaction as stavudine is renally excreted and undergoes minimal metabolism. Sofosbuvir is a prodrug and formation of its active metabolite is unlikely to be affected by comedications.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Solifenacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Solifenacin is metabolized by CYP3A4.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Sorafenib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Sorafenib is metabolized to a moderate extent by CYP3A4 and UGT1A9, UGT1A1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Spectinomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Spectinomycin is predominantly eliminated unchanged in the kidneys via glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Spironolactone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Spironolactone is partly metabolized by the flavin containing monooxygenases.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Stanozolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>St John&#39;s Wort</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. St Johns wort is unlikely to affect the exposure of NRTIs such as stavudine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Streptokinase</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Like other proteins, streptokinase is metabolised proteolytically in the liver and eliminated via the kidneys. Renal elimination of unchanged streptokinase is minimal. There is therefore little potential for interaction with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>The elimination kinetics of streptokinase follows a biphasic course. A small proportion of the dose is bound to anti-streptokinase antibodies and metabolised with a half-life of 18 minutes, whilst most of it forms the streptokinase-plasminogen activator complex and is biotransformed with a half-life of about 80 minutes. Like other proteins, streptokinase is metabolised proteolytically in the liver and eliminated via the kidneys.<br /><em>Streptokinase 750,000 iu UK Summary of Product Characteristics, Beacon Pharmaceuticals, updated August 2012</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Streptomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Streptomycin is excreted rapidly in the urine by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Strontium ranelate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as strontium ranelate is not metabolised and is excreted unchanged by the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Sufentanil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as sufentanil undergoes extensive CYP3A4 metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Sulfadiazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Sulfadiazine has been associated with crystalluria leading to renal toxicity and in some cases renal failure, and case reports in immunocompromised patients have suggested that AIDS patients may be particularly prone to sulfadiazine-induced renal toxicity. As stavudine is predominantly excreted via active renal transport, monitoring of renal function is warranted if sulfadiazine is administered with stavudine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>About 50% of a single dose of sulfadiazine given orally is excreted in the urine in 24 hours; 15 to 40% is excreted as the acetyl derivative. The urinary excretion of sulfadiazine and the acetyl derivative is dependent on pH. About 30% is excreted unchanged in both fast and slow acetylators when the urine is acidic whereas about 75% is excreted unchanged by slow acetylators when the urine is alkaline. The half-life of sulfadiazine ranges from 7 to 12 hours and that of its metabolite from 8 to 12 hours. There have been reports of crystalluria and renal failure associated with the use of sulfadiazine in immunocompromised patients, including the suggestion that AIDS patients may be particularly prone to sulfadiazine-induced renal toxicity<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 05-Dec-2011</em></p>
<p>A case report decribes a patient with newly-diagnosed HIV infection and biopsy-proven cerebral toxoplasmosis treated with sulphadiazine 2 g six-hourly with pyrimethamine 50 mg once daily. Despite adequate hydration and daily examination of urine for sulphadiazine crystals, renal function deteriorated suddenly after 13 days of sulphadiazine therapy. Obstructive uropathy due to bilateral ureteric stones with hydronephrosis occurred, resulting in rapid onset renal failure. Sulphadiazine was discontinued and clindamycin was substituted. With intravenous fluid hydration and bilateral nephrostomies the urolithiasis resolved. Sulphadiazine and its hepatic metabolite acetylsulphadiazine are excreted via the renal tract; they are poorly soluble in urine and may potentially precipitate in the acid environment, producing crystalluria and stones. Crystalluria is common, may occur in up to 28% of patients taking sulphadiazine, and is potentially nephrotoxic via both direct chemical irritation of the tubular epithelium and tubular obstruction due to urolithiasis.&nbsp; The authors suggest that if outpatient treatment of toxoplasmosis is contemplated, careful attention to fluid balance, daily checking of urine for the presence of crystalluria, and frequent monitoring of biochemical renal function (3 times a week) are required in order to avoid this potentially serious complication of treatment.<br /><em>Sulphadiazine-induced obstructive renal failure complicating treatment of HIV-associated toxoplasmosis. Allinson J, Topping W, Edwards SG, Miller RF. Int J STD AIDS. 2012 Mar;23(3):210-2</em></p>
<p>Various case reports describe renal toxicity in patients taking sulfadiazine, in HIV positive and negative patients:<br /><em>Mir N et al. Int J STD AIDS. 1997 Jan;8(1):61-2; Dong BJ et al. J Am Board Fam Pract. 1999 May-Jun;12(3):243-8; de la Prada Alvarez FJ et al. An Med Interna. 2007 May;24(5):235-8; Hyvernat H et al. Presse Med. 2006 Mar;35(3 Pt 1):423-4; Solano Rem&#237;rez M et al. An Med Interna. 2005 Aug;22(8):395-6; de Sequera P et al. Postgrad Med J. 1996 Sep;72(851):557-8; Rodr&#237;guez-Carballeira M et al. Enferm Infecc Microbiol Clin. 1996 Feb;14(2):125-7; D&#237;az F et al. Ann Pharmacother. 1996 Jan;30(1):41-2; Peh CA et al. Aust N Z J Med. 1995 Feb;25(1):58; Marques LP. Clin Nephrol. 1994 Jul;42(1):68-9.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Sulfadoxine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Sulfadoxine is rarely used alone, but is usually given in combination with pyrimethamine. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro data suggest that pyrimethamine inhibits the renal transporters OCT2 and MATE1. A clinically significant drug interaction is unlikely as stavudine is partly excreted via OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Sulfasalazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for interaction. Renal elimination of unchanged sulfasalazine is minimal. There is therefore little potential for clinically significant interactions with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Around 90% of a dose reaches the colon where bacteria split the drug into sulfapyridine (SP) and mesalazine (ME). These are also active, and the unsplit sulfasalazine (SASP) is also active on a variety of symptoms. Most SP is absorbed, hydroxylated or glucuronidated and a mix of unchanged and metabolised SP appears in the urine. Some ME is taken up and acetylated in the colon wall, such that renal excretion is mainly AC-ME. SASP is excreted unchanged in the bile and urine. Turning to mesalazine, in urine only AC-ME (not free ME) was demonstrable, the acetylation probably largely achieved in the colon mucosa. After a 3g SASP dose lag time was 6.1&#177;2.3 hours and plasma levels kept below 2&#181;g/ml total ME. Urinary excretion half life was 6.0&#177;3.1 hours and absorption half life based on these figures 3.0&#177;1.5 hours. Renal clearance constant was 125ml/min corresponding to the GFR.<br /><em>Salazopyrin En-Tabs&#174; (Sulfasalazine) UK Summary of Product Characteristics, Pfizer Limited, updated August 2010</em></p>
<p>Sulfasalazine is metabolised by intestinal bacteria to sulfapyridine (SP) and 5-ASA. Approximately 15% of a dose of sulfasalazine is absorbed as parent and is metabolised to some extent in the liver to the same two species. The observed plasma half life for IV sulfasalazine is 7.6 &#177;3.4 hrs. The primary route of metabolism of SP is via acetylation to form AcSP. The rate of metabolism of SP to AcSP is dependent upon acetylator phenotype. SP can also be metabolised to 5-hydroxy-sulfapyridine and N-acetyl-5-hydroxy-sulfapyridine. 5-ASA is primarily metabolised in both the liver and intestine to N-acetyl-5-aminosalicylic acid via a non-acetylation phenotype dependent route. Due to low plasma levels produced by 5-ASA after oral administration, reliable estimates of plasma half lives are not possible. Absorbed SP and 5-ASA and their metabolites are primarily eliminated in the urine either as free metabolites or glucuronide conjugates. The majority of 5-ASA stays within the colonic lumen and is excreted as 5-ASA and acetyl 5-ASA within the feces. The calculated clearance of sulfasalazine following IV administration was 1L/hr. Renal clearance was estimated to account for 37% of total clearance.<br /><em>Sulfasalazine tablets USP US Prescribing Information, Watson Laboratories Inc, updated May 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Sulpiride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sulpiride is mainly excreted in the urine and faeces as unchanged drug.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Sumatriptan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sumatriptan is eliminated primarily by metabolism mediated by monoamine oxidase A.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Sunitinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Sunitinib is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Suramin sodium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Suramin appears to be predominantly unchanged via renal glomerular filtration. There is therefore little potential for competition with stavudine for active renal transport pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>The clinical pharmacokinetics of suramin were studied in 4 patients with AIDS given 6.2 g intravenously over 5 weeks. Suramin accumulated during treatment and plasma concentrations exceeded 100 micrograms/mL for several weeks. After the last dose the terminal half-life of suramin ranged from 44 to 54 days. At least 99.7% was bound to plasma proteins. Renal clearance accounted for most (80%) of the elimination of suramin from the body. There appeared to be little or no metabolism of suramin.<br /><em>Collins JM, Klecker RW Jr, Yarchoan R, et al. Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol. 1986 Jan;26(1):22-6.</em></p>
<p>Suramin was administered to 49 patients in a Phase I cancer trial with real-time pharmacokinetic monitoring and dose individualization to achieve targeted mean plasma concentrations of 210 and 155 mg/liter during the 7-day period between days 15 and 22. Pharmacokinetic sampling after doses on days 1, 3, 5, and 8 was used to modify weekly suramin doses, beginning on day 15, in an attempt to achieve specific averaged plasma concentrations of 210 and 155 mg/liter. A 200-mg test dose was not effective in prospectively determining individual pharmacokinetic parameters and dosage requirements. Prospective use of surrogate substrates for CYP1A2, CYP3A3/4, and CYP2D6 showed no consistent effect of suramin on these enzymes. Although a correlation between creatinine clearance and suramin renal clearance was found (r2 = 0.38; P &lt; 0.00005), there was no correlation between creatinine clearance and total suramin clearance (P = 0.21). As expected for a drug eliminated renally by filtration, the extrapolated intercept of suramin renal clearance approximates zero at a creatinine clearance of 0 ml/min<br /><em>Hutson PR, Tutsch KD, Rago R, Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin. Clin Cancer Res. 1998 Jun;4(6):1429-36.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Suxamethonium (Succinylcholine)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Renal elimination of unchanged suxamethonium is minimal. Therefore there is little potential for interaction with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Following intravenous administration, there is rapid hydrolysis by pseudocholinesterase with the initial metabolite being succinylmonocholine a weak neuro-muscular drug. This is metabolised to succinic acid with only a small amount excreted in the urine.<br /><em>Suxamethonium Chloride Injection BP UK Summary of Product Characteristics, Mercury Pharma Group, updated May 2012</em></p>
<p>Succinylcholine is rapidly hydrolyzed by plasma cholinesterase to succinylmonocholine (which possesses clinically insignificant depolarizing muscle relaxant properties) and then more slowly to succinic acid and choline. About 10% of the drug is excreted unchanged in the urine.<br /><em>Anectine&#174; (Succinylcholine Chloride Injection, USP) US Prescribing Information, Sandoz Inc, updated September 2010</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Tacrolimus</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tacrolimus is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Tadalafil (Erectile Dysfunction)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tadalafil is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Tadalafil (Pulmonary Arterial Hypertension)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tadalafil is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Tamoxifen</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Tamoxifen metabolism occurs mostly via two pathways: the formation of N-desmethyltamoxifen (via mainly CYP3A4 and CYP3A5) is the main route (92%) and the formation of 4-hydroxytamoxifen (via CYP2D6 > 2C9/19, CYP3A4 and CYP2B6) is a minor route (7%). Further metabolism of both metabolites results in the formation of endoxifen which is thought to be the most important metabolite contributing to the pharmacologic activity of tamoxifen. Endoxifen is formed from N-desmethyltamoxifen via CYP2D6 and from 4-hydroxytamoxifen via CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Tamsulosin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tamsulosin is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Telaprevir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as telaprevir is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Telbivudine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Telbivudine is eliminated primarily by urinary excretion as unchanged drug. The renal clearance of telbivudine approaches normal glomerular filtration rate, suggesting that filtration is the main mechanism of excretion.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Telithromycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as telithromycin is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Telmisartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as telmisartan is mainly glucuronidated by UGT1A3.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Temazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely as temazepam is mainly glucuronidated. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Temsirolimus</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Temsirolimus is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Tenofovir-DF</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No significant interaction was observed following administration of a single dose of the extended release formulation of stavudine (d4T-XR 100 mg) and tenofovir-DF (300 mg once daily). No dose modification is required.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>The pharmacokinetic of tenofovir were investigated in 18 HIV-negative subjects following administration of a single dose of the extended release formulation of stavudine (d4T-XR 100 mg) and tenofovir (300 mg once daily). Serum tenofovir concentration-versus time profile for the d4T XR+TDF treatment was superimposable on the profile for the TDF alone treatment. The geometric mean (%CV) for Cmax and AUC, and median Tmax values for tenofovir were 320 ng/mL (20%), 3048 ng.h/mL (20%), and 2.0 h, respectively, for the TDF alone treatment; the corresponding values for the d4T XR+TDF treatment were 333 ng/ml (17%), 3032 ng.h/mL (16%), and 1.5 h, respectively. D4T XR did not influence the pharmacokinetics of tenofovir and no dose modification is required when coadministered with d4T XR. <br /><em>Stavudine extended release formulation and tenofovir disoproxil fumarate: lack of a pharmacokinetic drug interaction. Kaul S, et al. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2004, abstract 602. </em></p>
<p>The pharmacokinetics of a single dose of the extended release formulation of stavudine (d4T-XR 100 mg) and tenofovir (300 mg once daily) were studied in 18 HIV-negative subjects. Plasma d4T concentration-versus time profile for the d4T XR+TDF treatment was super-imposable on the profile for the d4T XR alone treatment. The geometric mean (%CV) for Cmax and AUC, and median Tmax values were 274 (31%) ng/ml, 2,682 (29%) ng.h/mL, and 5 h, respectively, for the d4T XR alone treatment; the corresponding values for the d4T XR+TDF treatment were 275 (26%) ng/ml, 2,765 (28%), and 4 h, respectively. TDF did not influence the pharmacokinetics of d4T-XR and dose modification is not required when co-administered with TDF. <br /><em>Lack of interaction between stavudine extended-release formulation and tenofovir disoproxil fumarate. Kaul S, et al. 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 2003, abstract 534. </em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Terazosin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as terazosin is extensively metabolized in the liver possibly via CYP3A4.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Terbinafine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely. Terbinafine is metabolized by CYP1A2, 2C9, 3A4 and to a lesser extent CYP2C8 and 2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Terfenadine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Terfenadine undergoes extensive metabolism mainly by CYP3A4 to form azacyclonol and terfenadine alcohol.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Testosterone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely as testosterone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Tetracaine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Absorbed tetracaine is predominantly metabolised by pseudocholinesterases in the plasma.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Tetracaine undergoes rapid mucosal absorption and is heavily protein-bound in blood. Tetracaine is metabolised in the liver (and sometimes in the kidney) to para-aminobenzoic acid<br /><em>Eludril&#174; Spray (Tetracaine hydrochloride/Chlorhexidine digluconate) UK Summary of Product Characteristics, Pierre Fabre Limited, updated January 2011</em></p>
<p>Tetracaine is hydrolysed in the body to p-amino-benzoic acid and should not therefore be used in patients being treated with sulphonamides.&nbsp; The primary site of metabolism for tetracaine is the plasma. Pseudocholinesterases in the plasma hydrolyse tetracaine to 4-aminobenzoic acid. Unmetabolised drug is excreted in the urine<br /><em>Minims Tetracaine Hydrochloride 1.0% w/v eye drops UK Summary of Product Characteristics, Bausch &amp; Lomb U.K Limited, updated July 2008</em></p>
<p>Tetracaine is reported to be about 15% bioavailable after application of a 4% gel to intact skin, with a mean absorption and elimination half-life of about 75 minutes.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via medicines Complete), latest modification: 05-Dec-2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Tetracyclines</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Tetracyclines are eliminated unchanged primarily by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Thalidomide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as thalidomide is cleared by non-enzymatic hydrolysis. However, use with caution due to the risk of peripheral neuropathy associated with both drugs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Theophylline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Theophylline is mainly metabolized by CYP1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Thiamine (Vitamin B1)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Thiamine is absorbed from the GI tract and is widely distributed to most body tissues. It is not stored to any appreciable extent in the body and amounts in excess of requirements are excreted in the urine as unchanged thiamine or metabolites.<br /><em>Vitamin B Compound Strong Tablets UK Summary of Product Characteristics, Actavis UK Ltd, updated July 2012</em></p>
<p>Small amounts of thiamine are well absorbed from the gastrointestinal tract after oral doses, but the absorption of doses larger than about 5 mg is limited. It is also rapidly absorbed on intramuscular injection. It is widely distributed to most body tissues. Within the cell, thiamine is mostly present as the diphosphate. Thiamine is not stored to any appreciable extent in the body and amounts in excess of the body's requirements are excreted in the urine unchanged or as metabolites.<br /><em>Martindale Complete Drug Reference. Pharmaceutical Press (via Medicines Complete), latest modification: 05-Dec-2011</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Thiopental</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Renal excretion of unchanged thiopental is thought to be minimal. There is therefore little potential for interaction with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>Thiopental is almost completely metabolised in the body with a very small percentage excreted unchanged in urine.<br /><em>Pharmacodynamics and pharmacokinetics of thiopental. Russo H, Bressolle F. Clin Pharmacokinet. 1998 Aug;35(2):95-134</em> </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Thioridazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Thioridazine is metabolized by CYP2D6 and to a lesser extent by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Tiapride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tiapride is excreted largely unchanged in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ticagrelor</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ticagrelor undergoes extensive CYP3A4 metabolism and is only a mild inhibitor of CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Timolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for interaction when timolol is used either orally or as eye drops. Renal elimination of unchanged timolol is minimal, there is therefore little potential for interaction with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Timolol undergoes significant hepatic metabolism, but first pass metabolism is low. 5% of timolol is excreted unchanged by the kidneys. The rate of timolol metabolism varies between individuals. Poor metabolisers (approximately 10%) show higher plasma levels and slower elimination of timolol than extensive metabolisers. Within individuals, however, plasma concentrations and half-life are reproducible. As the therapeutic response and some adverse effects are related to plasma concentrations of timolol, poor metabolisers may require lower than normal doses. <br /><em>Betim&#174; (Timolol) 10mg Tablets UK Summary of Product Characteristics, Meda Pharmaceuticals,updated October 2011</em></p>
<p>Like other topically applied ophthalmic drugs, 'Timoptol' may be absorbed systemically and adverse reactions seen with oral beta-blockers may occur.<br /><em>Timoptol&#174; (Timolol) 0.25% and 0.5% w/v Eye Drops Solution UK Summary of Product Characteristics, Merck Sharp &amp; Dohme Limited, updated June 2008</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Tipranavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Moderate
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No significant interaction observed. Stavudine AUC decreased by 0-16% (formal interaction studies performed with different doses of tipranavir/ritonavir - 250/200, 500/100, 750/100, 750/200 mg). No dosage adjustment of stavudine is recommended. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>No significant interaction was observed when stavudine (40 mg bid if 60 kg or over, 30 mg bid if under 60 kg) and tipranavir/ritonavir (750/100 mg bid) were coadministered. No dosage adjustment is necessary.<br /><em>Aptivus Summary of Product Characteristics, Boehringer Ingelheim International GmbH, December 2011.</em></p>
<p>Coadministration of stavudine (40 mg twice daily if 60 kg or above , 30 mg twice daily if &lt;60 kg) and tipranavir/ritonavir (250/200 mg twice daily) to 26 HIV+ subjects resulted in a 10% decrease in stavudine Cmax and no change in AUC. When the same weight related doses were administered with tipranavir/ritonavir (750/100 mg twice daily) to 22 HIV+ subjects, stavudine Cmax decreased by 24% and AUC decreased by 16%.<br /><em>Aptivus Prescribing Information, Boehringer Ingelheim, April 2012.</em></p>
<p>The addition of tipranavir/ritonavir (1250/100 mg, n=19; 750/100 mg, n=22; 250/100 mg, n=26) was studied in HIV+ subjects on stable HAART regimens containing stavudine. No clinically significant changes in stavudine AUC were observed.<br /><em>Pharmacokinetic drug interaction screen of three doses of tipranavir/ritonavir in HIV-infected patients on stable highly active antiretroviral therapy. Goebel FD, Sabo JP, MacGregor TR, et al. HIV DART, Naples (Florida), December 2002.</em></p>
<p>Coadministration of stavudine (40 mg bd, n=15) and tipranavir (900, 1200 or 1500 mg, three times daily) resulted in a decrease in stavudine AUC from 1230&#177;326 to 1050&#177;276 ng/ml.h.<br /><em>The pharmacokinetics of nucleoside reverse transcriptase inhibitors when coadministered with the HIV protease inhibitor tipranavir in HIV-1 infected patients. Phillips H, Borin MT, Hopkins NK, et al. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2000, abstract 81.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Tizanidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as tizanidine is metabolised by CYP1A2.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Tolbutamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tolbutamide is mainly metaboliized by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Tolterodine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Tolterodine is primarily metabolised by CYP2D6 with CYP3A4 having a major role in CYP2D6 poor metabolisers.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Topiramate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Topiramate is mainly eliminated by renal elimination in unchanged form (up to 60% of the dose) and partly by oxidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Topotecan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration has not been studied. Topotecan undergoes both hepatic and renal elimination. Hepatic elimination involves mainly non-enzymatic hydrolysis and, to a minor extent, CYP mediated N-demethylation as well as glucuronidation. Renal elimination is by both active secretion (mainly via OAT3) and glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Torasemide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as torasemide is mainly metabolized by CYP2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Toremifene</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Toremifene is mainly metabolized by CYP3A4 to N-demethyltoremifene.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Tramadol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Tramadol is metabolized by CYPs 3A4, 2B6, and 2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Trandolapril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as trandolapril is hydrolysed to trandolaprilat.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Tranexamic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tranexamic acid is mainly cleared by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Tranylcypromine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tranylcypromine is hydroxylated and acetylated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Trazodone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as trazodone is primarily metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Triamcinolone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as triamcinolone is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Triazolam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely as triazolam is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Triclabendazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Renal excretion of unchanged triclabendazole appears to be minimal (<10%), therefore there is little potential for interaction with stavudine via competition for renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>In vivo, triclabendazole is rapidly oxidised into its sulfoxide metabolite, which is further oxidised to the sulfone metabolite. The sulfoxide form is predominant in plasma, with the parent compound and the sulfone metabolite having AUCs respectively of approximately 1% and 10% of that of the sulfoxide. The rapid biotransformation of triclabendazole in man and the previous findings in animals produced evidence of presystemic biotransformation including first-pass metabolism of triclabendazole. In animals, the drug is largely excreted via the biliary tract in the faeces (90%), together with the sulfoxide and subsequently the sulfone metabolite. Less than 10% of an oral dose is excreted in the urine.<br /><em>Egaten&#174; Summary of product Charateristics, Novartis Pharma AG Basel, Switzerland, Produced July 2000</em></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Trimethoprim/Sulfamethoxazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Potential interaction due to competition for active renal secretion. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Since stavudine is actively secreted by the renal tubules, interactions with other actively secreted medicinal products are possible, e.g. with trimethoprim. <br /><em>Zerit Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, March 2011.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Trimipramine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Trospium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trospium is minimally metabolized and is mainly eliminated unchanged renally, in part by OCT2.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Turmeric (Curcuma longa)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ulipristal</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Ulipristal is mainly metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Valaciclovir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valaciclovir is converted to aciclovir which is eliminated renally via glomerular filtration and active renal secretion by OAT1. Stavudine is only partly eliminated via OAT1.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Valerian</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Valproate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Valproate is mainly glucuronidated by UGTs 1A6, 1A9 and 2B7 and metabolized by CYP2C9 and CYP2C19.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Valsartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely as valsartan is eliminated unchanged mostly through biliary excretion.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Vancomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Vancomycin is excreted unchanged via renal glomerular filtration. As little active renal secretion is thought to occur, there is low potential for interaction with stavudine via competition for active renal elimination mechanisms.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Vancomycin is metabolized only to a low extent. After parenteral administration it is excreted almost completely as microbiologically active substance (approx. 75-90% within 24 hours) through glomerular filtration via the kidneys. Biliary excretion is insignificant (less than 5% of a dose). The clearance of vancomycin from plasma correlates nearly with the glomerular filtration rate. No vancomycin metabolites have been identified so far in humans<br /><em>Vancomycin, 500 mg, powder for solution for infusion Summary of Product Characteristics, Sandoz Limited, updated November 2011</em></p>
<p>In the first 24 hours, about 75% of an administered dose of vancomycin is excreted in urine by glomerular filtration. Mean plasma clearance is about 0.058 L/kg/hr, and mean renal clearance is about 0.048 L/kg/hr. Renal dysfunction slows excretion of vancomycin. In anephric patients, the average half-life of elimination is 7.5 days. The distribution coefficient is from 0.3 to 0.43 L/kg. There is no apparent metabolism of the drug.<br /><em>Sterile vancomycin hydrochloride, USP Fliptop Vial For Intravenous Use, US Prescribing Information, Hospira Inc, updated December 2007</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Vardenafil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as vardenafil is metabolized by CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Varenicline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>No interactions due to cytochrome P450 metabolism or renal secretion expected. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Based on varenicline characteristics and clinical experience to date, varenicline has no clinically meaningful drug interactions. No dosage adjustment of varneicline or co-administered medicinal products listed below is recommended. In vitro studies indicate that varenicline is unlikely to alter the pharmacokinetics of compounds that are primarily metabolised by cytochrome P450 enzymes. Furthermore since metabolism of varenicline represents less than 10% of its clearance, active substances known to affect the cytochrome P450 system are unlikely to alter the pharmacokinetics of varenicline and therefore a dose adjustment of varenicline would not be required. In vitro studies demonstrate that varenicline does not inhibit human renal transport proteins at therapeutic concentrations. Therefore, active substances that are cleared by renal secretion are unlikely to be affected by varenicline. <br /><em>Champix Summary of Product Characteristics, Pfizer Ltd, August 2008.</em></p>
<p>No clinically meaningful pharmacokinetic drug-drug interactions have been identified. In vitro studies demonstrated that varenicline does not inhibit the following cytochrome P450 enzymes (IC50 &gt;6400 ng/mL): 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4/5. Also, in human hepatocytes in vitro, varenicline does not induce the cytochrome P450 enzymes 1A2 and 3A4. In vitro studies demonstrated the active renal secretion of varenicline is mediated by the human organic cation transporter, OCT2. Co-administration with inhibitors of OCT2 may not require a dose adjustment of varenicline as the increase in systemic exposure to varenicline is not expected to be clinically meaningful. Furthermore, since metabolism of varenicline represents less than 10% of its clearance, drugs known to affect the cytochrome P450 system are unlikely to alter the pharmacokinetics of varenicline and therefore a dose adjustment of varenicline would not be required. <br /><em>Chantix Prescribing Information, Pfizer Inc, May 2008.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Velpatasvir/Sofosbuvir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as stavudine is predominantly eliminated unchanged by the kidneys.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Venlafaxine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Venlafaxine is mainly metabolized by CYP2D6 and to a lesser extent by CYPs 3A4, 2C19 and 2C9. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Verapamil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as verapamil is metabolised mainly by CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Vercuronium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>This interaction has not been studied. Based on limited data concerning the metabolism/elimination and toxicity profile of vercuronium,  there is little potential for interaction via competition with stavudine for active renal elimination pathways.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>In man, urine recovery of vecuronium varies from 3 to 35% within 24 hours. Data derived from patients requiring insertion of a T-tube in the common bile duct suggests that 25 to 50% of a total intravenous dose of vecuronium may be excreted in bile within 42 hours. Only unchanged vecuronium has been detected in human plasma following use during surgery. In addition, one metabolite, 3-desacetyl vecuronium, has been rarely detected in human plasma following prolonged clinical use in intensive care units. The 3-desacetyl vecuronium metabolite has been recovered in the urine of some patients in quantities that account for up to 10% of injected dose; 3-desacetyl vecuronium has also been recovered by T-tube in some patients, accounting for up to 25% of the injected dose.<br /><em>Vecuronium bromide for injection US Prescribing Information, Pfizer Inc, updated February 2011</em></p>
<p>The metabolic fate of vecuronium bromide in humans has not been fully characterized. In vitro, vecuronium undergoes spontaneous deacetylation to form the hydroxy derivatives. The neuromuscular blocking activity of the 3&#945;-hydroxy derivative appears to be at least 50% that of the unchanged drug. In vitro, the 3&#945;-hydroxy derivative undergoes rapid conversion to the 3&#945;,17&#946;-dihydroxy derivative. The 17&#946;-hydroxy and 3&#945;,17&#946;-dihydroxy derivatives appear to have about 5 and 2% of the neuromuscular blocking activity of the unchanged drug respectively. The extent of spontaneous deacetylation and/or metabolism of vecuronium in humans remains to be clearly determined. Vecuronium bromide and its metabolite(s) appear to be excreted principally in feces via biliary elimination; the drug and its metabolite(s) are also excreted in urine. Although only unchanged drug has been detected in plasma in patients receiving the drug as an adjunct to surgical anesthesia, up to 10% of a dose of vecuronium bromide has been excreted in urine and 5&#8211;25% in bile as the 3&#945;-hydroxy derivative in some patients. Another metabolite, 3-desacetyl vecuronium, has been detected rarely in plasma following prolonged clinical use of the drug in an intensive care setting. Approximately 20&#8211;30% (range: 3&#8211;36%) of an IV dose of vecuronium bromide is excreted in urine within 24 hours after administration in humans, principally as unchanged drug and to a lesser extent as the 3&#945;-hydroxy derivative. In patients with a T-tube in the common bile duct, 12&#8211;45% of an IV dose of vecuronium was reportedly excreted in bile within 18&#8211;42 hours after administration, almost completely as unchanged drug. <br /><em>AHFS Drug Information (via Medicines Complete), published by the American Society of Health-System Pharmacists Inc, January 2009</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Vigabatrin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely as vigabatrin is cleared mainly by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Vildagliptin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as vildagliptin is inactivated via non-CYP mediated hydrolysis.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Vinblastine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as vinblastine undergoes extensive metabolism and is excreted primarily by the biliary route. However, coadministration can increase the risk of peripheral neuropathy due to additive toxicity.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Vincristine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as vincristine is excreted primarily by the biliary route. However, coadministration can increase the risk of peripheral neuropathy due to additive toxicity.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Vitamin E</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Voriconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as voriconazole is metabolised by CYPs 2C19, 2C9 and 3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Vorinostat</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Vorinostat is mainly metabolised by glucuronidation (UGT2B17) and hydrolysis followed by B oxidation (non CYP-mediated).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Warfarin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Warfarin is a mixture of enantiomers which are metabolized by different cytochromes. R-warfarin is primarily metabolized by CYPs 1A2 and 3A4 whereas S-warfarin (more potent) is metabolized by CYP2C9. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Xipamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 90% of xipamide is excreted in the urine, mainly as unchanged drug (50%) and glucuronides (30%).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Zaleplon</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as zaleplon is mainly metabolized by aldehyde oxidase and to a lesser extent CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary) </span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Zanamivir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. A small amount of the orally inhaled zanamivir is systematically absorbed. Absorbed zanamivir is excreted unchanged in the urine whereas unabsorbed zanamivir is excreted in the faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Zidovudine (AZT/ZDV)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration not recommended due to competition for metabolism with other thymidine analogues. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Zidovudine and stavudine are phosphorylated by the cellular enzyme (thymidine kinase), which preferentially phosphorylates zidovudine, thereby decreasing the phosphorylation of stavudine to its active triphosphate form. Zidovudine is therefore not recommended to be used in combination with stavudine. <br /><em>Zerit Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, March 2011.</em></p>
<p>Zidovudine competitively inhibits the intracellular phosphorylation of stavudine. Therefore, use of zidovudine in combination with stavudine should be avoided. <br /><em>Zerit Prescribing Information, Bristol-Myers Squibb Company, January 2012.</em></p>
<p>Zidovudine in combination with stavudine is antagonistic in vitro. The concomitant use of stavudine with zidovudine should be avoided. <br /><em>Retrovir Summary of Product Characteristics, ViiV Healthcare UK, Ltd, January 2012.</em></p>
<p>Concomitant use of zidovudine with stavudine should be avoided since an antagonistic relationship has been demonstrated in vitro. <br /><em>Retrovir Prescribing Information, ViiV Healthcare, November 2011.</em></p>
<p>The effect of adding stavudine (40 mg twice daily, n=35) to existing zidovudine therapy (300 mg twice daily) was studied in HIV-infected subjects and compared to those receiving stavudine monotherapy (40 mg twice daily, n=37). The most important finding in this study was that the combination of d4T and ZDV was inferior to d4T alone, with subjects receiving the combination showing progressive declines in CD4 cell counts over 16 weeks. Pharmacological antagonism between d4T and ZDV was the most likely mechanism. Intracellular d4T triphosphate concentrations were determined in 4 subjects receiving d4T alone and 2 subjects receiving d4T+ ZDV and were found to be lower when given in combination (65 vs. 10 fmol/10^6 cells).<br /><em>In vivo antagonism with zidovudine plus stavudine combination therapy. Havlir DV et al. J Infect Dis, 2000, 182: 321-325</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Ziprasidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately two thirds of ziprasidone metabolic clearance is by reduction, with less than one third by CYP enzymes (mainly CYP3A4).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Zoledronic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Zoledronic acid is eliminated unchanged renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Zolpidem</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Zolpidem is metabolized mainly by CYP3A4 and to a lesser extent by CYP2C9 and CYP1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Zonisamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zonisamide is metabolized partly by CYP3A4 and also by N-acetyl-transferases and conjugation. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Zopiclone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Zopiclone is metabolized mainly by CYP3A4 and to a lesser extent by CYP2C8.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Zotepine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zotepine is mainly metabolized by CYP3A4 and to a lesser extent CYP1A2 and CYP2D6. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>Stavudine (d4T)</p>
              <p>Zuclopenthixol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                    <strong>Quality of Evidence:</strong>
                    Very Low
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zuclopenthixol is metabolized by sulphoxidation, N-dealkylation (by CYP2D6 and CYP3A4) and glucuronidation. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


    </div>

  </div>

</div>

    <div class='commercial sponsors' id='sponsors'>
<div class='inner-wrapper'>
<div class='sponsors-title'>
SPONSORS
</div>
<a target="_blank" href="http://www.janssen.com/emea/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/001/tiny/sponsor-logo-janssen.png?1451996945" alt="Sponsor logo janssen" />
</a><a target="_blank" href="http://www.gilead.com/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/002/tiny/sponsor-logo-gilead.png?1451996988" alt="Sponsor logo gilead" />
</a><a target="_blank" href="http://www.msd-uk.com/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/003/tiny/sponsor-logo-msd.png?1451997044" alt="Sponsor logo msd" />
</a><a target="_blank" href="https://www.viivhealthcare.com/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/004/tiny/sponsor-logo-viiv.png?1451997075" alt="Sponsor logo viiv" />
</a><a target="_blank" href="http://www.abbvie.com/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/006/tiny/sponsor-logo-abbvie.png?1451997117" alt="Sponsor logo abbvie" />
</a><a target="_blank" href="http://www.bms.com/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/005/tiny/sponsor-logo-bristol-myers-squibb.png?1451997097" alt="Sponsor logo bristol myers squibb" />
</a></div>
</div>

<div class='editorial sponsors' id='sponsors'>
<div class='inner-wrapper'>
<div class='sponsors-title'>
EDITORIAL SPONSORS
</div>
<a target="_blank" href="http://www.bhiva.org/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/008/tiny/bhiva.jpg?1453297795" alt="Bhiva" />
</a><a target="_blank" href="http://www.hiv11.com/ContentPageView.aspx?ContentPageId=79"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/010/tiny/Glasgow.png?1453297904" alt="Glasgow" />
</a><a target="_blank" href="http://www.eacsociety.org/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/009/tiny/EACS_logo_2014.jpg?1453297878" alt="Eacs logo 2014" />
</a></div>
</div>


    <div class="footer">
  <div class="inner-wrapper">
    <div class="footer-left-column">
      <div class="footer-links">
        <a href="http://www.hiv-druginteractions.org/cookie-policy">Cookie Policy</a>
        <a href="http://www.hiv-druginteractions.org/privacy">Privacy Statement</a>
        <a href="http://www.hiv-druginteractions.org/terms">Terms &amp; Conditions</a>
      </div>
        <p>Last Review: January 25, 2017</p>

      <p>Copyright  2017 The University of Liverpool. All rights reserved.</p>
      <p>Designed and developed by the team at <a target="_blank" href="http://podmedics.org">Podmedics</a></p>
    </div>

    <div class="footer-right-column">

      <a href="https://www.liverpool.ac.uk/" target="_blank" class="footer-liverpool-logo"></a>

    </div>
  </div>
</div>

  </body>
  
</html>
